<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">83342</article-id><article-id pub-id-type="doi">10.7554/eLife.83342</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>A lncRNA identifies <italic>Irf8</italic> enhancer element in negative feedback control of dendritic cell differentiation</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-293090"><name><surname>Xu</surname><given-names>Huaming</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293091"><name><surname>Li</surname><given-names>Zhijian</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="pa1">†</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293092"><name><surname>Kuo</surname><given-names>Chao-Chung</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="pa2">‡</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293093"><name><surname>Götz</surname><given-names>Katrin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="pa3">§</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293094"><name><surname>Look</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="pa4">#</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-311155"><name><surname>de Toledo</surname><given-names>Marcelo AS</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-293096"><name><surname>Seré</surname><given-names>Kristin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="pa3">§</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-116092"><name><surname>Costa</surname><given-names>Ivan G</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2890-8697</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-116090"><name><surname>Zenke</surname><given-names>Martin</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1107-3251</contrib-id><email>martin.zenke@rwth-aachen.de</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04xfq0f34</institution-id><institution>Department of Cell Biology, Institute of Biomedical Engineering, RWTH Aachen University Medical School</institution></institution-wrap><addr-line><named-content content-type="city">Aachen</named-content></addr-line><country>Germany</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04xfq0f34</institution-id><institution>Helmholtz Institute for Biomedical Engineering, RWTH Aachen University</institution></institution-wrap><addr-line><named-content content-type="city">Aachen</named-content></addr-line><country>Germany</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04xfq0f34</institution-id><institution>Institute for Computational Genomics, RWTH Aachen University Medical School</institution></institution-wrap><addr-line><named-content content-type="city">Aachen</named-content></addr-line><country>Germany</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04xfq0f34</institution-id><institution>Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University</institution></institution-wrap><addr-line><named-content content-type="city">Aachen</named-content></addr-line><country>Germany</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Ginhoux</surname><given-names>Florent</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/036wvzt09</institution-id><institution>Agency for Science Technology and Research</institution></institution-wrap><country>Singapore</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Rath</surname><given-names>Satyajit</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00djv2c17</institution-id><institution>Indian Institute of Science Education and Research (IISER)</institution></institution-wrap><country>India</country></aff></contrib></contrib-group><author-notes><fn fn-type="present-address" id="pa1"><label>†</label><p>Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States</p></fn><fn fn-type="present-address" id="pa2"><label>‡</label><p>Interdisciplinary Centre for Clinical Research (IZKF) Aachen, RWTH Aachen University Medical School, Aachen, Germany</p></fn><fn fn-type="present-address" id="pa3"><label>§</label><p>Department of Cell and Tumor Biology, RWTH Aachen University Medical School, Aachen, Germany</p></fn><fn fn-type="present-address" id="pa4"><label>#</label><p>Laboratory for Molecular Neuro-Oncology, Department of Neurology, University Hospital Zurich and University of Zurich, Zurich, Switzerland</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>14</day><month>03</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e83342</elocation-id><history><date date-type="received" iso-8601-date="2022-09-08"><day>08</day><month>09</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-03-13"><day>13</day><month>03</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2022-08-12"><day>12</day><month>08</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.08.11.503623"/></event></pub-history><permissions><copyright-statement>© 2023, Xu et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Xu et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-83342-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-83342-figures-v2.pdf"/><abstract><p>Transcription factors play a determining role in lineage commitment and cell differentiation. Interferon regulatory factor 8 (IRF8) is a lineage determining transcription factor in hematopoiesis and master regulator of dendritic cells (DC), an important immune cell for immunity and tolerance. IRF8 is prominently upregulated in DC development by autoactivation and controls both DC differentiation and function. However, it is unclear how <italic>Irf8</italic> autoactivation is controlled and eventually limited. Here, we identified a novel long non-coding RNA transcribed from the +32 kb enhancer downstream of <italic>Irf8</italic> transcription start site and expressed specifically in mouse plasmacytoid DC (pDC), referred to as <italic>lncIrf8</italic>. The <italic>lncIrf8</italic> locus interacts with the <italic>lrf8</italic> promoter and shows differential epigenetic signatures in pDC versus classical DC type 1 (cDC1). Interestingly, a sequence element of the <italic>lncIrf8</italic> promoter, but not <italic>lncIrf8</italic> itself, is crucial for mouse pDC and cDC1 differentiation, and this sequence element confers feedback inhibition of <italic>Irf8</italic> expression. Taken together, in DC development <italic>Irf8</italic> autoactivation is first initiated by flanking enhancers and then second controlled by feedback inhibition through the <italic>lncIrf8</italic> promoter element in the +32 kb enhancer. Our work reveals a previously unrecognized negative feedback loop of <italic>Irf8</italic> that orchestrates its own expression and thereby controls DC differentiation.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>interferon regulatory factor 8</kwd><kwd>dendritic cell</kwd><kwd>enhancer</kwd><kwd>lncRNA</kwd><kwd>feedback loop</kwd><kwd>CRISPR</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>German Research Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Zenke</surname><given-names>Martin</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution>German Ministry of Science and Technology</institution></institution-wrap></funding-source><award-id>Fibromap</award-id><principal-award-recipient><name><surname>Costa</surname><given-names>Ivan G</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution>Interdisciplinary Center for Clinical Research Aachen</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Costa</surname><given-names>Ivan G</given-names></name><name><surname>Zenke</surname><given-names>Martin</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004543</institution-id><institution>China Scholarship Council</institution></institution-wrap></funding-source><award-id>202008080170</award-id><principal-award-recipient><name><surname>Xu</surname><given-names>Huaming</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution>CAPES-Alexander von Humboldt Foundation</institution></institution-wrap></funding-source><award-id>99999.001703/2014-05</award-id><principal-award-recipient><name><surname>de Toledo</surname><given-names>Marcelo AS</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>A novel lncRNA marks the <italic>Irf8</italic> downstream enhancer that is crucial for differentiation of plasmacytoid dendritic cells (pDC) and classical dendritic cells type 1 (cDC1) and confers feedback inhibition of <italic>Irf8</italic> transcription.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Lineage-determining transcription factors (TF) are master regulators of gene programs that frequently initiate self-reinforcing loops by autoactivation. TF autoactivation is important for cells to pass restriction points during development (referred to as points of no return) and to enforce cellular identity. Molecular circuitries of autoactivation have been studied for several TF, such as GATA-binding factor 1 (GATA1), PU.1 (encoded by Spi1), CCAAT enhancer-binding protein α and ε (C/EBPα and ε; <xref ref-type="bibr" rid="bib30">Graf and Enver, 2009</xref>; <xref ref-type="bibr" rid="bib53">Loughran et al., 2020</xref>; <xref ref-type="bibr" rid="bib58">Nishimura et al., 2000</xref>; <xref ref-type="bibr" rid="bib60">Okuno et al., 2005</xref>; <xref ref-type="bibr" rid="bib80">Theilgaard-Mönch et al., 2022</xref>). A further example is interferon regulatory factor 8 (IRF8), which shows autoactivation in cooperation with basic leucine zipper ATF-like transcription factor 3 (BATF3; <xref ref-type="bibr" rid="bib4">Anderson et al., 2021</xref>; <xref ref-type="bibr" rid="bib32">Grajales-Reyes et al., 2015</xref>). An important principle in nature is negative feedback control to avoid signal overshooting and toxicity. Negative feedback control applies also to lineage-determining TF; however, there is a paucity on our knowledge of the molecular mechanisms involved.</p><p>IRF8 is a hematopoietic TF positioned at the center of the regulatory gene network for dendritic cell (DC) development (<xref ref-type="bibr" rid="bib4">Anderson et al., 2021</xref>; <xref ref-type="bibr" rid="bib8">Belz and Nutt, 2012</xref>; <xref ref-type="bibr" rid="bib14">Chauvistré and Seré, 2020</xref>; <xref ref-type="bibr" rid="bib37">Kim et al., 2020</xref>; <xref ref-type="bibr" rid="bib51">Lin et al., 2015</xref>; <xref ref-type="bibr" rid="bib59">Nutt and Chopin, 2020</xref>; <xref ref-type="bibr" rid="bib79">Tamura et al., 2015</xref>; <xref ref-type="bibr" rid="bib83">Verlander et al., 2022</xref>). IRF8 is a member of the interferon regulatory factor (IRF) family of TF. Initially members of this TF family were found to mediate the induction of interferon induced genes, but are now known to serve diverse functions in regulating the immune system (<xref ref-type="bibr" rid="bib34">Honda and Taniguchi, 2006</xref>; <xref ref-type="bibr" rid="bib78">Tamura et al., 2008</xref>). <italic>Irf8</italic> knockout mice show abnormal development of classical DC type 1 (cDC1) and plasmacytoid DC (pDC) (<xref ref-type="bibr" rid="bib22">Durai et al., 2019</xref>; <xref ref-type="bibr" rid="bib71">Schiavoni et al., 2002</xref>; <xref ref-type="bibr" rid="bib74">Sichien et al., 2016</xref>; <xref ref-type="bibr" rid="bib82">Tsujimura et al., 2003</xref>). <italic>Irf8</italic> is prominently upregulated during DC development by autoactivation (<xref ref-type="bibr" rid="bib32">Grajales-Reyes et al., 2015</xref>; <xref ref-type="bibr" rid="bib51">Lin et al., 2015</xref>), yet how <italic>Irf8</italic> autoactivation is controlled and eventually limited, and the epigenetic mechanisms involved is largely unknown.</p><p><italic>Irf8</italic> expression in hematopoietic cells is induced and maintained by enhancers located at –50 kb,+32 kb,+41 kb and +56 kb relative to <italic>Irf8</italic> transcription start site (TSS) (<xref ref-type="bibr" rid="bib4">Anderson et al., 2021</xref>; <xref ref-type="bibr" rid="bib6">Bagadia et al., 2019</xref>; <xref ref-type="bibr" rid="bib22">Durai et al., 2019</xref>; <xref ref-type="bibr" rid="bib32">Grajales-Reyes et al., 2015</xref>; <xref ref-type="bibr" rid="bib57">Murakami et al., 2021</xref>; <xref ref-type="bibr" rid="bib72">Schönheit et al., 2013</xref>). Enhancers are <italic>cis</italic>-regulatory sequences with multiple TF binding sites that cooperatively bind TF and thereby activate transcription, as demonstrated by many studies including our work (<xref ref-type="bibr" rid="bib17">Davidson et al., 1986</xref>; <xref ref-type="bibr" rid="bib52">Long et al., 2016</xref>; <xref ref-type="bibr" rid="bib86">Wildeman et al., 1986</xref>; <xref ref-type="bibr" rid="bib90">Zenke et al., 1986</xref>). Enhancers regulate complex gene networks and can also produce non-coding RNA, referred to as enhancer RNA (eRNA). eRNA serve as an indicator for enhancer activity and some eRNA have an activity on their own and act in cis or trans to regulate cell fate decisions (<xref ref-type="bibr" rid="bib70">Sartorelli and Lauberth, 2020</xref>; <xref ref-type="bibr" rid="bib77">Statello et al., 2021</xref>). Enhancer-associated long non-coding RNA (lncRNA) represent a class of lncRNA transcribed from active enhancers. Thus, eRNA and enhancer-associated lncRNA provide opportunities to detect enhancer activity and to investigate enhancer function.</p><p>DC are highly specialized immune cells that play a critical role in regulating innate and adaptive immune responses (<xref ref-type="bibr" rid="bib10">Cabeza-Cabrerizo et al., 2021</xref>). DC develop from hematopoietic stem cells (HSC) via successive steps of lineage commitment and differentiation. More specifically, HSC develop into multipotent progenitors (MPP) that are committed to DC restricted common DC progenitors (CDP) and differentiate into classic DC (cDC) type 1 and type 2 (cDC1 and cDC2, respectively) and pDC (<xref ref-type="bibr" rid="bib4">Anderson et al., 2021</xref>; <xref ref-type="bibr" rid="bib10">Cabeza-Cabrerizo et al., 2021</xref>; <xref ref-type="bibr" rid="bib29">Ginhoux et al., 2022</xref>; <xref ref-type="bibr" rid="bib59">Nutt and Chopin, 2020</xref>; <xref ref-type="bibr" rid="bib68">Rodrigues and Tussiwand, 2020</xref>). pDC were recently also shown to develop from lymphoid progenitors (<xref ref-type="bibr" rid="bib21">Dress et al., 2019</xref>; <xref ref-type="bibr" rid="bib67">Rodrigues et al., 2018</xref>; <xref ref-type="bibr" rid="bib68">Rodrigues and Tussiwand, 2020</xref>). Differential expression of <italic>Irf8</italic> regulates DC and monocyte specification in a dose-dependent manner (<xref ref-type="bibr" rid="bib16">Cytlak et al., 2020</xref>; <xref ref-type="bibr" rid="bib57">Murakami et al., 2021</xref>). <italic>Irf8</italic> expression starts at the CDP stage, and is high in pDC and cDC1, which is attributed to the autoactivation of <italic>Irf8</italic> during DC subsets specification (<xref ref-type="bibr" rid="bib32">Grajales-Reyes et al., 2015</xref>; <xref ref-type="bibr" rid="bib51">Lin et al., 2015</xref>). Interestingly, IRF8 can act as a transcriptional activator or repressor in hematopoiesis by interacting with different partner TF and binding to specific DNA sequences (<xref ref-type="bibr" rid="bib79">Tamura et al., 2015</xref>).</p><p>As an activator, IRF8 binds to its own promoter in DC differentiation, which is considered as the autoactivation capacity of <italic>Irf8</italic> (<xref ref-type="bibr" rid="bib32">Grajales-Reyes et al., 2015</xref>; <xref ref-type="bibr" rid="bib51">Lin et al., 2015</xref>). For instance, IRF8 interacts with partner TF, such as PU.1, to initiate <italic>Irf8</italic> autoactivation at the CDP stage (<xref ref-type="bibr" rid="bib32">Grajales-Reyes et al., 2015</xref>). Inversely, IRF8 inhibits C/EBPα activity in neutrophil differentiation (<xref ref-type="bibr" rid="bib42">Kurotaki et al., 2014</xref>). IRF8 also represses C/EBPβ to generate and maintain DC lineage-specific enhancer landscapes (<xref ref-type="bibr" rid="bib9">Bornstein et al., 2014</xref>). In addition, IRF8 is important for the <italic>Myc-Mycl</italic> transition in DC differentiation (<xref ref-type="bibr" rid="bib5">Anderson lll et al., 2021</xref>). IRF8 represses <italic>Myc</italic> expression in progenitors, while IRF8 at high levels interacts with PU.1 and drives <italic>Mycl</italic> expression (<xref ref-type="bibr" rid="bib5">Anderson lll et al., 2021</xref>). All this emphasizes the central position of IRF8 in coordinating the gene network that regulates DC differentiation and function.</p><p>During DC differentiation, the <italic>Irf8</italic> gene locus shows high epigenetic dynamics, including histone modifications and TF binding identified by ChIP-seq (<xref ref-type="bibr" rid="bib14">Chauvistré and Seré, 2020</xref>; <xref ref-type="bibr" rid="bib22">Durai et al., 2019</xref>; <xref ref-type="bibr" rid="bib32">Grajales-Reyes et al., 2015</xref>; <xref ref-type="bibr" rid="bib51">Lin et al., 2015</xref>), chromatin accessibility measured by ATAC-seq (<xref ref-type="bibr" rid="bib43">Kurotaki et al., 2019</xref>; <xref ref-type="bibr" rid="bib49">Li et al., 2019</xref>), and three-dimensional chromatin structure remodeling determined by chromosome conformation capture (3 C) (<xref ref-type="bibr" rid="bib44">Kurotaki et al., 2022</xref>; <xref ref-type="bibr" rid="bib72">Schönheit et al., 2013</xref>). All this emphasizes the impact of epigenetic regulators on <italic>Irf8</italic> gene activity in DC differentiation. Notably, <italic>Irf8</italic> is flanked by multiple enhancers at –50 kb,+32 kb,+41 kb, and +56 kb that regulate <italic>Irf8</italic> expression in hematopoietic cells (<xref ref-type="bibr" rid="bib4">Anderson et al., 2021</xref>; <xref ref-type="bibr" rid="bib57">Murakami et al., 2021</xref>). These four enhancers were found to be driven by PU.1, BATF3, E proteins and Runt-related transcription factor (RUNX)-core binding factor beta (CBFβ) (RUNX-CBFβ), respectively (<xref ref-type="bibr" rid="bib6">Bagadia et al., 2019</xref>; <xref ref-type="bibr" rid="bib22">Durai et al., 2019</xref>; <xref ref-type="bibr" rid="bib32">Grajales-Reyes et al., 2015</xref>; <xref ref-type="bibr" rid="bib57">Murakami et al., 2021</xref>; <xref ref-type="bibr" rid="bib72">Schönheit et al., 2013</xref>).</p><p>Chromatin conformation, particularly enhancer promoter interactions, provides a platform for TF-driven gene regulation and serves as a driving force for cell-fate determinations (<xref ref-type="bibr" rid="bib56">Misteli and Finn, 2021</xref>; <xref ref-type="bibr" rid="bib62">Oudelaar and Higgs, 2021</xref>; <xref ref-type="bibr" rid="bib76">Stadhouders et al., 2019</xref>). Schönheit et al. demonstrated <italic>Irf8</italic> promoter interactions with its upstream enhancers by quantitative 3 C (<xref ref-type="bibr" rid="bib72">Schönheit et al., 2013</xref>). In this study PU.1 was found to regulate chromatin remodeling between the –50 kb enhancer and the <italic>Irf8</italic> promoter in myeloid differentiation. In a recent study <xref ref-type="bibr" rid="bib44">Kurotaki et al., 2022</xref> determined the higher-order chromatin structure in DC progenitors, cDC1 and cDC2 on a genome-wide scale by Hi-C. In this study, reorganization of chromatin conformation at DC-specific gene loci was observed during cDC differentiation, and IRF8 was found to promote chromatin activation in DC progenitors leading to cDC lineage-specific gene expression. However, high resolution maps of the physical chromatin interactions of the <italic>Irf8</italic> promoter with upstream and downstream enhancers in the full complement of DC subsets, including pDC, are required for understanding <italic>Irf8</italic> regulation during DC differentiation.</p><p>Frequently, chromatin data, including ATAC-seq and/or ChIP-seq data, are used to identify regulatory elements of gene transcription. Here we embarked on a different approach and searched for lncRNA, which by themselves might have regulatory functions or are indicative of enhancer activity. We identified a novel lncRNA transcribed from the <italic>Irf8</italic> +32 kb enhancer, which is specifically expressed in pDC, referred to as <italic>lncIrf8</italic>. We found that the <italic>lncIrf8</italic> promoter element but not <italic>lncIrf8</italic> itself impacts pDC and cDC1 development. Thus, <italic>lncIrf8</italic> acts as an indicator for the <italic>Irf8</italic> +32 kb enhancer activity. Importantly, our study revealed a previously unrecognized negative feedback loop of <italic>Irf8</italic> in DC differentiation. <italic>Irf8</italic> first activates its expression by autoactivation via the +32 kb enhancer and second limits its own expression through the <italic>lncIrf8</italic> promoter element in the +32 kb enhancer.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title><italic>lncIrf8</italic> marks a pDC-specific <italic>Irf8</italic> enhancer element</title><p><italic>Irf8</italic> expression in DC development is subject to complex epigenetic regulation. Here, we used an integrated approach with RNA-seq, ATAC-seq, ChIP-seq and Capture-C to track the dynamics of gene expression, histone modification and chromatin conformation in the sequel MPP, CDP, pDC, cDC1, and cDC2 (<xref ref-type="fig" rid="fig1">Figure 1</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplements 1</xref> and <xref ref-type="fig" rid="fig1s2">2</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title><italic>Irf8</italic> epigenetic signatures and promoter-enhancer interaction maps during DC differentiation.</title><p>(<bold>A</bold>) Gene expression and epigenetic signatures of <italic>Irf8</italic> downstream region in MPP, CDP, pDC, all cDC, cDC1, and cDC2 are visualized by IGV browser. Gene expression was measured by RNA-seq, chromatin accessibility by ATAC-seq, H3K27ac and IRF8 binding by ChIP-seq. Positions of <italic>Irf8</italic> 3’ end, <italic>Irf8</italic> enhancers, pDC specific <italic>lncIrf8</italic> and cDC1 specific <italic>Tcons_00190258</italic> lncRNA are indicated. For RNA-seq - and +strands are shown. Scale bar: 5 kb. (<bold>B</bold>) Physical interactions of <italic>Irf8</italic> promoter with flanking sequences in MPP, CDP, pDC, cDC1, and cDC2 by nuclear-titrated (NuTi) Capture-C (turquoise), and CTCF binding by ChIP-seq in DC (<xref ref-type="bibr" rid="bib27">Garber et al., 2012</xref>). Mean numbers of unique interactions normalized to a 300 kb region around the <italic>Irf8</italic> promoter viewpoint (green triangle) and scaled by a factor of 1,000,000 are shown (n=2). The orientations of CTCF binding are indicated with blue and red arrows. <italic>Tcons_00190258</italic> refers to the cDC1-specific lncRNA shown in (<bold>A</bold>). Scale bar: 100 kb. (<bold>C</bold>) Comparations of the chromatin interactions with <italic>Irf8</italic> promoter in pDC, cDC1 and cDC2. Differential tracks were created by subtraction of the mean normalized tracks of (<bold>B</bold>). Pairwise comparisons are shown and color coded. Turquoise and orange tracks represent specific interactions with the <italic>Irf8</italic> promoter in the indicated cell types. Scale bar: 100 kb. Purple bars and lines indicate the position of flanking enhancers relative to <italic>Irf8</italic> TSS. The purple bars from left to right represent –50 kb, –34 kb, –26 kb, –16 kb,+27 kb,+32 kb,+38 kb,+41 kb,+47 kb,+56 kb and +62 kb enhancer, respectively (panels B and C). <italic>Irf8</italic> +32 kb enhancer is highlighted by purple box.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83342-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Epigenetic signatures of <italic>Irf8</italic> locus during DC differentiation.</title><p>Gene expression and epigenetic signatures of <italic>Irf8</italic> gene and its flanking regions in MPP, CDP, pDC, all cDC, cDC1, and cDC2 are visualized by IGV browser. Gene expression by RNA-seq, chromatin interactions with <italic>Irf8</italic> promoter by Capture-C, chromatin accessibility by ATAC-seq, histone modification (H3K27ac, H3K4me3, H3K4me1, H3K9me3) and TF binding (CTCF, IRF8 and PU.1) by ChIP-seq are as in <xref ref-type="fig" rid="fig1">Figure 1A and B</xref>. Positions of upstream and downstream <italic>Irf8</italic> enhancers are in purple, Capture-C viewpoint (green triangle), <italic>Irf8</italic> gene, pDC-specific <italic>lncIrf8</italic> and cDC1 specific <italic>Tcons_00190258</italic> lncRNA are indicated. The orientation of CTCF binding is indicated with blue and red arrows. pDC and cDC super enhancers (<xref ref-type="bibr" rid="bib32">Grajales-Reyes et al., 2015</xref>) are indicated with black boxes. For RNA-seq – and +strands are shown. Scale bar: 20 kb.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83342-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>In vitro DC differentiation of HoxB8 MPP and nuclear-titrated (NuTi) Capture-C.</title><p>(<bold>A</bold>) HoxB8 MPP were obtained by infection of bone marrow MPP with HoxB8 retrovirus and cultured in growth medium with SCF, Flt3L, hyper-IL-6, IGF-1, and β-estradiol (E2) (MPP/CDP culture). DC differentiation is induced in growth medium plus high concentration of Flt3L and reduced E2 for 2 days (transition phase). Then growth factors and E2 are removed and cells are further differentiated into DC with high concentration of Flt3L only (DC differentiation). (<bold>B</bold>) For nuclear-titrated (NuTi) Capture-C FACS sorted cells were fixed with formaldehyde and nuclei were isolated (step 1 and 2). Nuclei were permeabilized with SDS and digested with DpnII (step 3). DNA fragments in nuclei were re-ligated by T4 ligase (step 4) and DNA was extracted to obtain 3C libraries (step 5). The 3C libraries were subjected to sonication (~200 bp fragments), sequencing adaptors were added and DNA was then hybridized with 70 bp biotinylated oligos of the viewpoint, followed by streptavidin bead pull-down and PCR amplification (steps 6–10). Steps 8–10 were repeated to increase capture efficiency. Finally, the captured DNA was subjected to next-generation sequencing (step 11). This scheme was adapted from Figure 1A of <xref ref-type="bibr" rid="bib20">Downes et al., 2022</xref>. (<bold>C</bold>) Comparison of the chromatin interactions with the <italic>Irf8</italic> promoter by Capture-C (viewpoint, green triangle) between MPP, CDP, pDC, cDC1, and cDC2. Positions of <italic>Irf8</italic> enhancers are indicated (purple). Pairwise comparisons are shown and color coded (turquoise vs orange) as in <xref ref-type="fig" rid="fig1">Figure 1C</xref>. Differential tracks were created by subtraction of the mean normalized tracks of <xref ref-type="fig" rid="fig1">Figure 1B</xref>. Scale bar: 100 kb.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83342-fig1-figsupp2-v2.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>pDC specific <italic>lncIrf8</italic> and cDC1 specific <italic>Tcons_00190258</italic> lncRNA expression in ex-vivo DC.</title><p>(<bold>A and B</bold>) UMAPs show the expression of <italic>lncIrf8</italic> and <italic>Tcons_00190258</italic> lncRNA and the indicated marker genes in BM and splenic pDC (Lin<sup>-</sup> CD11c<sup>+</sup> Bst2<sup>+</sup> Siglec-H<sup>+</sup>) from scRNA-seq data (GSE114313) (<xref ref-type="bibr" rid="bib67">Rodrigues et al., 2018</xref>). pDC marker genes, <italic>Tcf4</italic>, <italic>Bst2</italic> and <italic>Siglec-H</italic>; cDC marker genes, <italic>Zbtb46</italic>, <italic>Cx3cr1</italic> and <italic>Xcr1</italic>. (<bold>C</bold>) Gene expression of <italic>lncIrf8</italic> and <italic>Tcons_00190258</italic> lncRNA in splenic DC subsets in vivo and in DC subsets generated in in vitro BM Flt3L culture. Bulk RNA-seq data of splenic pDC (CD11c<sup>int</sup> CD317<sup>hi</sup> CD11b<sup>-</sup>), cDC1 (CD11c<sup>hi</sup> CD317<sup>low</sup> CD8<sup>+</sup> CD11b<sup>-</sup>), and cDC2 (CD11c<sup>hi</sup> CD317<sup>low</sup> CD8<sup>-</sup> CD11b<sup>-</sup>) were obtained from GSE188992 (<xref ref-type="bibr" rid="bib64">Pang et al., 2022</xref>). The bulk RNA-seq data of DC from Flt3L culture are from this study. Gene expression is visualized by IGV browser. Positions of <italic>Irf8</italic> 3’ end, <italic>Irf8</italic> enhancers, pDC-specific <italic>lncIrf8</italic> and cDC1 specific <italic>Tcons_00190258</italic> lncRNA are indicated. Scale bar: 5 kb.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83342-fig1-figsupp3-v2.tif"/></fig></fig-group><p>We performed de novo transcript assembly of the RNA-seq data and detected two previously unknown transcripts without coding potential downstream of <italic>Irf8</italic>: a pDC specific lncRNA (<italic>Tcons_00190250</italic>) in the following referred to as <italic>lncIrf8</italic> and a cDC1 specific lncRNA (<italic>Tcons_00190258</italic>; <xref ref-type="fig" rid="fig1">Figure 1A</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). <italic>lncIrf8</italic> and <italic>Tcons_00190258</italic> show the same expression pattern in pDC and cDC1, respectively, in BM and spleen (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>), as revealed by reanalyzing scRNA-seq and bulk RNA-seq data (<xref ref-type="bibr" rid="bib64">Pang et al., 2022</xref>; <xref ref-type="bibr" rid="bib67">Rodrigues et al., 2018</xref>). <italic>lncIrf8</italic> is transcribed within an enhancer region located 32 kb downstream of the <italic>Irf8</italic> TSS labeled by H3K27ac and H3K4me1 and occupied by DC differentiation-associated TF, such as IRF8 and PU.1 (<xref ref-type="fig" rid="fig1">Figure 1A</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). This region is largely devoid of H3K9me3, a chromatin modification frequently associated with heterochromatin, indicating an open chromatin configureuration in DC (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). In addition, sequences of this region have been implicated in DC development and referred to as +32 kb enhancer (<xref ref-type="bibr" rid="bib22">Durai et al., 2019</xref>). Thus, we proceeded to study <italic>lncIrf8</italic> in detail.</p><p>ATAC-seq analysis revealed further details of the <italic>lncIrf8</italic> region in CDP, pDC, cDC1 and cDC2 (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, <xref ref-type="fig" rid="fig2">Figure 2A</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). In cDC1 the prominent ATAC-seq and IRF8 peaks mark the cDC1 specific +32 kb enhancer (<xref ref-type="bibr" rid="bib22">Durai et al., 2019</xref>). In pDC the ATAC-seq peak is smaller and shifted further towards downstream but aligns well with the valley in the prominent H3K27ac peak. This ATAC-seq peak marks the <italic>lncIrf8</italic> promoter and aligns with p300 (<xref ref-type="bibr" rid="bib22">Durai et al., 2019</xref>) and H3K4me3 (<xref ref-type="fig" rid="fig2">Figure 2A</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). All this indicates that this chromatin region is open and transcriptionally active in pDC, enabling <italic>lncIrf8</italic> transcription.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title><italic>IncIrf8</italic> promoter KO compromises pDC and cDC1 development in vitro.</title><p>(<bold>A</bold>) Genomic anatomy of <italic>lncIrf8</italic> locus determined by 3’ and 5’ RACE PCR. Blue box, exon 2 and 3 (48 bp and 468 bp, respectively). The 1010 bp intron and polyA tail are shown. Data of RNA-seq, ATAC-seq, ChIP-seq of H3K27ac (enhancer mark) and H3K4me3 (active promoter mark, near TSS) are visualized by IGV browser for the indicated cell populations (pDC, all cDC, cDC1 and cDC2). Grey box, <italic>lncIrf8</italic> promoter KO region; open box, cDC1 specific +32 kb enhancer by <xref ref-type="bibr" rid="bib22">Durai et al., 2019</xref>. <italic>Irf8</italic> +32 kb enhancer based on the H3K27ac enhancer mark is indicated with a purple line. Scale bar: 1 kb. (<bold>B</bold>) Gene expression of <italic>lncIrf8</italic> and <italic>Irf8</italic> in <italic>lncIrf8</italic> promoter KO and control at day 0, 5, and 7 of Flt3L directed DC differentiation. Gene expression was determined by RT-qPCR and normalized to <italic>GAPDH</italic>. n=4. (<bold>C</bold>) Representative flow cytometry analysis of Flt3L directed DC differentiation of <italic>lncIrf8</italic> promoter KO HoxB8 MPP and control (<xref ref-type="bibr" rid="bib54">Lutz et al., 2022</xref>; <xref ref-type="bibr" rid="bib88">Xu et al., 2022</xref>). pDC, all cDC, cDC1, and cDC2 were gated as in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref> and are shown. Bar diagrams depict quantification of pDC, cDC1 and cDC2 normalized to living single cells on DC differentiation day 0, 3, 5, 7, and 9. n=6–7. (<bold>D</bold>) Representative phase-contrast microscopy images of <italic>lncIrf8</italic> promoter KO HoxB8 MPP and control on day 7 of Flt3L directed DC differentiation. Scale bar: 200 μm. (<bold>E</bold>) Representative flow cytometry analysis of spontaneous DC differentiation of <italic>lncIrf8</italic> promoter KO HoxB8 MPP and control with growth factors but without E2 (<xref ref-type="bibr" rid="bib54">Lutz et al., 2022</xref>; <xref ref-type="bibr" rid="bib88">Xu et al., 2022</xref>) at day 8. Gr1<sup>+</sup> monocytes and CD11c<sup>+</sup> DC are shown. Quantification of Gr1<sup>+</sup> monocytes of living single cells on day 3, 6, 8, and 10 of spontaneous DC differentiation. n=6, <italic>lncIrf8</italic> promoter KO; n=4, control. Empty gRNA vector or non-targeting gRNA vector HoxB8 MPP were used as controls. Data represent mean ± SD of at least three independent experiments with different HoxB8 MPP clones of <italic>lncIrf8</italic> promoter KO and control without deletion. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, multiple t-tests. Data that have no difference (p&gt;0.05) are not labeled.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83342-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Generating <italic>lncIrf8</italic> promoter KO HoxB8 MPP and its impact on DC differentiation.</title><p>(<bold>A</bold>) Mx-Cas9-GFP HoxB8 MPP were infected with 2 gRNA in RFP and RFP657 lentiviral vectors. Mouse interferon α (mIFNα) was applied for 4 hours to induce Cas9 and GFP expression. Cells were cultured for another 2 days and FACS sorted for GFP<sup>+</sup> RFP<sup>+</sup> RFP657<sup>+</sup> cells and 3000 FACS sorted HoxB8 MPP were subjected to limiting dilution to obtain single cell colonies. Single cell HoxB8 MPP were genotyped by genomic PCR and clones with homozygous deletions in the <italic>lncIrf8</italic> promoter were used for further studies. (<bold>B</bold>) Mx-Cas9-GFP mice contain a mIFNα inducible Cre recombinase that removes the stop cassette and allows Cas9 and GFP expression. Cas9 and GFP protein are separated by the 2 A self-cleaving peptide (P2A) and thus all GFP<sup>+</sup> cells express Cas9. (<bold>C and D</bold>) Representative genotyping of <italic>lncIrf8</italic> promoter KO in single-cell Mx-Cas9-GFP HoxB8 MPP. Homozygous deletions in <italic>lncIrf8</italic> promoter (red) were detected by PCR and agarose gel electrophoresis (<bold>C</bold>). <italic>lncIrf8</italic> promoter deletions determined by Sanger sequencing in three representative KO clones of (<bold>C</bold>) are depicted in (<bold>D</bold>). <italic>lncIrf8</italic>-F and <italic>lncIrf8</italic>-R refers to primers for genotyping and Sanger sequencing, and sequences for both directions, referred to F and R, of clones 19, 21, and 24 are shown. Positions of gRNA1 and gRNA2, which were used for generating the deletion in the <italic>lncIrf8</italic> promoter, are indicated. (<bold>E</bold>) Gating strategy for Flt3L directed DC differentiation. CD11c<sup>+</sup> DC were gated on CD11b<sup>-</sup> B220<sup>+</sup> pDC, CD11b<sup>+</sup> B220<sup>-</sup> cDC, CD11b<sup>low/-</sup> XCR1<sup>+</sup> cDC1, and CD11b<sup>+</sup> XCR1<sup>-</sup> cDC2. (<bold>F and G</bold>) Quantification of CD11c<sup>+</sup> DC and cDC of panel (<bold>E</bold>) of living single cells in <italic>lncIrf8</italic> promoter KO HoxB8 MPP and control on Flt3L directed DC differentiation at day 0, 3, 5, 7, and 9. n=6–7. Data represent mean ± SD of at least three independent experiments with different HoxB8 MPP clones of <italic>lncIrf8</italic> promoter KO and control. *p&lt;0.05, multiple t-tests. Data that have no difference (p&gt;0.05) are not labeled.</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Full raw unedited gel of genotyping of <italic>lncIrf8</italic> promoter KO HoxB8 MPP clones in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>.</title></caption><media mimetype="image" mime-subtype="tiff" xlink:href="elife-83342-fig2-figsupp1-data1-v2.tif"/></supplementary-material></p><p><supplementary-material id="fig2s1sdata2"><label>Figure 2—figure supplement 1—source data 2.</label><caption><title>Labeled uncropped gel of genotyping of <italic>lncIrf8</italic> promoter KO HoxB8 MPP clones in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C</xref>.</title></caption><media mimetype="image" mime-subtype="tiff" xlink:href="elife-83342-fig2-figsupp1-data2-v2.tif"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83342-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Information of <italic>lncIrf8</italic> promoter KO.</title><p>(<bold>A</bold>) Schematic representation of <italic>lncIrf8</italic> locus. The sequences deleted in the <italic>lncIrf8</italic> promoter KO are indicated by a grey filled box and multiple potential IRF8 and PU.1 binding sites are depicted. The cDC1 specific +32 kb enhancer by <xref ref-type="bibr" rid="bib22">Durai et al., 2019</xref> is shown by an open box. Gene expression was by RNA-seq and IRF8 and PU.1 TF binding was by ChIP-seq as in <xref ref-type="fig" rid="fig1">Figure 1A</xref>, <xref ref-type="fig" rid="fig2">Figure 2A</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>. Scale bar: 500 bp. (<bold>B</bold>) Sequence of <italic>lncIrf8</italic> promoter and cDC1 specific +32 kb enhancer. Sequences underlined in black indicate gRNAs used for generating the deletions. Sequence motives for AP1-IRF composite elements (AICE), IRF8, PU.1, and BATF3 were indicated with green, orange, purple, and blue lines, respectively. <italic>lncIrf8</italic> exon 2 is in turquoise; arrow indicates <italic>lncIrf8</italic> transcriptional start site and direction. The shaded sequences represent the KO region of <italic>lncIrf8</italic> promoter and the cDC1 specific +32 kb enhancer by <xref ref-type="bibr" rid="bib22">Durai et al., 2019</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83342-fig2-figsupp2-v2.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 3.</label><caption><title>Impact of <italic>lncIrf8</italic> promoter KO on spontaneous DC differentiation.</title><p>(<bold>A</bold>) Gating strategy for spontaneous DC differentiation. Gr1<sup>+</sup> monocytes, and the pDC, all cDC, cDC1 and cDC2 subsets from Gr1<sup>-</sup> CD11c<sup>+</sup> cells were gated as in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref>. (<bold>B</bold>) Representative phase-contrast microscopy images of <italic>lncIrf8</italic> promoter KO HoxB8 MPP and control on spontaneous DC differentiation (-E2) day 8. Scale bar: 200 μm. (<bold>C–G</bold>) Quantification of CD11c<sup>+</sup> DC, pDC, all cDC, cDC1 and cDC2 of panel (<bold>A</bold>) of living single cells in <italic>lncIrf8</italic> promoter KO HoxB8 MPP and control on spontaneous DC differentiation (-E2) day 3, 6, 8, and 10. n=6 for <italic>lncIrf8</italic> promoter KO; n=4 for KO control. Data represent mean ± SD of at least three independent experiments with different HoxB8 MPP clones of <italic>lncIrf8</italic> promoter KO and control without deletion. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, multiple t-tests. Data that have no difference (p&gt;0.05) are not labeled. (<bold>H</bold>) Quantification of cDC2 normalized to CD11c<sup>+</sup> cells of (<bold>G</bold>) at days 6, 8, and 10. Spontaneous DC differentiation of control cells progressed slower than differentiation of <italic>lncIrf8</italic> promoter KO cells and therefore a lower frequency of cDC2 was observed at day 6. At later time points <italic>lncIrf8</italic> promoter KO left cDC2 differentiation unaffected. (<bold>I</bold>) Gating strategy for identification of Gr1<sup>+</sup> monocytes upon spontaneous DC differentiation in panel (<bold>A</bold>) and <xref ref-type="fig" rid="fig2">Figure 2E</xref>. Mouse BM cells were used and Gr1<sup>+</sup> monocytes (Mo) were gated as 7-AAD<sup>-</sup> CD11b<sup>+</sup> CD11c<sup>-</sup> Ly6C<sup>+</sup> Ly6G<sup>-</sup>. Neutrophils (Neut) were gated as 7-AAD<sup>-</sup> CD11b<sup>+</sup> CD11c<sup>-</sup> Ly6C<sup>low/-</sup> Ly6G<sup>+</sup> . (<bold>J</bold>) Representative flow cytometry analysis of Gr1<sup>+</sup> monocytes at day 6 of spontaneous DC differentiation of <italic>lncIrf8</italic> promoter KO and control. Cells were gated as in panel (<bold>I</bold>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83342-fig2-figsupp3-v2.tif"/></fig><fig id="fig2s4" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 4.</label><caption><title>cDC1 specific +32 kb enhancer KO compromises cDC1 development in vitro.</title><p>(<bold>A</bold>) Position of cDC1 specific +32 kb enhancer. Data of ATAC-seq, ChIP-seq of H3K27ac (enhancer mark) are visualized by IGV browser for the indicated cell populations (pDC, all cDC, cDC1, and cDC2). Open box, cDC1 specific +32 kb enhancer by <xref ref-type="bibr" rid="bib22">Durai et al., 2019</xref>; grey box, <italic>lncIrf8</italic> promoter KO region; <italic>Irf8</italic> +32 kb enhancer based on the H3K27ac enhancer mark is indicated with a purple line. Scale bar: 1 kb. (<bold>B and C</bold>) Representative genotyping of cDC1 specific +32 kb enhancer KO in single-cell Mx-Cas9-GFP HoxB8 MPP. Homozygous deletions in cDC1 specific +32 kb enhancer KO (red) were detected by PCR and agarose gel electrophoresis (<bold>B</bold>). cDC1 specific +32 kb enhancer KO deletions determined by Sanger sequencing in five representative KO clones of (<bold>B</bold>) are depicted in (<bold>C</bold>). cDC1 +32 kb-F1 and cDC1 +32 kb-R refers to primers for genotyping. Sanger sequencing was performed from on both DNA strands: cDC1 +32 kb-F2 and cDC1 +32 kb-R was used for forward and reverse sequencing, respectively. Clones 1–14, 1–35, 1–51, 1–61, and 2–56 are shown. Positions of gRNAs used for generating the deletion of cDC1 +32 kb enhancer KO are indicated. gRNA-KO1-5' and gRNA-KO1-3' are from <xref ref-type="bibr" rid="bib22">Durai et al., 2019</xref>; gRNA-KO2-5' and gRNA-KO2-3' were designed in the present study. (<bold>D</bold>) Gene expression of <italic>lncIrf8</italic> and <italic>Irf8</italic> in cDC1 specific +32 kb enhancer KO and control at day 0 and 7 of Flt3L directed DC differentiation. n=6, cDC1 specific +32 kb enhancer KO; n=4, control. (<bold>E</bold>) Representative flow cytometry analysis of Flt3L directed DC differentiation of cDC1 specific +32 kb enhancer KO HoxB8 MPP and control. pDC, all cDC, cDC1, and cDC2 were gated as in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref> and are shown. Bar diagrams on the left depict quantification of pDC, cDC1 and cDC2 normalized to CD11c<sup>+</sup> cells on DC differentiation day 7 and 9. Bar diagrams on the right depict CD11c<sup>+</sup> DC and all cDC. CD11c<sup>+</sup> DC were gated on living single cells. Frequencies of pDC were compromised in +32 kb enhancer KO at day 7, however this was not statistically significant. n=6, cDC1 specific +32 kb enhancer KO; n=4, control. (<bold>F</bold>) Representative flow cytometry analysis of spontaneous DC differentiation of cDC1 specific +32 kb enhancer KO and control with growth factors but without E2 at day 8. Gr1<sup>+</sup> monocytes and CD11c<sup>+</sup> DC are shown. Quantification of Gr1<sup>+</sup> monocytes of living single cells on days 3, 6, 8, and 10 of spontaneous DC differentiation. n=6, cDC1 specific +32 kb enhancer KO; n=4, control. Empty gRNA vector or non-targeting gRNA vector HoxB8 MPP were used as controls. Data represent mean ± SD of three independent experiments with different HoxB8 MPP clones of cDC1 specific +32 kb enhancer KO and control without deletion. Differentiation kinetics of clones were normatized to control without deletion if required. *p&lt;0.05, **p&lt;0.01, ****p&lt;0.0001, multiple t-tests. Data that have no difference (p&gt;0.05) are not labeled.</p><p><supplementary-material id="fig2s4sdata1"><label>Figure 2—figure supplement 4—source data 1.</label><caption><title>Full raw unedited gel of genotyping of cDC1 specific +32 kb enhancer KO clones in <xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4B</xref>.</title></caption><media mimetype="image" mime-subtype="tiff" xlink:href="elife-83342-fig2-figsupp4-data1-v2.tif"/></supplementary-material></p><p><supplementary-material id="fig2s4sdata2"><label>Figure 2—figure supplement 4—source data 2.</label><caption><title>Labeled uncropped gel of genotyping of cDC1 specific +32 kb enhancer KO clones in <xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4B</xref>.</title></caption><media mimetype="image" mime-subtype="tiff" xlink:href="elife-83342-fig2-figsupp4-data2-v2.tif"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83342-fig2-figsupp4-v2.tif"/></fig></fig-group><p>Next, we determined the chromatin conformation of the <italic>Irf8</italic> locus and the <italic>lncIrf8</italic> region. We generated interaction profiles by nuclear-titrated (NuTi) Capture-C in MPP, CDP, pDC, cDC1, and cDC2 (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A and B</xref>) using <italic>Irf8</italic> promoter as viewpoint. The <italic>Irf8</italic> promoter shows multiple interactions with regions spanning up to ~100 kb upstream and downstream of <italic>Irf8</italic> (<xref ref-type="fig" rid="fig1">Figure 1B</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). In pDC, the <italic>Irf8</italic> promoter interactions are stronger with the upstream sequences than with downstream sequences (<xref ref-type="fig" rid="fig1">Figure 1C</xref> and <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C</xref>). In cDC1 <italic>Irf8</italic> promoter interactions are more confined to the regions downstream of <italic>Irf8</italic> compared to MPP, CDP and pDC (<xref ref-type="fig" rid="fig1">Figure 1C</xref> and <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C</xref>). This suggests that upstream and downstream sequences of <italic>Irf8</italic> gene are involved in differentially regulating <italic>Irf8</italic> expression and controlling the development of pDC and cDC1, respectively.</p><p>The CCCTC-binding factor (CTCF) is important for regulation of chromatin conformation through loop extrusion (<xref ref-type="bibr" rid="bib69">Sanborn et al., 2015</xref>) and we therefore visualized CTCF binding sites in the <italic>Irf8</italic> locus in DC (<xref ref-type="bibr" rid="bib27">Garber et al., 2012</xref>). Interestingly, most of the <italic>Irf8</italic> flanking enhancers (<xref ref-type="bibr" rid="bib22">Durai et al., 2019</xref>; <xref ref-type="bibr" rid="bib32">Grajales-Reyes et al., 2015</xref>; <xref ref-type="bibr" rid="bib57">Murakami et al., 2021</xref>; <xref ref-type="bibr" rid="bib72">Schönheit et al., 2013</xref>) are located within convergent CTCF binding sites upstream and downstream of the <italic>Irf8</italic> gene (<xref ref-type="fig" rid="fig1">Figure 1B</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). There are also multiple interactions within this region without convergent CTCF binding sites, suggesting interactions with <italic>Irf8</italic> promoter in a CTCF independent manner, such as by TF binding, active histone modifications and gene transcription (<xref ref-type="fig" rid="fig1">Figure 1B</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>; <xref ref-type="bibr" rid="bib63">Owens et al., 2022</xref>).</p><p>Surprisingly, in pDC H3K27ac at the <italic>lncIrf8</italic> promoter is high, but this locus shows less interactions with the <italic>Irf8</italic> promoter in pDC compared to CDP, cDC1 and cDC2 (<xref ref-type="fig" rid="fig1">Figure 1C</xref> and <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2C</xref>). In addition, in pDC the IRF8 protein occupancy at the <italic>lncIrf8</italic> promoter is low and much higher in cDC (<xref ref-type="fig" rid="fig1">Figure 1A</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>; <xref ref-type="bibr" rid="bib22">Durai et al., 2019</xref>; <xref ref-type="bibr" rid="bib32">Grajales-Reyes et al., 2015</xref>).</p><p>These observations warrant further studies and we thus proceeded to investigate the <italic>lncIrf8</italic> locus in detail.</p></sec><sec id="s2-2"><title><italic>lncIrf8</italic> promoter KO compromises pDC and cDC1 development</title><p>First, we annotated <italic>lncIrf8</italic>. Our de-novo transcript assembly of RNA-seq data revealed different isoforms of <italic>lncIrf8</italic>, with the most prominent isoform comprising exon 2 and 3 (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, <xref ref-type="fig" rid="fig2">Figure 2A</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Additionally, 3' end and 5' end RACE PCR confirmed the anatomy of this <italic>lncIrf8</italic> isoform: two exons, one intron, and a polyA tail (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). As expected <italic>lncIrf8</italic> is not conserved across species (data not shown), which is in line with the general characteristics of lncRNA. Then second, we deleted 300 bp in the <italic>lncIrf8</italic> promoter by CRISPR/Cas9 editing in conditionally immortalized HoxB8 MPP (<xref ref-type="fig" rid="fig2">Figure 2A</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A–D</xref>). The <italic>lncIrf8</italic> promoter is located in the <italic>Irf8</italic> +32 kb enhancer region and is in close proximity to the cDC1 specific +32 kb enhancer (<xref ref-type="bibr" rid="bib22">Durai et al., 2019</xref>; <xref ref-type="fig" rid="fig2">Figure 2A</xref> and <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). The 300 bp deletion comprises the H3K4me3 promoter mark and is confined to open chromatin identified by ATAC-seq and positioned in the valley of the H3K27ac mark (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Additionally, it contains binding sites for IRF8, PU.1, and BATF3 TF, which are important for DC development (<xref ref-type="fig" rid="fig2">Figure 2A</xref> and <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2B</xref>).</p><p>Generation of a precise deletion requires clonal cell populations, which is hardly achieved in somatic cells due to their limited lifespan. Therefore, we developed a Mx-Cas9-GFP system of conditionally immortalized HoxB8 MPP, which upon differentiation faithfully recapitulate DC development (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A, B</xref>; <xref ref-type="bibr" rid="bib88">Xu et al., 2022</xref>). HoxB8 MPP were obtained from bone marrow of Mx-Cas9-GFP mice by infection with the estrogen (E2) inducible HoxB8-ER. These HoxB9 MPP exhibited an extended lifespan and robust clonogenic potential and differentiated into all DC subsets in vitro and in vivo (<xref ref-type="bibr" rid="bib88">Xu et al., 2022</xref>). Infection of gRNA targeting <italic>lncIrf8</italic> promoter in Mx-Cas9-GFP HoxB8 MPP and induction of Cas9 by interferon generated single-cell <italic>lncIrf8</italic> promoter KO clones. Five out of 71 single-cell colonies with homozygous deletions were further studied and subjected to DC differentiation (<xref ref-type="fig" rid="fig2">Figure 2C–E</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C–G</xref> and <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref>).</p><p><italic>lncIrf8</italic> promoter KO abolished <italic>lncIrf8</italic> expression during DC differentiation compared to control without deletion (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Surprisingly, <italic>Irf8</italic> expression was also severely compromised, which points to a cross-talk of the <italic>lncIrf8</italic> promoter element with the <italic>Irf8</italic> promoter. To determine whether <italic>lncIrf8</italic> promoter KO also impacts DC subsets, CD11c<sup>+</sup> DC, pDC and cDC subsets cDC1 and cDC2 were analyzed (<xref ref-type="fig" rid="fig2">Figure 2C</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E–G</xref>). Frequencies of pDC and cDC1 were severely reduced, while cDC2 were unaffected (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Accordingly, <italic>lncIrf8</italic> promoter KO cultures contained mainly cDC2 and some undifferentiated cells and were more homogenous compared to control without deletion, which contain multiple DC subsets (<xref ref-type="fig" rid="fig2">Figure 2C and D</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1F, G</xref>).</p><p><italic>lncIrf8</italic> promoter KO affected also the differentiation propensity of progenitors upon E2 withdrawal from MPP/CDP culture (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2A</xref> and <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3</xref>). <italic>lncIrf8</italic> promoter KO showed a marked increase in strongly adhesive cells compared to control (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3B</xref>). <italic>lncIrf8</italic> promoter KO cultures had higher frequencies of Gr1<sup>+</sup> monocytes (<xref ref-type="fig" rid="fig2">Figure 2E</xref>, <xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3I, J</xref>) and lower frequencies of all DC subsets CD11c<sup>+</sup> DC, pDC, cDC1, and cDC2 (<xref ref-type="fig" rid="fig2s3">Figure 2—figure supplement 3C–G</xref>) compared to control without deletion.</p><p>The <italic>lncIrf8</italic> promoter element is in close proximity to the cDC1 specific +32 kb enhancer previously described in mice by <xref ref-type="bibr" rid="bib22">Durai et al., 2019</xref> and thus we generated the cDC1 specific +32 kb enhancer KO following the same procedure as for the <italic>lncIrf8</italic> promoter KO. Five out of 165 single-cell clones with homozygous deletions of cDC1 +32 kb enhancer were subjected to DC differentiation and further analyzed (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4</xref>). Similar to <italic>lncIrf8</italic> promoter KO, cDC1 specific +32 kb enhancer KO abolished <italic>lncIrf8</italic> expression and also decreased <italic>Irf8</italic> expression during DC differentiation (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4D</xref>). The cDC1 +32 kb enhancer KO also compromised the frequency of cDC1 in Flt3L directed DC differentiation, while cDC2 were unaffected (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4E</xref>). Frequencies of pDC were also compromised at day 7; however, this was not statistically significant. These observations are in line with previous studies in mice that cDC1 +32 kb enhancer KO compromised cDC1 differentiation and left pDC and cDC2 largely unaffected (<xref ref-type="bibr" rid="bib22">Durai et al., 2019</xref>; <xref ref-type="bibr" rid="bib57">Murakami et al., 2021</xref>). In addition, cDC1 +32 kb enhancer KO cultures had higher frequencies of Gr1<sup>+</sup> monocytes upon spontaneous DC differentiation by withdrawal of E2 (<xref ref-type="fig" rid="fig2s4">Figure 2—figure supplement 4F</xref>) and thus showed a similar phenotype as the <italic>lncIrf8</italic> promoter KO upon spontaneous DC differentiation (<xref ref-type="fig" rid="fig2">Figure 2E</xref>).</p><p>Given the novel phenotype of the <italic>lncIrf8</italic> promoter KO, we proceeded to investigate the impact of the <italic>lncIrf8</italic> promoter KO on DC differentiation in vivo in mice. We transplanted CD45.2 <italic>lncIrf8</italic> promoter KO and CD45.2 control HoxB8 MPP into irradiated CD45.1 recipient mice (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). DC in bone marrow and spleen were analyzed by flow cytometry on day 7 and 14 after cell transplantation (<xref ref-type="fig" rid="fig3">Figure 3</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A, B</xref>). In bone marrow, <italic>lncIrf8</italic> promoter KO cells mostly differentiated into Gr1<sup>+</sup> monocytes, and lower frequencies of all DC subsets were observed on day 7 for <italic>lncIrf8</italic> promoter KO cells compared to control (<xref ref-type="fig" rid="fig3">Figure 3A–F</xref>). In spleen, frequencies of cell populations from <italic>lncIrf8</italic> promoter KO and control were similar to bone marrow, including lower frequencies of all DC subsets for <italic>lncIrf8</italic> promoter KO (<xref ref-type="fig" rid="fig3">Figure 3G–L</xref>). CD45.2 donor HoxB8 cells were largely lost at day 14 after cell transplantation (<xref ref-type="fig" rid="fig3">Figure 3B–F</xref> and <xref ref-type="fig" rid="fig3">Figure 3H–L</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title><italic>lncIrf8</italic> promoter KO comprises pDC and cDC1 development in vivo upon cell transplantation.</title><p>(<bold>A</bold>) Representative flow cytometry analysis of CD45.2 <italic>lncIrf8</italic> promoter KO and control HoxB8 MPP in BM at day 7 after cell transplantation (for details see <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A, B</xref>). Donor cell populations were gated from 7-AAD<sup>-</sup> CD45.2<sup>+</sup> Lin<sup>-</sup> cells and Gr1<sup>+</sup> monocytes, pDC, cDC1 and cDC2 are shown. (<bold>B–F</bold>) Quantification of Gr1<sup>+</sup> monocytes, MHCII<sup>+</sup> CD11c<sup>+</sup> DC, pDC, cDC1, and cDC2 of living single cells in BM on day 7 and 14 after cell transplantation (n=3–4). (<bold>G</bold>) Representative flow cytometry analysis of <italic>lncIrf8</italic> promoter KO and control HoxB8 MPP in spleen at day 7 after cell transplantation. Gating was as in panel (<bold>A</bold>). (<bold>H–L</bold>) Quantification of Gr1<sup>+</sup> monocytes, MHCII<sup>+</sup> CD11c<sup>+</sup> DC, pDC, cDC1 and cDC2 on day 7 and 14 after cell transplantation (n=3–4). Data represent mean ± SD from 3 to 4 mice. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, multiple t-tests. Data that have no difference (p&gt;0.05) are not labeled.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83342-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Cell transplantation of HoxB8 MPP.</title><p>(<bold>A</bold>) Workflow of HoxB8 MPP transplantation. CD45.1 recipient mice were sublethal irradiated and injected with CD45.2 <italic>lncIrf8</italic> promoter KO and control HoxB8 MPP. Seven and 14 days after cell transplantation, mice were sacrificed and cells from bone marrow and spleen were isolated and subjected to flow cytometry analysis for DC subsets. (<bold>B</bold>) Gating strategy for CD45.2 DC subsets following transplantation of CD45.2 <italic>lncIrf8</italic> promoter KO HoxB8 MPP into CD45.1 recipient mice. 7-AAD<sup>-</sup> CD45.2<sup>+</sup> lineage<sup>-</sup> donor cells were gated on Gr1<sup>+</sup> monocytes, Gr1<sup>-</sup> Siglec H<sup>+</sup> pDC, and Gr1<sup>-</sup>Siglec H<sup>-</sup> CD11c<sup>+</sup> MHCII<sup>+</sup> DC, and further on cDC1 and cDC2 subsets. cDC1 are Gr1<sup>-</sup> Siglec H<sup>-</sup> MHCII<sup>+</sup> CD11c<sup>+</sup> CD11b<sup>low/-</sup> XCR1<sup>+</sup> and cDC2 are Gr1<sup>-</sup> Siglec H<sup>-</sup> MHCII<sup>+</sup> CD11c<sup>+</sup> CD11b<sup>+</sup> XCR1<sup>-</sup>. The lineage cocktail (Lin) was: Ter119, CD19, CD3e, NK1.1, F4/80.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83342-fig3-figsupp1-v2.tif"/></fig></fig-group><p>Thus, <italic>lncIrf8</italic> promoter KO compromised pDC and cDC1 development both in vitro and in vivo.</p></sec><sec id="s2-3"><title><italic>lncIrf8</italic> acts as an indicator of <italic>Irf8</italic> +32 kb enhancer activity in pDC</title><p>Knockout of <italic>lncIrf8</italic> promoter and thus abolishment of <italic>lncIrf8</italic> expression severely diminished pDC and cDC1 development in vitro and in vivo. The <italic>lncIrf8</italic> promoter is located within <italic>Irf8</italic> +32 kb enhancer (<xref ref-type="bibr" rid="bib22">Durai et al., 2019</xref>) and thus it was important to determine whether <italic>lncIrf8</italic> itself plays a role in regulating pDC and cDC1 development. To address this question, we (i) overexpressed <italic>lncIrf8</italic> in wild-type MPP and (ii) re-expressed <italic>lncIrf8</italic> in <italic>lncIrf8</italic> promoter KO MPP and monitored its impact on DC development (<xref ref-type="fig" rid="fig4">Figure 4</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title><italic>lncIrf8</italic> overexpression leaves pDC and cDC1 development unaffected.</title><p>(<bold>A and B</bold>) Schematic representation of <italic>lncIrf8</italic> overexpression in WT HoxB8 MPP and of p<italic>lncIrf8</italic>-pA (<italic>lncIrf8</italic> overexpression) and pGFP-pA (control) plasmids. A polyA signal AATAAA for transcription termination was inserted at the 3’ end of <italic>lncIrf8</italic> and GFP. (<bold>C</bold>) Gene expression of <italic>lncIrf8</italic> and <italic>Irf8</italic> in p<italic>lncIrf8</italic>-pA and pGFP-pA HoxB8 MPP on day 0, 3, 5, and 7 of Flt3L directed DC differentiation (n=4–5). Gene expression was by RT-qPCR and normalized to <italic>GAPDH</italic>. (<bold>D</bold>) Representative flow cytometry of DC subsets at day 5 and 9 of Flt3L directed DC differentiation of p<italic>lncIrf8</italic>-pA and pGFP-pA HoxB8 MPP. Quantification of pDC and cDC1 of living single cells on Flt3L directed DC differentiation day 0, 3, 5, 7, and 9 (n=5) is shown. Gating for pDC and cDC1 was as in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref>. (<bold>E</bold>) Heatmap representation of DC subsets of panel (<bold>D</bold>) at day 0, 3, 5, 7, and 9 of DC differentiation. Red, high frequency; white, intermediate frequency and blue, low frequency. Data represent mean ± SD of at least three independent experiments with different HoxB8 MPP clones of p<italic>lncIrf8</italic>-pA and pGFP-pA. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, multiple t-tests. Data that have no difference (p&gt;0.05) are not labeled.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83342-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title><italic>lncIrf8</italic> overexpression and rescue left DC differentiation unaffected.</title><p>(<bold>A</bold>) WT HoxB8 MPP were infected with p<italic>lncIrf8</italic>-pA (<italic>lncIrf8</italic> overexpression) and pGFP-pA (control) lentiviral particles, followed by limiting dilution to obtain single cell colonies. HoxB8 MPP clones were screened by genomic PCR and the positive colonies were subjected to DC differentiation. (<bold>B–D</bold>) Quantification of CD11c<sup>+</sup> DC, all cDC and cDC2 of living single cells in p<italic>lncIrf8</italic>-pA and pGFP-pA HoxB8 MPP on day 0, 3, 5, 7, and 9 of Flt3L directed DC differentiation (n=5). Gating was as in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref>. Data represent mean ± SD of at least three independent experiments with different HoxB8 MPP clones of p<italic>lncIrf8</italic>-pA and pGFP-pA. Data were calculated by multiple t-tests and data that have no difference (p&gt;0.05) are not labeled. (<bold>E</bold>) Schematic representation of <italic>lncIrf8</italic> rescue in <italic>lncIrf8</italic> promoter KO HoxB8 MPP (bulk). (<bold>F</bold>) Gene expression of <italic>lncIrf8</italic> in <italic>lncIrf8</italic> promoter KO and KO rescue HoxB8 MPP. Gene expression was by RT-qPCR and normalized to <italic>GAPDH</italic>. Data represent mean ± SD of at least three independent experiments and were calculated by unpaired t test. *p&lt;0.05. (<bold>G</bold>) Representative flow cytometry analysis of DC subsets pDC, cDC1 and cDC2 at day 5 and 9 of Flt3L directed DC differentiation of <italic>lncIrf8</italic> promoter KO rescue and control (KO). (<bold>H</bold>) DC subsets pDC, all cDC, cDC1 and cDC2 were calculated in percent of living single cells in <italic>lncIrf8</italic> promoter KO and KO rescue on day 0, 3, 5, 7, and 9 of Flt3L directed DC differentiation and data are represented in heat map format; n=3–4 from at least three independent experiments. Red, high frequency; white, intermediate frequency and blue, low frequency.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83342-fig4-figsupp1-v2.tif"/></fig></fig-group><p><italic>lncIrf8</italic> cDNA was cloned into a polyA lentivirus vector. An ‘AATAAA’ stop signal (<xref ref-type="bibr" rid="bib3">Alvarez-Dominguez et al., 2015</xref>) was inserted at the 3’ end of <italic>lncIrf8</italic> to avoid longer transcripts than <italic>lncIrf8</italic> (p<italic>lncIrf8</italic>-pA, <xref ref-type="fig" rid="fig4">Figure 4B</xref>). The respective pGFP-pA vector was used as control. <italic>lncIrf8</italic> overexpressing single-cell clones were generated by limiting dilution (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>), expanded and subjected to DC differentiation. As expected <italic>lncIrf8</italic> expression was markedly increased in p<italic>lncIrf8</italic>-pA infected cells compared to control, while there were no significant differences in <italic>Irf8</italic> expression between the two groups during DC differentiation (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). Further, there were no differences in the frequencies of pDC, cDC1, and cDC2 between p<italic>lncIrf8</italic>-pA infected cells and controls (<xref ref-type="fig" rid="fig4">Figure 4D and E</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B–D</xref>), indicating that <italic>lncIrf8</italic> overexpression has no effect on <italic>Irf8</italic> expression and DC differentiation.</p><p>To further extend this observation we performed a <italic>lncIrf8</italic> rescue in <italic>lncIrf8</italic> promoter KO MPP. <italic>lncIrf8</italic> was re-expressed in <italic>lncIrf8</italic> promoter KO MPP by lentiviral vector and cells were subjected to DC differentiation (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1E</xref>). <italic>lncIrf8</italic> RNA was effectively expressed and cells differentiated in response to Flt3L (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1F</xref>). Yet frequencies of pDC and cDC1 were very low to absent and not rescued by <italic>lncIrf8</italic> expression (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1G, H</xref>).</p><p>In a nutshell, <italic>lncIrf8</italic> overexpression and rescue had no effects on pDC and cDC1 development. This strongly suggests that <italic>lncIrf8</italic> has no activity on its own in DC differentiation but rather acts as an indicator for the activation state of sequences within the <italic>Irf8</italic> +32 kb enhancer. In addition, the <italic>lncIrf8</italic> promoter comprises a sequence element with impact on pDC and cDC1 development.</p></sec><sec id="s2-4"><title>Activation of <italic>lncIrf8</italic> promoter promotes cDC1 development</title><p>Next, we proceeded to study the impact of the sequence element within <italic>lncIrf8</italic> promoter on <italic>Irf8</italic> expression and DC differentiation using CRISPR activation by dCas9-VP64 (<xref ref-type="fig" rid="fig5">Figure 5A</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). dCas9-VP64 is a mutated Cas9 deficient in nuclease activity, which is fused to the VP64 effector domain and confers gene activation. Targeting of dCas9-VP64 to the <italic>lncIrf8</italic> promoter was achieved with specific gRNAs (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1I</xref>). We also included targeting dCas9-VP64 to the <italic>Irf8</italic> promoter to study the interplay with the <italic>lncIrf8</italic> promoter. FACS sorted HoxB8 MPP expressing dCas9-VP64 and gRNA were subjected to DC differentiation and analyzed for <italic>lncIrf8</italic> and <italic>Irf8</italic> expression and DC subset composition (<xref ref-type="fig" rid="fig5">Figure 5B–E</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A–E</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Activation of <italic>lncIrf8</italic> promoter promotes cDC1 development.</title><p>(<bold>A</bold>) Schematic representation of <italic>lncIrf8</italic> and <italic>Irf8</italic> promoter activation (top and middle, respectively) by CRISPR activation with dCas9-VP64. gRNAs were positioned upstream of <italic>lncIrf8</italic> and <italic>Irf8</italic> TSS for gene activation. dCas9-VP64 cells with non-targeting gRNA were used as control (bottom). Green and purple wavy lines represent <italic>Irf8</italic> and <italic>lncIrf8</italic> RNA, respectively. The number of wavy lines indicates levels of gene transcription determined by RT-qPCR in (<bold>C</bold>). Different length of blue arrows represents the frequencies of pDC and cDC1 according to panel B, D and E. Nc, No change; Ctrl, Control. (<bold>B</bold>) Representative flow cytometry analysis of CRISPR activation targeting the <italic>lncIrf8</italic> and <italic>Irf8</italic> promoters at day 7 and 9 of Flt3L directed DC differentiation. Two non-targeting gRNAs were used as controls and one representative non-targeting gRNA is shown (Non-targeting-VP64). Top row, CD11b<sup>+</sup> B220<sup>-</sup> cDC and CD11b<sup>-</sup> B220<sup>+</sup> pDC at day 7 of Flt3L directed DC differentiation; bottom row, CD11b<sup>low/-</sup> XCR1<sup>+</sup> cDC1 and CD11b<sup>+</sup> XCR1<sup>-</sup> cDC2 at day 9 of DC differentiation. For gating strategy see <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>. (<bold>C</bold>) Gene expression of <italic>lncIrf8</italic> and <italic>Irf8</italic> in <italic>lncIrf8</italic>-VP64, <italic>Irf8</italic>-VP64 and non-targeting-VP64 HoxB8 MPP on day 0, 5, 7, and 9 of Flt3L directed DC differentiation (n=3). Gene expression analysis was by RT-qPCR and data are normalized to <italic>GAPDH</italic>. Data represent mean ± SD of three independent experiments. *p&lt;0.05, **p&lt;0.01, ****p&lt;0.0001, two-way ANOVA, Tukey’s multiple comparisons test. Data that have no difference (p&gt;0.05) are not labeled. (<bold>D and E</bold>) Quantification of pDC and cDC1 in percent of living single cells as in panel (<bold>B</bold>) on various days of Flt3L directed DC differentiation (n=3). Non-targeting-VP64 refers to both non-targeting-VP64 controls (n=6). Data represent mean ± SD of 3 independent experiments. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001, two-way ANOVA, Tukey’s multiple comparisons test. Data that have no difference (p&gt;0.05) are not labeled.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83342-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>CRISPR/dCas9 mediated gene activation and repression, and gRNA positions.</title><p>(<bold>A</bold>) WT HoxB8 MPP were infected with dCas9-VP64-GFP and KRAB-dCas9-GFP lentiviral vectors followed by 1<sup>st</sup> FACS sorting for GFP<sup>+</sup> cells to obtain dCas9-VP64-GFP and dCas9-KRAB-GFP HoxB8 MPP. Gene targeting of dCas9-VP64 and dCas9-KRAB was achieved by infection of MPP with specific gRNA vectors and 2<sup>nd</sup> FACS sorting for GFP<sup>+</sup> RFP<sup>+</sup> cells. (<bold>B</bold>) Gating strategy for DC subsets in CRISPR/dCas9 HoxB8 MPP upon DC differentiation. DC subsets were gated from 7-AAD<sup>-</sup> CD11c<sup>+</sup> cells, and further gated on all cDC, cDC1, cDC2 and pDC as in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1E</xref>. (<bold>C–H</bold>) Quantification of CD11c<sup>+</sup> cells, all cDC, and cDC2 of panel (<bold>B</bold>) in percent of living single cells in dCas9-VP64 cells and dCas9-KRAB cells on day 0, 3, 5, 7, and 9 of Flt3L directed DC differentiation (n=3). Non-targeting-VP64 and Non-targeting-KRAB refers to non-targeting-VP64 and KRAB controls, respectively (n=6). Data represent mean ± SD of 3 independent experiments. *<italic>P</italic>&lt;0.05, **<italic>P</italic>&lt;0.01, ***<italic>P</italic>&lt;0.001, ****<italic>P</italic>&lt;0.0001, two-way ANOVA, Tukey’s multiple comparisons test. Data that have no difference (<italic>P</italic>&gt;0.05) are not labeled. (<bold>I</bold>) Gene expression and epigenetic landscape of <italic>Irf8</italic> gene and its flanking regions in MPP, CDP, pDC, all cDC, cDC1 and cDC2 are depicted as in <xref ref-type="fig" rid="fig1">Figure 1A</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>. <italic>Irf8</italic> +27 kb and +32 kb enhancer (purple line and box, respectively), transcription start sites of <italic>Irf8</italic> (<italic>Irf8</italic>-TSS) and <italic>lncIrf8</italic> (<italic>lncIrf8</italic>-TSS) are indicated. Bottom, positions of gRNAs used in this study: gRNA1 and gRNA2, <italic>lncIrf8</italic> promoter KO by the CRISPR/Cas9 system; <italic>Irf8</italic>-VP64 and KRAB gRNAs for activation and repression of <italic>Irf8</italic> promoter, respectively; <italic>lncIrf8</italic>-VP64 and KRAB gRNAs for activation and repression of <italic>lncIrf8</italic> promoter, respectively.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83342-fig5-figsupp1-v2.tif"/></fig></fig-group><p>Activation of the <italic>lncIrf8</italic> promoter by dCas9-VP64 caused a massive increase of <italic>lncIrf8</italic> expression at DC differentiation day 0 (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). The activation of the <italic>lncIrf8</italic> promoter led also to <italic>Irf8</italic> upregulations at DC differentiation day 5, 7, and 9 compared to non-targeting control (<xref ref-type="fig" rid="fig5">Figure 5A and C</xref>). This demonstrates the positive impact of the <italic>lncIrf8</italic> promoter element on <italic>Irf8</italic> expression during DC differentiation and is in accord with the physical interaction of <italic>lncIrf8</italic> and <italic>Irf8</italic> promoters by Capture-C (<xref ref-type="fig" rid="fig1">Figure 1B</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>).</p><p>Intriguingly, in <italic>lncIrf8</italic>-VP64 cells <italic>lncIrf8</italic> expression was downregulated at DC differentiation day 5, 7 and 9, while <italic>Irf8</italic> expression was upregulated (<xref ref-type="fig" rid="fig5">Figure 5A and C</xref>). This indicates a repressive effect of IRF8 on <italic>lncIrf8</italic> promoter and is in accord with IRF8 binding to the <italic>lncIrf8</italic> region by ChIP-seq (<xref ref-type="fig" rid="fig1">Figure 1</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). This observation suggests a negative feedback loop of IRF8 on the <italic>lncIrf8</italic> promoter during DC differentiation (<xref ref-type="fig" rid="fig5">Figure 5A and C</xref>).</p><p>Activation of <italic>Irf8</italic> promoter by dCas9-VP64 increased <italic>Irf8</italic> expression at DC differentiation day 0, 5, 7, and 9, while expression of <italic>lncIrf8</italic> was unaffected compared to non-targeting control (<xref ref-type="fig" rid="fig5">Figure 5A and C</xref>). As expected <italic>Irf8</italic> promoter activation led to higher pDC frequencies (<xref ref-type="fig" rid="fig5">Figure 5B and D</xref>), and also increased cDC1 frequencies compared to the non-targeting controls (<xref ref-type="fig" rid="fig5">Figure 5B and E</xref>). Importantly, <italic>lncIrf8</italic> promoter activation by dCas9-VP64 also increased cDC1 frequencies and this was particular prominent at day 9 of DC differentiation (<xref ref-type="fig" rid="fig5">Figure 5B and E</xref>). Frequencies of cDC2 were decreased at day 9 and other populations, including pDC, remained unchanged (<xref ref-type="fig" rid="fig5">Figure 5B and D</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1C–E</xref>).</p><p>Taken together our CRISPR activation of the <italic>lncIrf8</italic> and <italic>Irf8</italic> promoters by dCas9-VP64 suggest a negative feedback loop of <italic>Irf8</italic> for pDC and cDC1 development.</p></sec><sec id="s2-5"><title>Negative feedback regulation of <italic>lncIrf8</italic> and <italic>Irf8</italic> promoters controls DC differentiation</title><p>To directly investigate the negative feedback loop of <italic>Irf8</italic> regulation, we repressed <italic>lncIrf8</italic> and <italic>Irf8</italic> promoters by targeted repression with dCas9-KRAB and analyzed the DC subsets during DC differentiation (<xref ref-type="fig" rid="fig6">Figure 6A–F</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A, B, F-H</xref>). dCas9-KRAB is a nuclease deficient Cas9 fused to the KRAB effector domain, which confers gene repression when positioned with specific gRNA (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1I</xref>).</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Repression of <italic>lncIrf8</italic> promoter compromises pDC and cDC1 development.</title><p>(<bold>A</bold>) Schematic representation of <italic>lncIrf8</italic> and <italic>Irf8</italic> promoter repression (top and middle, respectively) by CRISPR interference with dCas9-KRAB. gRNAs were positioned downstream of <italic>lncIrf8</italic> and <italic>Irf8</italic> TSS to block gene transcription. dCas9-KRAB cells with non-targeting gRNA were used as control (bottom). Green and purple wavy lines represent <italic>Irf8</italic> and <italic>lncIrf8</italic> RNA, respectively. The number of wavy lines indicates levels of gene transcription determined by RT-qPCR in (<bold>C</bold>). (<bold>B</bold>) Representative flow cytometry analysis of CRISPR interference targeting the <italic>lncIrf8</italic> and <italic>Irf8</italic> promoters at day 5 and 7 of Flt3L directed DC differentiation. Two non-targeting gRNAs were used as controls and one representative non-targeting gRNA is shown (Non-targeting-KRAB). cDC and pDC at day 5 and cDC1 and cDC2 at day 7 of Flt3L directed DC differentiation are shown similar to <xref ref-type="fig" rid="fig5">Figure 5B</xref>. (<bold>C</bold>) Gene expression of <italic>lncIrf8</italic> and <italic>Irf8</italic> in <italic>lncIrf8</italic>-KRAB, <italic>Irf8</italic>-KRAB and non-targeting-KRAB HoxB8 MPP on day 0, 3, 5, and 7 of Flt3L directed DC differentiation (n=3). Gene expression analysis was by RT-qPCR and data are normalized to <italic>GAPDH</italic>. Data represent mean ± SD of three independent experiments. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001, two-way ANOVA, Tukey’s multiple comparisons test. Data that have no difference (p&gt;0.05) are not labeled. (<bold>D and E</bold>) Quantification of pDC and cDC1 in percent of living single cells as in panel (<bold>B</bold>) on various days of Flt3L directed DC differentiation (n=3). Non-targeting-KRAB refers to both non-targeting-KRAB controls (n=6). Data represent mean ± SD of three independent experiments. *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001, two-way ANOVA, Tukey’s multiple comparisons test. Data that have no difference (p&gt;0.05) are not labeled. (<bold>F</bold>) Representative phase-contrast microscopy image of <italic>lncIrf8</italic>-KRAB, <italic>Irf8</italic>-KRAB and non-targeting-KRAB on day 7 of Flt3L directed DC differentiation. Scale bar: 200 μm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83342-fig6-v2.tif"/></fig><p>Targeted repression of the <italic>Irf8</italic> promoter decreased <italic>Irf8</italic> expression as expected but massively increased <italic>lncIrf8</italic> expression compared to non-targeting control (<xref ref-type="fig" rid="fig6">Figure 6A and C</xref>). This is very much in line with <italic>Irf8</italic> impacting <italic>lncIrf8</italic> expression by a negative feedback loop. Positioning the dCas9-KRAB repressor in the Inc<italic>IRF8</italic> promoter led to downregulation of both <italic>Irf8</italic> and <italic>lncIrf8</italic> expression, which confirms the <italic>lncIrf8</italic> promoter element acting on the <italic>Irf8</italic> promoter (<xref ref-type="fig" rid="fig6">Figure 6A and C</xref>).</p><p>Interestingly, targeted repression of the <italic>Irf8</italic> promoter severely compromised development of all DC subsets, including pDC, cDC1, and cDC2, compared to non-targeting controls and yielded CD11c<sup>+</sup> cells with progenitor-like spherical morphology (<xref ref-type="fig" rid="fig6">Figure 6B and D–F</xref>, <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1F–H</xref>). This reemphasizes the pivotal role of IRF8 for DC development known from studies on <italic>Irf8</italic> knockout mice (<xref ref-type="bibr" rid="bib57">Murakami et al., 2021</xref>; <xref ref-type="bibr" rid="bib71">Schiavoni et al., 2002</xref>; <xref ref-type="bibr" rid="bib74">Sichien et al., 2016</xref>; <xref ref-type="bibr" rid="bib82">Tsujimura et al., 2003</xref>). In addition, targeted repression of the <italic>lncIrf8</italic> promoter (<italic>lncIrf8</italic>-KRAB) also compromised pDC and cDC1 development (<xref ref-type="fig" rid="fig6">Figure 6B, D and E</xref>). This result is very similar to the <italic>lncIrf8</italic> promoter KO analyzed above (<xref ref-type="fig" rid="fig2">Figure 2A–C</xref>).</p><p>All these findings support a model of <italic>Irf8</italic> regulating its own expression by a negative feedback loop acting on the <italic>Irf8</italic> +32 kb enhancer to limit <italic>Irf8</italic> autoactivation (<xref ref-type="fig" rid="fig7">Figure 7</xref>). This regulatory <italic>Irf8</italic> +32 kb enhancer element is marked by <italic>lncIrf8. Irf8</italic> expression starts in CDP and further increases in pDC and cDC1, with particularly high expression in pDC (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, <xref ref-type="fig" rid="fig7">Figure 7A and B</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). The increase in <italic>Irf8</italic> expression is proposed to be due to an increase in the interactions of the <italic>Irf8</italic> promoter with upstream and downstream sequences. In pDC, the <italic>Irf8</italic> promoter-enhancer interactions are more with upstream chromatin regions (<xref ref-type="fig" rid="fig1">Figure 1C</xref> and <xref ref-type="fig" rid="fig7">Figure 7A</xref>), which relates to high <italic>Irf8</italic> expression. In cDC1, the <italic>Irf8</italic> promoter interactions are stronger with the regions downstream of <italic>Irf8</italic> (<xref ref-type="fig" rid="fig1">Figure 1C</xref> and <xref ref-type="fig" rid="fig7">Figure 7A</xref>) and the <italic>Irf8</italic> +32 kb enhancer marked by <italic>lncIrf8</italic> confers transcriptional repression.</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Negative feedback loop of <italic>Irf8</italic> through +32 kb enhancer governs DC differentiation.</title><p>(<bold>A</bold>) Schematic representation of <italic>Irf8</italic> gene regulation during DC differentiation. <italic>Irf8</italic> transcription is induced at the CDP stage by its flanking enhancers, including the +32 kb enhancer, and is further increased in pDC and cDC1 (green wavy lines; the number of wavy lines indicates levels of gene transcription as in <xref ref-type="fig" rid="fig5">Figure 5A</xref> and <xref ref-type="fig" rid="fig6">Figure 6A</xref>). The increase in <italic>Irf8</italic> expression is due to an increase in the interactions of the <italic>Irf8</italic> promoter with upstream and downstream sequences. <italic>Irf8</italic> promoter interactions with upstream sequences are stronger in pDC and <italic>Irf8</italic> promoter interactions with downstream sequences are stronger in cDC1. In pDC the +32 kb enhancer marked by <italic>lncIrf8</italic> is less repressed by IRF8 repressor complex compared to cDC1, resulting in particularly high <italic>Irf8</italic> expression and <italic>lncIrf8</italic> transcription in pDC (purple wavy lines). This negative feedback inhibition of IRF8 on the +32 kb enhancer allows <italic>Irf8</italic> to regulate its own expression and thus DC differentiation. (<bold>B</bold>) Negative feedback regulation of <italic>Irf8</italic> through the +32 kb enhancer in cDC1 and pDC specification as described in panel (<bold>A</bold>). The RNA-seq and IRF8 ChIP-seq data are shown as in <xref ref-type="fig" rid="fig1">Figure 1A</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref> and <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref>. (<bold>C</bold>) Recapitulating <italic>Irf8</italic> and <italic>lncIrf8</italic> transcription by repression and activation of the <italic>Irf8</italic> +32 kb enhancer in HoxB8 MPP by targeted dCas9-KRAB and dCas9-VP64, respectively. Green and purple wavy lines represent gene expression as described in <xref ref-type="fig" rid="fig5">Figure 5A</xref> and <xref ref-type="fig" rid="fig6">Figure 6A</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83342-fig7-v2.tif"/></fig><p>In our model, we propose an IRF8 repressor complex that differentially acts on the <italic>Irf8</italic> +32 kb enhancer element in a DC subset specific manner to limit <italic>Irf8</italic> autoactivation. In cDC1 the +32 kb enhancer is repressed by the IRF8 repressor complex through negative feedback inhibition (prominent IRF8 binding in cDC by ChIP-seq; <xref ref-type="fig" rid="fig7">Figure 7A and B</xref>), which limits <italic>Irf8</italic> autoactivation and expression. Conversely, in pDC there is less IRF8 repressor complex binding to the +32 kb enhancer, which results in high <italic>Irf8</italic> and <italic>lncIrf8</italic> transcription (<xref ref-type="fig" rid="fig7">Figure 7A and B</xref>). Recapitulating the IRF8 repressor complex with dCas9-KRAB and targeting <italic>lncIrf8</italic> promoter in the +32 kb enhancer reduced <italic>Irf8</italic> expression (<xref ref-type="fig" rid="fig7">Figure 7C</xref>). Conversely, activation of the +32 kb enhancer boosted <italic>lncIrf8</italic> and <italic>Irf8</italic> expression (<xref ref-type="fig" rid="fig7">Figure 7C</xref>). Thus, an intricate feedback loop of IRF8 on the +32 kb enhancer orchestrates <italic>Irf8</italic> expression and thus DC differentiation.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Hematopoiesis is a particularly well studied stem cell system and therefore provides an excellent model for studying TF in lineage commitment and cell differentiation, and the molecular principles involved (<xref ref-type="bibr" rid="bib8">Belz and Nutt, 2012</xref>; <xref ref-type="bibr" rid="bib30">Graf and Enver, 2009</xref>; <xref ref-type="bibr" rid="bib48">Laurenti and Göttgens, 2018</xref>; <xref ref-type="bibr" rid="bib59">Nutt and Chopin, 2020</xref>). This work revealed a previously unrecognized negative feedback loop of <italic>Irf8</italic> in DC differentiation and shows how <italic>Irf8</italic> autoactivation is controlled and ultimately limited. IRF8 is crucial for DC lineage specification both in humans and mice (<xref ref-type="bibr" rid="bib4">Anderson et al., 2021</xref>; <xref ref-type="bibr" rid="bib8">Belz and Nutt, 2012</xref>; <xref ref-type="bibr" rid="bib10">Cabeza-Cabrerizo et al., 2021</xref>; <xref ref-type="bibr" rid="bib16">Cytlak et al., 2020</xref>; <xref ref-type="bibr" rid="bib43">Kurotaki et al., 2019</xref>; <xref ref-type="bibr" rid="bib59">Nutt and Chopin, 2020</xref>). <italic>Irf8</italic> is upregulated by autoactivation via the +32 kb enhancer (<xref ref-type="bibr" rid="bib32">Grajales-Reyes et al., 2015</xref>; <xref ref-type="bibr" rid="bib51">Lin et al., 2015</xref>). However, how <italic>Irf8</italic> expression is controlled at late stages of DC differentiation and eventually limited is not known. Here we demonstrate that <italic>Irf8</italic> expression is limited by a negative feedback loop via a sequence element marked by <italic>lncIrf8</italic> in the <italic>Irf8</italic> +32 kb enhancer.</p><p><italic>Irf8</italic> expression in hematopoiesis is regulated by its flanking enhancers, which determine lineage specification and DC subset development (<xref ref-type="bibr" rid="bib6">Bagadia et al., 2019</xref>; <xref ref-type="bibr" rid="bib22">Durai et al., 2019</xref>; <xref ref-type="bibr" rid="bib32">Grajales-Reyes et al., 2015</xref>; <xref ref-type="bibr" rid="bib57">Murakami et al., 2021</xref>; <xref ref-type="bibr" rid="bib72">Schönheit et al., 2013</xref>). Frequently, enhancers are identified by ATAC-seq and ChIP-seq (<xref ref-type="bibr" rid="bib22">Durai et al., 2019</xref>; <xref ref-type="bibr" rid="bib57">Murakami et al., 2021</xref>), and here we embarked on a different approach and searched for eRNA and enhancer-associated lncRNA by RNA-seq. We identified a novel pDC-specific lncRNA (<italic>lncIrf8</italic>) transcribed from the <italic>Irf8</italic> +32 kb enhancer. <italic>lncIrf8</italic> itself lacks activities in DC differentiation but a <italic>lncIrf8</italic> promoter element is crucial for pDC and cDC1 development. Upon deletion of this <italic>lncIrf8</italic> promoter element pDC and cDC1 development was severely compromised, demonstrating that this sequence is important for both pDC and cDC1 development.</p><p>We propose a model where <italic>Irf8</italic> expression during DC differentiation is in a first step initiated and activated through flanking enhancers, including the +32 kb enhancer by autoactivation (<xref ref-type="bibr" rid="bib32">Grajales-Reyes et al., 2015</xref>; <xref ref-type="bibr" rid="bib51">Lin et al., 2015</xref>; <xref ref-type="fig" rid="fig7">Figure 7</xref>). In a second step, the <italic>lncIrf8</italic> promoter element confers feedback inhibition, which limits <italic>Irf8</italic> expression. This feedback inhibition is different for pDC and cDC1, both of which express high levels of <italic>Irf8</italic> (<xref ref-type="bibr" rid="bib9">Bornstein et al., 2014</xref>; <xref ref-type="bibr" rid="bib32">Grajales-Reyes et al., 2015</xref>; <xref ref-type="bibr" rid="bib51">Lin et al., 2015</xref>). In cDC1, <italic>Irf8</italic> expression is attributed to <italic>Irf8</italic> autoactivation through the +32 kb enhancer driven by the BATF3-IRF8 complex (<xref ref-type="bibr" rid="bib22">Durai et al., 2019</xref>; <xref ref-type="bibr" rid="bib32">Grajales-Reyes et al., 2015</xref>). In pDC, <italic>Irf8</italic> expression is even higher than in cDC1 (<xref ref-type="bibr" rid="bib9">Bornstein et al., 2014</xref>; <xref ref-type="bibr" rid="bib51">Lin et al., 2015</xref>), which we propose is due to less feedback inhibition at late stages of DC differentiation.</p><p>A candidate for mediating <italic>Irf8</italic> feedback inhibition is IRF8 itself, since IRF8 works as transcriptional activator or repressor, depending on context. IRF8 activator or repressor function depends largely on the heterodimers (or even heterotrimers) with partner TF that bind to specific DNA sequences (<xref ref-type="bibr" rid="bib13">Chang et al., 2018</xref>; <xref ref-type="bibr" rid="bib35">Huang et al., 2016</xref>; <xref ref-type="bibr" rid="bib36">Humblin et al., 2017</xref>; <xref ref-type="bibr" rid="bib79">Tamura et al., 2015</xref>; <xref ref-type="bibr" rid="bib89">Yoon et al., 2014</xref>). Modifications on IRF8 protein, such as phosphorylation and small molecule conjugation, also alter IRF8 activity (<xref ref-type="bibr" rid="bib12">Chang et al., 2012</xref>; <xref ref-type="bibr" rid="bib39">Konieczna et al., 2008</xref>). Potential IRF8 heterodimer partners, to form repressor complexes, are ETV6 or IRF2 (<xref ref-type="bibr" rid="bib35">Huang et al., 2016</xref>; <xref ref-type="bibr" rid="bib36">Humblin et al., 2017</xref>; <xref ref-type="bibr" rid="bib47">Lau et al., 2018</xref>). The IRF8 repressor complex is proposed to bind to the +32 kb enhancer in cDC but not in pDC. This notion is in line with a prominent IRF8 signal at the +32 kb enhancer in cDC, which is absent in pDC (<xref ref-type="bibr" rid="bib22">Durai et al., 2019</xref>; <xref ref-type="bibr" rid="bib32">Grajales-Reyes et al., 2015</xref>; <xref ref-type="fig" rid="fig1">Figure 1A</xref>, <xref ref-type="fig" rid="fig7">Figure 7A and B</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref> and <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A</xref>).</p><p>Further support of our model stems from our CRIPSR activation/interference experiments (<xref ref-type="fig" rid="fig7">Figure 7C</xref>). CRIPSR activation of <italic>Irf8</italic> promoter by dCas9-VP64 mimics <italic>Irf8</italic> up-regulation during DC differentiation and causes an increase in pDC and cDC1 (<xref ref-type="fig" rid="fig5">Figure 5</xref>). CRIPSR interference of <italic>lncIrf8</italic> promoter by dCas9-KRAB recapitulates transcriptional repressor binding to the +32 kb enhancer and causes <italic>Irf8</italic> promoter inhibition (<xref ref-type="fig" rid="fig6">Figure 6</xref>).</p><p>We extended our study to delineate the chromatin conformation of the <italic>Irf8</italic> promoter with flanking sequences by Capture-C. The <italic>Irf8</italic> promoter was found to interact with its flanking enhancers already at the CDP stage and then interactions with specific upstream and downstream sequences are proposed to guide pDC and cDC specification, respectively. This is in accord with previous studies where some of these <italic>Irf8</italic> flanking enhancers were required to maintain high levels of <italic>Irf8</italic> expression (<xref ref-type="bibr" rid="bib4">Anderson et al., 2021</xref>; <xref ref-type="bibr" rid="bib57">Murakami et al., 2021</xref>).</p><p>We demonstrate that deletion of the <italic>lncIrf8</italic> promoter element severely decreased <italic>Irf8</italic> expression and abolished both pDC and cDC1 development in vitro and in vivo upon cell transplantation. These results are very similar to a previous study on cDC1 specific +32 kb enhancer knockout mice, which demonstrates the impact of +32 kb enhancer for cDC1 development in vivo (<xref ref-type="bibr" rid="bib22">Durai et al., 2019</xref>). The <italic>lncIrf8</italic> promoter is located in close proximity to the cDC1 specific +32 kb enhancer and thus can be expected to have overlapping functions. Indeed, deletion of the cDC1 +32 kb enhancer in HoxB8 MPP showed some similar activities on DC differentiation as the deletion of the <italic>lncIrf8</italic> promoter element, including regulation of <italic>lncIrf8</italic> and <italic>Irf8</italic> expression, but mainly affected cDC1 differentiation. These observations indicate that the <italic>lncIrf8</italic> promoter element has further functions compared to the cDC1 specific +32 kb enhancer, for example for pDC development, and the underlying mechanisms warrant further investigation.</p><p>eRNA and enhancer-associated lncRNA are indicative of enhancer activity, however whether the process of their transcription, the transcripts themselves, or both are functionally linked to enhancer activity, remains unclear (<xref ref-type="bibr" rid="bib70">Sartorelli and Lauberth, 2020</xref>; <xref ref-type="bibr" rid="bib77">Statello et al., 2021</xref>). Previous studies revealed that some eRNA and enhancer-associated lncRNA are indeed functionally connected with expression of the respective target genes (<xref ref-type="bibr" rid="bib70">Sartorelli and Lauberth, 2020</xref>; <xref ref-type="bibr" rid="bib77">Statello et al., 2021</xref>). Here, we found no apparent activity of <italic>lncIrf8</italic> on its own in pDC and cDC1 development, as demonstrated by <italic>lncIrf8</italic> overexpression and rescue experiments. <italic>lncIrf8</italic> appears to rather serve as an indicator for <italic>Irf8</italic> +32 kb enhancer activity. However, <italic>lncIrf8</italic> might have additional functions in DC biology, which are not revealed in the current study and remain to be identified.</p><p>In conclusion, by analyzing the gene expression and epigenetic profiles of the <italic>Irf8</italic> locus, we identified an enhancer element marked by <italic>lncIrf8</italic> that regulates <italic>Irf8</italic> and controls DC differentiation through a negative feedback loop. Our results suggest that <italic>Irf8</italic> regulates itself by its flanking enhancers in DC fate determination: First, <italic>Irf8</italic> induces its expression by autoactivation via flanking enhancers, including the <italic>Irf8</italic> +32 kb enhancer, to initiate DC differentiation, and second limits its expression at late stages via the <italic>lncIrf8</italic> promoter element within the same +32 kb enhancer by feedback inhibition. This molecular principle of feedback inhibition is expected to also apply to other TF and cell differentiation systems.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Mice</title><p>Wild type C57BL/6, Mx-Cas9-GFP knock-in mice (<xref ref-type="bibr" rid="bib41">Kühn et al., 1995</xref>; <xref ref-type="bibr" rid="bib65">Platt et al., 2014</xref>; <xref ref-type="bibr" rid="bib88">Xu et al., 2022</xref>), and CD45.1 recipient C57BL/6 mice were used in this study. Mice were kept under specific pathogen-free conditions in the central animal facility of RWTH Aachen University Hospital, Aachen, Germany. All the animal experiments were approved by the local authorities of the German State North Rhine-Westphalia, Germany according to the German animal protection law (reference number: 81–02.04.2018 .A228).</p></sec><sec id="s4-2"><title>Cell culture</title><p>Multipotent progenitors (MPP) were obtained from mouse bone marrow and expanded in vitro with a two-step protocol as described in <xref ref-type="bibr" rid="bib23">Felker et al., 2010</xref>. Conditionally immortalized HoxB8 MPP were generated by retrovirus infection of bone marrow cells from wild-type or Mx-Cas9-GFP knock-in mice with an estrogen (E2) inducible HoxB8 estrogen receptor (ER) fusion gene (HoxB8-ER) (<xref ref-type="bibr" rid="bib66">Redecke et al., 2013</xref>; <xref ref-type="bibr" rid="bib88">Xu et al., 2022</xref>). MPP were grown in RPMI 1640 medium with 10% FCS (Gibco, 10270106), 100 U/ml penicillin/streptomycin, 2 mM L-glutamine and 50 μM β-ME with a four-cytokine cocktail of SCF, Flt3 ligand (Flt3L), IGF-1, and IL-6/soluble IL-6 receptor fusion protein (hyper-IL-6) as before (referred to as MPP growth medium) (<xref ref-type="bibr" rid="bib23">Felker et al., 2010</xref>; <xref ref-type="bibr" rid="bib54">Lutz et al., 2022</xref>; <xref ref-type="bibr" rid="bib88">Xu et al., 2022</xref>) (Appendix 1-key resources table). E2 (1 µM) was added to activate HoxB8-ER and to maintain the conditionally immortalized state of HoxB8 MPP. Cell density was adjusted to 1.5 million cells/ml every day. HEK293T cells for retrovirus and lentivirus production were grown in DMEM supplemented with 10% FCS (PAA, A01125-499), 100 U/ml penicillin/streptomycin, 2 mM L-glutamine (Appendix 1-key resources table).</p></sec><sec id="s4-3"><title>In vitro DC differentiation with HoxB8 MPP</title><p>HoxB8 MPP were differentiated into DC using a two-step protocol modified from <xref ref-type="bibr" rid="bib23">Felker et al., 2010</xref> and described in <xref ref-type="bibr" rid="bib54">Lutz et al., 2022</xref>; <xref ref-type="bibr" rid="bib88">Xu et al., 2022</xref>. In brief, 0.75 million cells/ml were grown in MPP growth medium with 50 ng/ml Flt3L (Peprotech, 300–19) and reduced E2 (0.01 μM) for two days and cell density was kept to 0.75 million cells/ml. To induce DC differentiation, HoxB8 MPP were then washed with PBS to remove cytokines and E2, and cultured in RPMI 1640 medium supplemented with FCS, penicillin/streptomycin, L-glutamine, β-ME (same concentrations as above), and Flt3L (50 ng/ml, Peprotech) (referred to as DC differentiation day 0). Partial medium changes were performed on differentiation day 3 and 6. Spontaneous DC differentiation of HoxB8 MPP was achieved simply by removing E2 from growth medium (SCF, Flt3L, IGF1 and hyper-IL6), and culturing the cells at 1.5 million cells/ml (<xref ref-type="bibr" rid="bib54">Lutz et al., 2022</xref>; <xref ref-type="bibr" rid="bib88">Xu et al., 2022</xref>).</p></sec><sec id="s4-4"><title>Nuclear-Titrated (NuTi) Capture-C</title><p>Wild-type bone marrow cell-derived MPP, CDP, cDC1, cDC2, and pDC were generated in vitro with the two-step protocol as described in <xref ref-type="bibr" rid="bib23">Felker et al., 2010</xref>. Cell populations were sorted by BD FACSAria IIu or BD FACSMelody, MPP are Gr1<sup>-</sup> CD117<sup>hi</sup> CD135<sup>low/-</sup>, CDP are Gr1<sup>-</sup> CD117<sup>int</sup> CD135<sup>+</sup> CD115<sup>+</sup>, cDC1 are CD11c<sup>+</sup> CD11b<sup>low/-</sup> XCR1<sup>+</sup>, cDC2 are CD11c<sup>+</sup> CD11b<sup>+</sup> XCR1<sup>-</sup>, pDC are CD11c<sup>+</sup> CD11b<sup>-</sup> B220<sup>+</sup>.</p><p>The chromatin conformation capture (3 C) library preparation protocol used in this study was modified from <xref ref-type="bibr" rid="bib19">Downes et al., 2021</xref>; <xref ref-type="bibr" rid="bib20">Downes et al., 2022</xref> with the reagents listed in Appendix 1-key resources table. MPP, CDP, cDC1, cDC2 and pDC were fixed with formaldehyde (final concentration 2%) and subjected to nuclear isolation according to the protocol in <xref ref-type="bibr" rid="bib20">Downes et al., 2022</xref>; <xref ref-type="bibr" rid="bib49">Li et al., 2019</xref>. Nuclei (15–20 million per sample) were digested with DpnII and DNA fragments were ligated by T4 DNA HC ligase. DNA was extracted and purified with Phenol-Chloroform-Isoamyl alcohol (PCI, 25:24:1). DpnII digestion efficiency was determined by SYBR qPCR with the primers listed in Appendix 1-key resources table and the quality of 3 C libraries was investigated by agarose gel (1%) electrophoresis; 3 C samples were used only if the DpnII digestion efficiency was more than 70%.</p><p>For <italic>Irf8</italic> promoter viewpoint 2 oligonucleotide probes targeting <italic>Irf8</italic> promoter were designed with the design tool Oligo (<ext-link ext-link-type="uri" xlink:href="https://oligo.readthedocs.io/en/latest/index.html">https://oligo.readthedocs.io/en/latest/index.html</ext-link>). Oligonucleotide probes are positioned adjacent to the DpnII cut sites on a restriction fragment spanning the <italic>Irf8</italic> promoter (chr8:123,259,948–123,260,530) and 70 bp ssDNA biotinylated oligonucleotides were synthetized by Sigma-Aldrich (listed in Appendix 1-key resources table).</p><p>To enrich for fragments containing ligation events with <italic>Irf8</italic> promoter viewpoint, NuTi Capture-C was performed as previously described (<xref ref-type="bibr" rid="bib19">Downes et al., 2021</xref>; <xref ref-type="bibr" rid="bib20">Downes et al., 2022</xref>). Briefly, the 3 C libraries prepared from MPP, CDP, cDC1, cDC2 and pDC were sonicated using Covaris S220 to an average size of ~200 bp using standard settings recommended by the manufacturer (time: 180 s, duty cycle: 10%, peak incident power: 175 W, cycles per burst: 200, temperature: 5–9°C). End repair was performed with the NEBNext Ultra II kit (New England Biolabs, E7645S) using 2 µg of sonicated 3 C library in duplicate for each sample. Illumina NEBNext Indices (New England Biolabs, E7500S, and E7335S) were added with a total of 6 cycles of amplification to allow for multiplexing. After this step, duplicates were pooled to increase sample complexity. We enriched samples as per NuTi Capture-C protocol, with two capture rounds in a multiplexed reaction, using 2 µg of each indexed sample as an input for the first capture. The hybridization with biotinylated probes was performed with the KAPA Hyper Capture Reagent Kit (Roche, 9075828001). Each ssDNA biotinylated probe was used at a concentration of 2.9 nM, with a final pool concentration of 5.8 nM, and 4.5 µl of the pooled oligonucleotides were used per sample. Captured DNA was pulled-down with M-270 Streptavidin Dynabeads (Invitrogen, 65305), washed and amplified off the beads with a total of PCR 14 cycles. The DNA obtained after the first capture was used as an input in the second capture round. The experiments were performed for the first and the second biological replicate separately, and then sequenced with NextSeq 550 Illumina System with 300 paired-end or 150 paired-end, respectively.</p></sec><sec id="s4-5"><title>NuTi Capture-C data analysis</title><p>The Capture-C data was analyzed with CapCruncher (v0.1.1a1) pipeline (<ext-link ext-link-type="uri" xlink:href="https://github.com/sims-lab/CapCruncher">https://github.com/sims-lab/CapCruncher</ext-link>; <xref ref-type="bibr" rid="bib75">sims-lab, 2022</xref>) in capture mode (<xref ref-type="bibr" rid="bib20">Downes et al., 2022</xref>). The reads were aligned to the mm9 genome assembly with Bowtie2 (<xref ref-type="bibr" rid="bib46">Langmead and Salzberg, 2012</xref>), with specific options: -p6--very-sensitive. Viewpoint coordinates used were: chr8:123,259,948–123,260,530, 1000 bp around viewpoint was excluded. The data were normalized to ~300 kb region around the viewpoint (chr8:123,132,865–123,433,117).</p><p>The Capture-C profiles in <xref ref-type="fig" rid="fig1">Figure 1</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref> show the mean number of unique interactions in two biological replicates, normalized to ~300 kb region around the viewpoint. Differential tracks were created by subtraction of the mean normalized tracks.</p></sec><sec id="s4-6"><title>ATAC-seq, ChIP-seq, RNA-seq, and scRNA-seq</title><p>ATAC-seq analysis of MPP, CDP, cDC1, cDC2, and pDC was performed by Omni-ATAC-seq (<xref ref-type="bibr" rid="bib15">Corces et al., 2017</xref>) with minor modifications as described in <xref ref-type="bibr" rid="bib49">Li et al., 2019</xref>. RNA-seq analysis and ChIP-seq analysis was done as previously described (<xref ref-type="bibr" rid="bib2">Allhoff et al., 2016</xref>; <xref ref-type="bibr" rid="bib51">Lin et al., 2015</xref>).</p><p>To determin lncRNA expression in mouse ex-vivo pDC, scRNA-seq data of BM and splenic pDC were downloaded from GSE114313 (<xref ref-type="bibr" rid="bib67">Rodrigues et al., 2018</xref>) and BAM files were converted back into FASTQ files using bamtofastq (<ext-link ext-link-type="uri" xlink:href="https://support.10xgenomics.com/docs/bamtofastq">https://support.10xgenomics.com/docs/bamtofastq</ext-link>). For visualization of lncRNA expression, we created a custom reference genome of mm9 by following the tutorial: <ext-link ext-link-type="uri" xlink:href="https://support.10xgenomics.com/single-cell-gene-expression/software/pipelines/latest/using/tutorial_mr">available here</ext-link>. Cellranger pipeline was then processed to generate an expression count matrix of pDC. We next used scanpy (<xref ref-type="bibr" rid="bib87">Wolf et al., 2018</xref>) to analyze the scRNA-seq data. We filtered cells based on the number of detected genes (&lt;200 or&gt;3500), and the proportion of mitochondrial genes (&gt;10%). After data quality control, we retained 7044 cells for splenic pDC and 8158 cells for BM pDC, respectively. We then log-normalized the count matrix using a scaling factor of 10,000 and selected the top 3000 highly variable genes, which were used for dimensionality reduction based on principle component analysis. The cells were visualized using uniform manifold approximation and projection (UMAP) (<xref ref-type="bibr" rid="bib7">Becht et al., 2019</xref>).</p></sec><sec id="s4-7"><title>Plasmids</title><p>psPAX2 (Addgene #12260) and pMD2.G (Addgene #12259) for lentiviral packaging and envelope expressing plasmids were kind gifts from Didier Trono, EPFL, Lausanne, Switzerland. The gRNA expressing vector pLKO5.sgRNA.EFS.tRFP (Addgene #57823) and pLKO5.sgRNA.EFS.tRFP657 (Addgene #57824) were kind gifts from Benjamin Ebert, Harvard Medical School, Boston, USA (<xref ref-type="bibr" rid="bib33">Heckl et al., 2014</xref>).</p><p>For <italic>lncIrf8</italic> overexpression and rescue, <italic>lncIrf8</italic> cDNA was introduced into polyA containing lentivirus vector pGFP-pA to generate p<italic>lncIrf8</italic>-pA. pGFP-pA was constructed from pCIG3 (Addgene #78264; <xref ref-type="bibr" rid="bib11">Caviness et al., 2014</xref>) by Gibson Assembly (New England Biolabs, E5510S; <xref ref-type="bibr" rid="bib28">Gibson et al., 2009</xref>). In brief, the WPRE element was removed and a polyA signal ‘AATAAA’ was inserted at the 3’ end of GFP to construct pGFP-pA. <italic>lncIrf8</italic> cDNA was sub-cloned into pGFP-pA using XhoI and SalI with the primers shown in Appendix 1-key resources table to obtain p<italic>lncIrf8</italic>-pA. CRISPR activation and repression of <italic>lncIrf8</italic> and <italic>Irf8</italic> promoters were achieved by dCAS9-VP64_GFP (Addgene #61422) (<xref ref-type="bibr" rid="bib38">Konermann et al., 2015</xref>) and pTet-KRAB-dCas9-GFP (<xref ref-type="bibr" rid="bib88">Xu et al., 2022</xref>), respectively.</p></sec><sec id="s4-8"><title>Lentivirus infection</title><p>gRNAs, <italic>lncIrf8</italic>, dCas9-VP64-GFP, and KRAB-dCas9-GFP were delivered into HoxB8 MPP by lentiviral infection. Briefly, lentiviral particles were produced by calcium phosphate transfection (<xref ref-type="bibr" rid="bib31">Graham and van der Eb, 1973</xref>) of HEK293T cells with psPAX2, pMD2.G, and the lentiviral transfer vector. At 48 and 72 hours after HEK293T cell transfection, supernatant containing virus particles was collected and concentrated using chondroitin sulfate sodium salt (CSS) and polybrene precipitation (<xref ref-type="bibr" rid="bib45">Landazuri et al., 2007</xref>; Appendix 1-key resources table). HoxB8 MPP were infected twice with concentrated virus and subjected to Ficoll (Pancoll) purification to remove precipitate and dead cells.</p></sec><sec id="s4-9"><title>Genetically modified HoxB8 MPP cell lines</title><sec id="s4-9-1"><title><italic>lncIrf8</italic> promoter and cDC1 specific +32 kb enhancer KO:</title><p>Mx-Cas9-GFP HoxB8 MPP were used to generate <italic>lncIrf8</italic> promoter and cDC1 specific +32 kb enhancer knockout (KO) HoxB8 MPP by CRISPR/Cas9. Briefly, pairs of gRNAs each for <italic>lncIrf8</italic> promoter KO and cDC1 specific +32 kb enhancer KO (Appendix 1-key resources table) were designed with the <ext-link ext-link-type="uri" xlink:href="https://eu.idtdna.com/site/order/designtool/index/CRISPR_SEQUENCE">IDT online gRNA design tool</ext-link>. For cDC1 specific +32 kb enhancer KO we additionally used the same gRNA sequences from <xref ref-type="bibr" rid="bib22">Durai et al., 2019</xref> listed in Appendix 1-key resources table. gRNAs were cloned into pLKO5.sgRNA.EFS.tRFP and pLKO5.sgRNA.EFS.tRFP657 vectors (<xref ref-type="bibr" rid="bib33">Heckl et al., 2014</xref>) using BsmBI-v2 (Appendix 1-key resources table), respectively.</p><p>One 10 cm dish (Bio-One) with 1.8 million HEK293T cells (70%–80% confluency) in 10 ml DMEM plus supplements (see above) was used to produce gRNA expressing lentivirus particles. HEK293T cells were transfected with 10 μg gRNA vector, 7.5 μg psPAX2, and 2.5 μg pMD2.G per gRNA by calcium phosphate transfection and lentivirus particles were harvested 48 and 72 h after transfection.</p><p>The gRNA expressing lentiviral particles were used to infect 3 million Mx-Cas9-GFP HoxB8 MPP. Cas9 and GFP expression were induced by mIFNα (1000 IU/ml; Appendix 1-key resources table) for 4 h, followed by FACS sorting for cells expressing the two gRNAs and Cas9 (GFP<sup>+</sup> RFP<sup>+</sup> RFP657<sup>+</sup> cells). Single-cell clones were obtained by single-cell FACS sorting or limiting dilution.</p><p>Single-cell clones were genotyped by genomic PCR with primers listed in Appendix 1-key resources table. PCR products were sequenced by Eurofins Genomics and sequences were analyzed by SnapGene. Potential off-targets were routinely predicted by online software tools such as CRISPR-Cas9 gRNA checker (<ext-link ext-link-type="uri" xlink:href="https://eu.idtdna.com/site/order/designtool/in-dex/CRISPR">https://eu.idtdna.com/site/order/designtool/in-dex/CRISPR</ext-link> _SEQUENCE). For <italic>lncIrf8</italic> promoter KO, 5 out of 71 single-cell colonies with homozygous deletions were subjected to off-target analysis. The top 2–5 predicted coding or non-coding targets were selected and HoxB8 MPP clones without off-target effects, or where off-target effects occurred in genes that were not expressed in MPP, CDP and DC subsets, were used for further studies (<xref ref-type="table" rid="table1">Table 1</xref>). For cDC1 specific +32 kb enhancer KO, 5 out of 165 single-cell clones with homozygous deletions were subjected to DC differentiation and further analyzed. Potential off-target genes of self-designed gRNAs for cDC1 +32 kb enhancer KO were not expressed in MPP, CDP, and DC subsets, and thus these gRNAs were used in the study.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Off-target analysis.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="2" colspan="3">Potential off-targets</th><th align="left" valign="bottom" rowspan="2">KO bulk(100 cells)</th><th align="left" valign="bottom" colspan="5">KO single-cell clones</th><th align="left" valign="bottom" colspan="4">Gene expression</th></tr><tr><th align="left" valign="bottom">6</th><th align="left" valign="bottom">7</th><th align="left" valign="bottom">19</th><th align="left" valign="bottom">21</th><th align="left" valign="bottom">24</th><th align="left" valign="bottom">MPP</th><th align="left" valign="bottom">CDP</th><th align="left" valign="bottom">cDC</th><th align="left" valign="bottom">pDC</th></tr></thead><tbody><tr><td align="left" valign="bottom" rowspan="2">gRNA1</td><td align="left" valign="bottom">Chr 13: –48032179</td><td align="left" valign="bottom"><italic>Gm36101</italic></td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td></tr><tr><td align="left" valign="bottom">Chr 2: –131293076</td><td align="left" valign="bottom">Non-coding</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td></tr><tr><td align="left" valign="bottom" rowspan="5">gRNA2</td><td align="left" valign="bottom">Chr 1: –136050990</td><td align="left" valign="bottom"><italic>AsCl5</italic></td><td align="char" char="." valign="bottom">16 bp deletion</td><td align="char" char="." valign="bottom">16 bp deletion</td><td align="char" char="." valign="bottom">16 bp deletion</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">1 bp insertion</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td></tr><tr><td align="left" valign="bottom">Chr 6:+119352090</td><td align="left" valign="bottom"><italic>CACNA2D4</italic></td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom">Chr 3:+33982811</td><td align="left" valign="bottom">Non-coding</td><td align="left" valign="bottom">3–29 bp deletion;<break/>1–3 bp insertion</td><td align="char" char="endash" valign="bottom">3–29 bp deletion</td><td align="char" char="." valign="bottom">3 bp deletion</td><td align="left" valign="bottom">1–2 bp insertion</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td></tr><tr><td align="left" valign="bottom">Chr 2: –132060887</td><td align="left" valign="bottom">Non-coding</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td></tr><tr><td align="left" valign="bottom">Chr 2: –150624255</td><td align="left" valign="bottom">Non-coding</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td></tr></tbody></table><table-wrap-foot><fn><p>Top potential off-targets of gRNA1 and gRNA2 predicted by CRISPR-Cas9 gRNA checker (see Materials and methods) were analyzed in <italic>lncIrf8</italic> promoter KO bulk culture and KO single-cell clones by PCR analysis of genomic DNA. Potential off-target genes (coding) and non-coding sequences are listed. The absence of off-targets (No) and off-target deletions/insertion are shown.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s4-9-2"><title><italic>lncIrf8</italic> overexpression and <italic>lncIrf8</italic> knockout rescue</title><p><italic>lncIrf8</italic> overexpression was performed in wild-type HoxB8 MPP. Lentiviral particles expressing <italic>lncIrf8</italic> were produced from ten 6 cm dishes (Bio-One), each consisting of 0.75 million HEK293T cells (70–80% confluency) in 5 ml DMEM with supplements (see above). HEK293T cells were transfected with 5 μg p<italic>lncIrf8</italic>-pA or pGFP-pA, 2.5 μg psPAX2, and 2.5 μg pMD2.G. Lentivirus particles were concentrated as above and used to infect 0.5 million HoxB8 MPP; single-cell clones were generated by limiting dilution and genotyped using the primers listed in Appendix 1-key resources table. Two out of 47 HoxB8 MPP colonies with p<italic>lncIrf8</italic>-pA and 3 out of 19 HoxB8 MPP colonies with pGFP-pA (control) were expanded and subjected to Flt3L-directed DC differentiation.</p><p><italic>lncIrf8</italic> knockout rescue was carried out in <italic>lncIrf8</italic> promoter KO HoxB8 MPP. FACS sorted cells that genotyped as <italic>lncIrf8</italic> promoter KO homozygous deletion cells, were infected with lentiviral particles expressing <italic>lncIrf8</italic>. Lentiviral infection conditions were the same as for <italic>lncIrf8</italic> overexpression in wild-type HoxB8 MPP (see above).</p></sec><sec id="s4-9-3"><title>CRISPR activation and CRISPR interference</title><p>CRISPR activation and CRISPR interference were performed by infecting wild-type HoxB8 MPP with lentiviral particles expressing dCAS9-VP64_GFP and pTet-KRAB-dCas9-GFP, respectively. The virus particles were produced as in the <italic>lncIrf8</italic> overexpression experiments. In brief, virus particles from ten 6 cm dishes were used to infect 0.5 million wild-type HoxB8 MPP, followed by FACS sorting for GFP<sup>+</sup> cells expressing dCas9-VP64 or dCas9-KRAB. Doxycycline (1 μg/ml) was used to induce dCas9-KRAB expression 2 days before cell sorting.</p><p>gRNAs targeting <italic>lncIrf8</italic> and <italic>Irf8</italic> promoters were cloned into pLKO5.sgRNA.EFS.tRFP as above. The dCas9-VP64-GFP and dCas9-KRAB-GFP HoxB8 MPP were then infected with specific gRNAs for gene activation and repression. The conditions for gRNA infection were the same as in <italic>lncIrf8</italic> promoter KO experiments. Doxycycline (1 μg/ml) was given to the sorted dCas9-KRAB-GFP cells every 3 days to ensure sustained dCas9-KRAB expression.</p></sec></sec><sec id="s4-10"><title>Flow cytometry analysis and cell sorting</title><p>DC subsets were analyzed by flow cytometry using FACS Canto II or LSR Fortessa (both from BD Biosciences). The information for flow cytometry antibodies is shown in Appendix 1-key resources table. For live/dead staining, cells were incubated with 3 μl 7-AAD per test for 5–10 min before flow cytometry measurement. Cells were sorted by FACS Aria IIu or FACS Melody, and flow cytometry data were analyzed by FlowJo V10 (all from BD Biosciences). Data on DC frequencies were subjected to the hierarchical clustering and represented in heatmap format using the online tool MORPHEUS (<ext-link ext-link-type="uri" xlink:href="https://software.broadinstitute.org/morpheus/">https://software.broadinstitute.org/morpheus/</ext-link>).</p></sec><sec id="s4-11"><title>Cell transplantation</title><p>CD45.1 recipient mice were sublethal irradiated (6.0 Gy, CP-160 Faxitron) 1 day before transplantation. <italic>lncIrf8</italic> promoter KO and control HoxB8 MPP (single-cell clones) were expanded in vitro as described above. Cells were injected into recipient mice via the tail vein (5 million cells in 100 μl PBS per mouse). Donor cells from bone marrow and spleen were subjected to flow cytometry analysis at 7 and 14 days after cell transplantation.</p></sec><sec id="s4-12"><title>RT-qPCR</title><p>RNA was isolated by using the NucleoSpin RNA kit (Macherey-Nagel, 740955.250) according to the manufacturer’s instructions. RNA was subjected to cDNA synthesis using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 4368814) with Murine RNase Inhibitor (New England Biolabs, M0314S) (Appendix 1-key resources table). RT-qPCR was performed by a StepOnePlus Real-Time PCR system (Applied Biosystems) with SYBR-green fluorescence (Applied Biosystems, 4385610). The primers for qPCR were listed in Appendix 1-key resources table. Mouse <italic>GAPDH</italic> was used for normalization of <italic>lncIrf8</italic> and <italic>Irf8</italic> gene expression.</p></sec><sec id="s4-13"><title>Identification of <italic>lncIrf8</italic></title><p>De-novo transcript assembly of RNA-seq data was used to search for unknown transcripts with no coding potential and this identified the pDC specific lncRNA <italic>Tcons_00190250</italic> (referred to as <italic>lncIrf8</italic>) and the cDC1-specific lncRNA <italic>Tcons_00190258</italic>. In brief, paired end 2×100 bps reads from RNA-seq of MPP, CDP, cDC1, cDC2, and pDC were aligned to mm9 genome using Star aligner (version 2.4) (<xref ref-type="bibr" rid="bib18">Dobin et al., 2013</xref>) and run for Cufflinks (version 2.0; <xref ref-type="bibr" rid="bib81">Trapnell et al., 2012</xref>). Data were subjected to lenient filtering with the parameters: min isoform fraction 0.1% and pre-RNA-fraction of 0.1%, and ribosomal genes were also filtered. Next, all the predicted transcripts were merged with cuffmerge and all transcripts with no overlap with known transcripts in mouse GENCODE were selected for further analysis (<xref ref-type="bibr" rid="bib26">Frankish et al., 2019</xref>). The coding potential and conservation of coding elements of the lncRNAs were checked with CPAT (<xref ref-type="bibr" rid="bib84">Wang et al., 2013</xref>) and PhyloCSF (<xref ref-type="bibr" rid="bib50">Lin et al., 2011</xref>), respectively. <italic>lncIrf8</italic> (<italic>Tcons_00190250</italic>) and <italic>Tcons_00190258</italic> show low scores in both analyses, which faithfully supports their role as non-coding genes and exhibit low cross-species conservation.</p><p>To further characterize the major transcripts of <italic>lncIrf8</italic>, 3' and 5' end Rapid Amplification of cDNA Ends (RACE) PCR was performed using template-switching RT enzyme mix (New England Biolabs, M0466) and TA cloning kit (Thermo Fisher Scientific, K202020) (Appendix 1-key resources table). The primers (listed in Appendix 1-key resources table) used for RACE PCR were synthesized by Eurofins Genomics except for 5' RACE-TSO, which was from IDT.</p></sec><sec id="s4-14"><title>3' RACE PCR</title><p>Reverse transcript (RT) and template-switching: 4 μl (10 ng to 1 μg) total RNA (from DC differentiation day 5) were incubated at 80°C for 3 min and cooled rapidly on ice. RNA was then incubated with template-switching RT buffer, 1 mM dNTP, 5 mM DTT, 10 μM QT primer (<xref ref-type="bibr" rid="bib73">Scotto-Lavino et al., 2006</xref>) and 1 μl RT enzyme in 10 μl at room temperature for 5 min, followed by 1 hr at 42°C, 10 min at 50°C, and 85°C for 5 min to inactive the RT enzyme mix and sample was then kept at 4°C and diluted with 20 μl MilliQ water.</p><p>First-round PCR: 1 μl of diluted sample was subjected to the first round PCR with Q0 primer and 3' RACE-GSP-<italic>lncIrf8</italic>-F1 (10 μM) using Q5 high fidelity DNA polymerase. Second-round PCR: the PCR products from the first round PCR (1:20 dilution) was then used as template for the second round of PCR by using Q1 primer (10 μM), 3' RACE-GSP-<italic>lncIrf8</italic>-F2 (10 μM). Q0 and Q1 primers and the PCR programs are described in <xref ref-type="bibr" rid="bib73">Scotto-Lavino et al., 2006</xref>. Products from the second-round PCR were purified using the PCR clean-up kit (Macherey-Nagel<italic>,</italic> 740609.50).</p><p>A-tailing and TA cloning: a reaction containing 5 μl of PCR clean-up product in Taq buffer, 1 mM MgCl<sub>2</sub>, 0.4 mM dATP and 1 μl Taq DNA polymerase in 25 μl was prepared and incubated at 70°C for 20 min for A-tailing of PCR products. Five μl of the A-tailed products were subjected to TA cloning into pCR2.1 vector according to the manufacturer’s instruction followed by Sanger sequencing.</p></sec><sec id="s4-15"><title>5' RACE PCR</title><p>In order to identify the TSS of <italic>lncIrf8</italic>, template RNA from bone marrow cell-derived pDC was used to perform 5' RACE PCR using template-switching RT enzyme mix (New England Biolabs, M0466) according to the manufacturer’s instructions. Template switching was by 5' RACE-GSP-<italic>lncIrf8</italic>-R2 primer (10 μM) and template switching oligo (TSO) (75 μM). Similar to the 3' RACE PCR, two rounds of PCR were used to improve PCR specificity. In brief, 5' RACE-GSP-<italic>lncIrf8</italic>-R2 (10 μM) and TSO-specific primer (10 μM) were used to perform the first-round PCR, 5' RACE-GSP-<italic>lncIrf8</italic>-R1 primer (10 μM) and the TSO-specific primer (10 μM) were used to perform the second round PCR, followed by fragments A-tailing, TA cloning, and Sanger sequencing as described above for 3' RACE PCR.</p></sec><sec id="s4-16"><title>Identification of transcription factor binding sites</title><p>Transcription factor binding sites (TFBS) in the <italic>Irf8</italic> +32 kb enhancer were predicted using a motif matching tool based on the MOODS (<xref ref-type="bibr" rid="bib40">Korhonen et al., 2009</xref>) and position weight matrixes (PWMs) were obtained from the JASPAR database (<xref ref-type="bibr" rid="bib25">Fornes et al., 2020</xref>). The bit-score cut-off thresholds were determined by applying the dynamic programming approach as described in <xref ref-type="bibr" rid="bib85">Wilczynski et al., 2009</xref> with an FPR of 0.0001. DC TF were considered and are depicted.</p></sec><sec id="s4-17"><title>Statistical analysis</title><p>Statistical analyses were performed using Prism (GraphPad). Unpaired t test and Multiple t-tests were used to compare data from two groups, two-way ANOVA with Tukey’s multiple comparisons test was used to analyze data from more than two groups.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Resources, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Resources, Data curation, Software, Visualization, Methodology</p></fn><fn fn-type="con" id="con3"><p>Resources, Data curation, Software, Visualization, Methodology</p></fn><fn fn-type="con" id="con4"><p>Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Investigation, Methodology</p></fn><fn fn-type="con" id="con6"><p>Conceptualization, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Conceptualization, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Conceptualization, Resources, Data curation, Software, Formal analysis, Supervision, Funding acquisition, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All the animal experiments were approved by the local authorities of the German Federal State North Rhine-Westphalia, Germany according to the German animal protection law (reference number 81-02.04.2018.A228).</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-83342-mdarchecklist1-v2.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>ATAC-seq (MPP, CDP and cDC2), Capture-C targeting <italic>Irf8</italic> promoter (MPP, CDP, cDC1, cDC2 and pDC), IRF8 ChIP-seq (cDC and pDC), and RNA-seq (MPP, CDP, cDC1, cDC2 and pDC) data generated in this study have been deposited in Gene Expression Omnibus and are accessible through GEO Series accession numbers GSE198651.ATAC-seq data of cDC1 and pDC (GSE118221) are published (<xref ref-type="bibr" rid="bib51">Lin et al., 2015</xref>), and the ATAC-seq data of MPP, CDP and cDC2 of the same study are described here (GSE198651). ChIP-seq of CTCF in DC (GSE36099) (<xref ref-type="bibr" rid="bib27">Garber et al., 2012</xref>), H3K27ac (GSE73143) (<xref ref-type="bibr" rid="bib2">Allhoff et al., 2016</xref>), H3K4me1 and PU.1 (GSE57563) (<xref ref-type="bibr" rid="bib1">Allhoff et al., 2014</xref>), H3K4me3 and H3K9me3 (GSE64767) (<xref ref-type="bibr" rid="bib51">Lin et al., 2015</xref>) in MPP, CDP, cDC and pDC were re-analyzed in this study. scRNA-seq data were reanalyzed from GSE114313 (<xref ref-type="bibr" rid="bib67">Rodrigues et al., 2018</xref>). Bulk RNA-seq data of splenic pDC, cDC1 and cDC2 were reanalyzed from GSE188992 (<xref ref-type="bibr" rid="bib64">Pang et al., 2022</xref>).The sequence of the pDC specific lncRNA (<italic>lncIrf8</italic> identified by RACE PCR) and the cDC1 specific lncRNA (<italic>Tcons_00190258</italic> identified by RNA-seq) has been submitted to GenBank. The GenBank accession numbers for <italic>lncIrf8</italic> and <italic>Tcons_00190258</italic> are ON134061 and ON134062, respectively.</p><p>The following datasets were generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Kuo</surname><given-names>C</given-names></name><name><surname>Götz</surname><given-names>K</given-names></name><name><surname>Look</surname><given-names>T</given-names></name><name><surname>Toledo</surname><given-names>MA</given-names></name><name><surname>Seré</surname><given-names>K</given-names></name><name><surname>Costa</surname><given-names>IG</given-names></name><name><surname>Zenke</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>A lncRNA identifies Irf8 enhancer element in negative feedback control of dendritic cell differentiation</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE198651">GSE198651</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset2"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Kuo</surname><given-names>CC</given-names></name><name><surname>Goetz</surname><given-names>K</given-names></name><name><surname>Look</surname><given-names>T</given-names></name><name><surname>de Toldeo</surname><given-names>MAS</given-names></name><name><surname>Sere</surname><given-names>K</given-names></name><name><surname>Costa</surname><given-names>IG</given-names></name><name><surname>Zenke</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Mus musculus lncIRF8 lncRNA, partial sequence</data-title><source>NCBI Nucleotide</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/ON134061">ON134061</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset3"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Kuo</surname><given-names>CC</given-names></name><name><surname>Goetz</surname><given-names>K</given-names></name><name><surname>Look</surname><given-names>T</given-names></name><name><surname>de Toldeo</surname><given-names>MAS</given-names></name><name><surname>Sere</surname><given-names>K</given-names></name><name><surname>Costa</surname><given-names>IG</given-names></name><name><surname>Zenke</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Mus musculus TCONS_00190258 lncRNA, partial sequence</data-title><source>NCBI Nucleotide</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/ON134062">ON134062</pub-id></element-citation></p><p>The following previously published datasets were used:</p><p><element-citation publication-type="data" specific-use="references" id="dataset4"><person-group person-group-type="author"><collab>Li et al</collab></person-group><year iso-8601-date="2019">2019</year><data-title>Identification of Transcription Factor Binding Sites using ATAC-seq</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE118221">GSE118221</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset5"><person-group person-group-type="author"><collab>Garber et al</collab></person-group><year iso-8601-date="2012">2012</year><data-title>A high throughput in vivo protein-DNA mapping approach reveals principles of dynamic gene regulation in mammals (ChIP-Seq)</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE36099">GSE36099</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset6"><person-group person-group-type="author"><collab>Allhoff et al</collab></person-group><year iso-8601-date="2016">2016</year><data-title>Differential Peak Calling of ChIP-Seq Signals with Replicates with THOR</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE73143">GSE73143</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset7"><person-group person-group-type="author"><collab>Allhoff et al</collab></person-group><year iso-8601-date="2014">2014</year><data-title>Detecting differential peaks in ChIP-seq signals with ODIN</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE57563">GSE57563</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset8"><person-group person-group-type="author"><collab>Lin et al</collab></person-group><year iso-8601-date="2015">2015</year><data-title>Epigenetic Program and Transcription Factor Circuitry of Dendritic Cell Development</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE64767">GSE64767</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset9"><person-group person-group-type="author"><collab>Rodrigues et al</collab></person-group><year iso-8601-date="2018">2018</year><data-title>A distinct lineage of origin reveals heterogeneity of plasmacytoid dendritic cells II (scRNAseq)</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE114313">GSE114313</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset10"><person-group person-group-type="author"><collab>Pang et al</collab></person-group><year iso-8601-date="2022">2022</year><data-title>Bulk RNAseq of Mouse Splenic Dendritic Cell Subsets</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE188992">GSE188992</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We acknowledge the support of the Interdisciplinary Center for Clinical Research Aachen (IZKF Aachen) FACS Core Facility and Genomics Facility. We thank Magdalena Karpinska and Marieke Oudelaar for help with the Capture-C experiments and analysis, Susanne Schmitz and Paul Wanek for assistance, Stefan Rose-John for hyper-IL-6, Lisa Weixler and Carmen Schalla for help with enzyme purification, and Thomas Hieronymus for valuable discussion and suggestions. Part of this work was supported in part by funds from German Research Foundation (DFG) to MZ and from the Germany Ministry of Science and Technology (BMBF - Fibromap) and the Interdisciplinary Center for Clinical Research Aachen (IZKF Aachen) from the RWTH Medical Faculty to IC. HX was supported by a fellowship of China Scholarship Council (CSC) (Grant number 202008080170). MAST was funded by CAPES-Alexander von Humboldt postdoctoral fellowship (99999.001703/2014–05) and donation by U Lehmann.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allhoff</surname><given-names>M</given-names></name><name><surname>Seré</surname><given-names>K</given-names></name><name><surname>Chauvistré</surname><given-names>H</given-names></name><name><surname>Lin</surname><given-names>Q</given-names></name><name><surname>Zenke</surname><given-names>M</given-names></name><name><surname>Costa</surname><given-names>IG</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Detecting differential peaks in ChIP-seq signals with ODIN</article-title><source>Bioinformatics</source><volume>30</volume><fpage>3467</fpage><lpage>3475</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btu722</pub-id><pub-id pub-id-type="pmid">25371479</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allhoff</surname><given-names>M</given-names></name><name><surname>Seré</surname><given-names>K</given-names></name><name><surname>F Pires</surname><given-names>J</given-names></name><name><surname>Zenke</surname><given-names>M</given-names></name><name><surname>G Costa</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Differential peak calling of ChIP-seq signals with replicates with THOR</article-title><source>Nucleic Acids Research</source><volume>44</volume><elocation-id>e153</elocation-id><pub-id pub-id-type="doi">10.1093/nar/gkw680</pub-id><pub-id pub-id-type="pmid">27484474</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alvarez-Dominguez</surname><given-names>JR</given-names></name><name><surname>Bai</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>D</given-names></name><name><surname>Yuan</surname><given-names>B</given-names></name><name><surname>Lo</surname><given-names>KA</given-names></name><name><surname>Yoon</surname><given-names>MJ</given-names></name><name><surname>Lim</surname><given-names>YC</given-names></name><name><surname>Knoll</surname><given-names>M</given-names></name><name><surname>Slavov</surname><given-names>N</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Peng</surname><given-names>C</given-names></name><name><surname>Lodish</surname><given-names>HF</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>De novo reconstruction of adipose tissue transcriptomes reveals long non-coding RNA regulators of brown adipocyte development</article-title><source>Cell Metabolism</source><volume>21</volume><fpage>764</fpage><lpage>776</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2015.04.003</pub-id><pub-id pub-id-type="pmid">25921091</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>D.A</given-names></name><name><surname>Dutertre</surname><given-names>CA</given-names></name><name><surname>Ginhoux</surname><given-names>F</given-names></name><name><surname>Murphy</surname><given-names>KM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Genetic models of human and mouse dendritic cell development and function</article-title><source>Nature Reviews. Immunology</source><volume>21</volume><fpage>101</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1038/s41577-020-00413-x</pub-id><pub-id pub-id-type="pmid">32908299</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson lll</surname><given-names>DA</given-names></name><name><surname>Ou</surname><given-names>F</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Murphy</surname><given-names>TL</given-names></name><name><surname>Murphy</surname><given-names>KM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Transition from cMyc to L-Myc during dendritic cell development coordinated by rising levels of IRF8</article-title><source>The Journal of Experimental Medicine</source><volume>219</volume><elocation-id>e20211483</elocation-id><pub-id pub-id-type="doi">10.1084/jem.20211483</pub-id><pub-id pub-id-type="pmid">34958351</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bagadia</surname><given-names>P</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>TT</given-names></name><name><surname>Durai</surname><given-names>V</given-names></name><name><surname>Grajales-Reyes</surname><given-names>GE</given-names></name><name><surname>Nitschké</surname><given-names>M</given-names></name><name><surname>Modrusan</surname><given-names>Z</given-names></name><name><surname>Granja</surname><given-names>JM</given-names></name><name><surname>Satpathy</surname><given-names>AT</given-names></name><name><surname>Briseño</surname><given-names>CG</given-names></name><name><surname>Gargaro</surname><given-names>M</given-names></name><name><surname>Iwata</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Chang</surname><given-names>HY</given-names></name><name><surname>Shaw</surname><given-names>AS</given-names></name><name><surname>Murphy</surname><given-names>TL</given-names></name><name><surname>Murphy</surname><given-names>KM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>An Nfil3-Zeb2-Id2 pathway imposes Irf8 enhancer switching during cDC1 development</article-title><source>Nature Immunology</source><volume>20</volume><fpage>1174</fpage><lpage>1185</lpage><pub-id pub-id-type="doi">10.1038/s41590-019-0449-3</pub-id><pub-id pub-id-type="pmid">31406377</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becht</surname><given-names>E</given-names></name><name><surname>McInnes</surname><given-names>L</given-names></name><name><surname>Healy</surname><given-names>J</given-names></name><name><surname>Dutertre</surname><given-names>CA</given-names></name><name><surname>Kwok</surname><given-names>IWH</given-names></name><name><surname>Ng</surname><given-names>LG</given-names></name><name><surname>Ginhoux</surname><given-names>F</given-names></name><name><surname>Newell</surname><given-names>EW</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Dimensionality reduction for visualizing single-cell data using UMAP</article-title><source>Nature Biotechnology</source><volume>37</volume><fpage>38</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1038/nbt.4314</pub-id><pub-id pub-id-type="pmid">30531897</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belz</surname><given-names>GT</given-names></name><name><surname>Nutt</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Transcriptional programming of the dendritic cell network</article-title><source>Nature Reviews. Immunology</source><volume>12</volume><fpage>101</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1038/nri3149</pub-id><pub-id pub-id-type="pmid">22273772</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bornstein</surname><given-names>C</given-names></name><name><surname>Winter</surname><given-names>D</given-names></name><name><surname>Barnett-Itzhaki</surname><given-names>Z</given-names></name><name><surname>David</surname><given-names>E</given-names></name><name><surname>Kadri</surname><given-names>S</given-names></name><name><surname>Garber</surname><given-names>M</given-names></name><name><surname>Amit</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A negative feedback loop of transcription factors specifies alternative dendritic cell chromatin states</article-title><source>Molecular Cell</source><volume>56</volume><fpage>749</fpage><lpage>762</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2014.10.014</pub-id><pub-id pub-id-type="pmid">25453760</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cabeza-Cabrerizo</surname><given-names>M</given-names></name><name><surname>Cardoso</surname><given-names>A</given-names></name><name><surname>Minutti</surname><given-names>CM</given-names></name><name><surname>Pereira da Costa</surname><given-names>M</given-names></name><name><surname>Reis e Sousa</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Dendritic cells revisited</article-title><source>Annual Review of Immunology</source><volume>39</volume><fpage>131</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-061020-053707</pub-id><pub-id pub-id-type="pmid">33481643</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caviness</surname><given-names>K</given-names></name><name><surname>Cicchini</surname><given-names>L</given-names></name><name><surname>Rak</surname><given-names>M</given-names></name><name><surname>Umashankar</surname><given-names>M</given-names></name><name><surname>Goodrum</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Complex expression of the UL136 gene of human cytomegalovirus results in multiple protein isoforms with unique roles in replication</article-title><source>Journal of Virology</source><volume>88</volume><fpage>14412</fpage><lpage>14425</lpage><pub-id pub-id-type="doi">10.1128/JVI.02711-14</pub-id><pub-id pub-id-type="pmid">25297993</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>TH</given-names></name><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Tailor</surname><given-names>P</given-names></name><name><surname>Kanno</surname><given-names>T</given-names></name><name><surname>Ozato</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The small ubiquitin-like modifier-deconjugating enzyme sentrin-specific peptidase 1 switches IFN regulatory factor 8 from a repressor to an activator during macrophage activation</article-title><source>Journal of Immunology</source><volume>189</volume><fpage>3548</fpage><lpage>3556</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1201104</pub-id><pub-id pub-id-type="pmid">22942423</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>YK</given-names></name><name><surname>Zuo</surname><given-names>Z</given-names></name><name><surname>Stormo</surname><given-names>GD</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Quantitative profiling of BATF family proteins/JUNB/IRF hetero-trimers using spec-seq</article-title><source>BMC Molecular Biology</source><volume>19</volume><elocation-id>5</elocation-id><pub-id pub-id-type="doi">10.1186/s12867-018-0106-7</pub-id><pub-id pub-id-type="pmid">29587652</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chauvistré</surname><given-names>H</given-names></name><name><surname>Seré</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Epigenetic aspects of DC development and differentiation</article-title><source>Molecular Immunology</source><volume>128</volume><fpage>116</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2020.10.011</pub-id><pub-id pub-id-type="pmid">33126080</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corces</surname><given-names>MR</given-names></name><name><surname>Trevino</surname><given-names>AE</given-names></name><name><surname>Hamilton</surname><given-names>EG</given-names></name><name><surname>Greenside</surname><given-names>PG</given-names></name><name><surname>Sinnott-Armstrong</surname><given-names>NA</given-names></name><name><surname>Vesuna</surname><given-names>S</given-names></name><name><surname>Satpathy</surname><given-names>AT</given-names></name><name><surname>Rubin</surname><given-names>AJ</given-names></name><name><surname>Montine</surname><given-names>KS</given-names></name><name><surname>Wu</surname><given-names>B</given-names></name><name><surname>Kathiria</surname><given-names>A</given-names></name><name><surname>Cho</surname><given-names>SW</given-names></name><name><surname>Mumbach</surname><given-names>MR</given-names></name><name><surname>Carter</surname><given-names>AC</given-names></name><name><surname>Kasowski</surname><given-names>M</given-names></name><name><surname>Orloff</surname><given-names>LA</given-names></name><name><surname>Risca</surname><given-names>VI</given-names></name><name><surname>Kundaje</surname><given-names>A</given-names></name><name><surname>Khavari</surname><given-names>PA</given-names></name><name><surname>Montine</surname><given-names>TJ</given-names></name><name><surname>Greenleaf</surname><given-names>WJ</given-names></name><name><surname>Chang</surname><given-names>HY</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>An improved ATAC-seq protocol reduces background and enables interrogation of frozen tissues</article-title><source>Nature Methods</source><volume>14</volume><fpage>959</fpage><lpage>962</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4396</pub-id><pub-id pub-id-type="pmid">28846090</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cytlak</surname><given-names>U</given-names></name><name><surname>Resteu</surname><given-names>A</given-names></name><name><surname>Pagan</surname><given-names>S</given-names></name><name><surname>Green</surname><given-names>K</given-names></name><name><surname>Milne</surname><given-names>P</given-names></name><name><surname>Maisuria</surname><given-names>S</given-names></name><name><surname>McDonald</surname><given-names>D</given-names></name><name><surname>Hulme</surname><given-names>G</given-names></name><name><surname>Filby</surname><given-names>A</given-names></name><name><surname>Carpenter</surname><given-names>B</given-names></name><name><surname>Queen</surname><given-names>R</given-names></name><name><surname>Hambleton</surname><given-names>S</given-names></name><name><surname>Hague</surname><given-names>R</given-names></name><name><surname>Lango Allen</surname><given-names>H</given-names></name><name><surname>Thaventhiran</surname><given-names>JED</given-names></name><name><surname>Doody</surname><given-names>G</given-names></name><name><surname>Collin</surname><given-names>M</given-names></name><name><surname>Bigley</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Differential IRF8 transcription factor requirement defines two pathways of dendritic cell development in humans</article-title><source>Immunity</source><volume>53</volume><fpage>353</fpage><lpage>370</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2020.07.003</pub-id><pub-id pub-id-type="pmid">32735845</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>I</given-names></name><name><surname>Fromental</surname><given-names>C</given-names></name><name><surname>Augereau</surname><given-names>P</given-names></name><name><surname>Wildeman</surname><given-names>A</given-names></name><name><surname>Zenke</surname><given-names>M</given-names></name><name><surname>Chambon</surname><given-names>P</given-names></name></person-group><year iso-8601-date="1986">1986</year><article-title>Cell-type specific protein binding to the enhancer of simian virus 40 in nuclear extracts</article-title><source>Nature</source><volume>323</volume><fpage>544</fpage><lpage>548</lpage><pub-id pub-id-type="doi">10.1038/323544a0</pub-id><pub-id pub-id-type="pmid">3020434</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobin</surname><given-names>A</given-names></name><name><surname>Davis</surname><given-names>CA</given-names></name><name><surname>Schlesinger</surname><given-names>F</given-names></name><name><surname>Drenkow</surname><given-names>J</given-names></name><name><surname>Zaleski</surname><given-names>C</given-names></name><name><surname>Jha</surname><given-names>S</given-names></name><name><surname>Batut</surname><given-names>P</given-names></name><name><surname>Chaisson</surname><given-names>M</given-names></name><name><surname>Gingeras</surname><given-names>TR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>STAR: ultrafast universal RNA-seq aligner</article-title><source>Bioinformatics</source><volume>29</volume><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/bts635</pub-id><pub-id pub-id-type="pmid">23104886</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Downes</surname><given-names>DJ</given-names></name><name><surname>Beagrie</surname><given-names>RA</given-names></name><name><surname>Gosden</surname><given-names>ME</given-names></name><name><surname>Telenius</surname><given-names>J</given-names></name><name><surname>Carpenter</surname><given-names>SJ</given-names></name><name><surname>Nussbaum</surname><given-names>L</given-names></name><name><surname>De Ornellas</surname><given-names>S</given-names></name><name><surname>Sergeant</surname><given-names>M</given-names></name><name><surname>Eijsbouts</surname><given-names>CQ</given-names></name><name><surname>Schwessinger</surname><given-names>R</given-names></name><name><surname>Kerry</surname><given-names>J</given-names></name><name><surname>Roberts</surname><given-names>N</given-names></name><name><surname>Shivalingam</surname><given-names>A</given-names></name><name><surname>El-Sagheer</surname><given-names>A</given-names></name><name><surname>Oudelaar</surname><given-names>AM</given-names></name><name><surname>Brown</surname><given-names>T</given-names></name><name><surname>Buckle</surname><given-names>VJ</given-names></name><name><surname>Davies</surname><given-names>JOJ</given-names></name><name><surname>Hughes</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>High-resolution targeted 3C interrogation of cis-regulatory element organization at genome-wide scale</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>531</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-20809-6</pub-id><pub-id pub-id-type="pmid">33483495</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Downes</surname><given-names>DJ</given-names></name><name><surname>Smith</surname><given-names>AL</given-names></name><name><surname>Karpinska</surname><given-names>MA</given-names></name><name><surname>Velychko</surname><given-names>T</given-names></name><name><surname>Rue-Albrecht</surname><given-names>K</given-names></name><name><surname>Sims</surname><given-names>D</given-names></name><name><surname>Milne</surname><given-names>TA</given-names></name><name><surname>Davies</surname><given-names>JOJ</given-names></name><name><surname>Oudelaar</surname><given-names>AM</given-names></name><name><surname>Hughes</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Capture-C: a modular and flexible approach for high-resolution chromosome conformation capture</article-title><source>Nature Protocols</source><volume>17</volume><fpage>445</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1038/s41596-021-00651-w</pub-id><pub-id pub-id-type="pmid">35121852</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dress</surname><given-names>RJ</given-names></name><name><surname>Dutertre</surname><given-names>C-A</given-names></name><name><surname>Giladi</surname><given-names>A</given-names></name><name><surname>Schlitzer</surname><given-names>A</given-names></name><name><surname>Low</surname><given-names>I</given-names></name><name><surname>Shadan</surname><given-names>NB</given-names></name><name><surname>Tay</surname><given-names>A</given-names></name><name><surname>Lum</surname><given-names>J</given-names></name><name><surname>Kairi</surname><given-names>MFBM</given-names></name><name><surname>Hwang</surname><given-names>YY</given-names></name><name><surname>Becht</surname><given-names>E</given-names></name><name><surname>Cheng</surname><given-names>Y</given-names></name><name><surname>Chevrier</surname><given-names>M</given-names></name><name><surname>Larbi</surname><given-names>A</given-names></name><name><surname>Newell</surname><given-names>EW</given-names></name><name><surname>Amit</surname><given-names>I</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Ginhoux</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Plasmacytoid dendritic cells develop from Ly6D<sup>+</sup> lymphoid progenitors distinct from the myeloid lineage</article-title><source>Nature Immunology</source><volume>20</volume><fpage>852</fpage><lpage>864</lpage><pub-id pub-id-type="doi">10.1038/s41590-019-0420-3</pub-id><pub-id pub-id-type="pmid">31213723</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Durai</surname><given-names>V</given-names></name><name><surname>Bagadia</surname><given-names>P</given-names></name><name><surname>Granja</surname><given-names>JM</given-names></name><name><surname>Satpathy</surname><given-names>AT</given-names></name><name><surname>Kulkarni</surname><given-names>DH</given-names></name><name><surname>Davidson</surname><given-names>JT</given-names></name><name><surname>Wu</surname><given-names>R</given-names></name><name><surname>Patel</surname><given-names>SJ</given-names></name><name><surname>Iwata</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>TT</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Briseño</surname><given-names>CG</given-names></name><name><surname>Grajales-Reyes</surname><given-names>GE</given-names></name><name><surname>Wöhner</surname><given-names>M</given-names></name><name><surname>Tagoh</surname><given-names>H</given-names></name><name><surname>Kee</surname><given-names>BL</given-names></name><name><surname>Newberry</surname><given-names>RD</given-names></name><name><surname>Busslinger</surname><given-names>M</given-names></name><name><surname>Chang</surname><given-names>HY</given-names></name><name><surname>Murphy</surname><given-names>TL</given-names></name><name><surname>Murphy</surname><given-names>KM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cryptic activation of an Irf8 enhancer governs cDC1 fate specification</article-title><source>Nature Immunology</source><volume>20</volume><fpage>1161</fpage><lpage>1173</lpage><pub-id pub-id-type="doi">10.1038/s41590-019-0450-x</pub-id><pub-id pub-id-type="pmid">31406378</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Felker</surname><given-names>P</given-names></name><name><surname>Seré</surname><given-names>K</given-names></name><name><surname>Lin</surname><given-names>Q</given-names></name><name><surname>Becker</surname><given-names>C</given-names></name><name><surname>Hristov</surname><given-names>M</given-names></name><name><surname>Hieronymus</surname><given-names>T</given-names></name><name><surname>Zenke</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>TGF-β1 accelerates dendritic cell differentiation from common dendritic cell progenitors and directs subset specification toward conventional dendritic cells</article-title><source>Journal of Immunology</source><volume>185</volume><fpage>5326</fpage><lpage>5335</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0903950</pub-id><pub-id pub-id-type="pmid">20881193</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>M</given-names></name><name><surname>Goldschmitt</surname><given-names>J</given-names></name><name><surname>Peschel</surname><given-names>C</given-names></name><name><surname>Brakenhoff</surname><given-names>JP</given-names></name><name><surname>Kallen</surname><given-names>KJ</given-names></name><name><surname>Wollmer</surname><given-names>A</given-names></name><name><surname>Grötzinger</surname><given-names>J</given-names></name><name><surname>Rose-John</surname><given-names>S</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion</article-title><source>Nature Biotechnology</source><volume>15</volume><fpage>142</fpage><lpage>145</lpage><pub-id pub-id-type="doi">10.1038/nbt0297-142</pub-id><pub-id pub-id-type="pmid">9035138</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fornes</surname><given-names>O</given-names></name><name><surname>Castro-Mondragon</surname><given-names>JA</given-names></name><name><surname>Khan</surname><given-names>A</given-names></name><name><surname>van der Lee</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Richmond</surname><given-names>PA</given-names></name><name><surname>Modi</surname><given-names>BP</given-names></name><name><surname>Correard</surname><given-names>S</given-names></name><name><surname>Gheorghe</surname><given-names>M</given-names></name><name><surname>Baranašić</surname><given-names>D</given-names></name><name><surname>Santana-Garcia</surname><given-names>W</given-names></name><name><surname>Tan</surname><given-names>G</given-names></name><name><surname>Chèneby</surname><given-names>J</given-names></name><name><surname>Ballester</surname><given-names>B</given-names></name><name><surname>Parcy</surname><given-names>F</given-names></name><name><surname>Sandelin</surname><given-names>A</given-names></name><name><surname>Lenhard</surname><given-names>B</given-names></name><name><surname>Wasserman</surname><given-names>WW</given-names></name><name><surname>Mathelier</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>JASPAR 2020: update of the open-access database of transcription factor binding profiles</article-title><source>Nucleic Acids Research</source><volume>48</volume><fpage>D87</fpage><lpage>D92</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz1001</pub-id><pub-id pub-id-type="pmid">31701148</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frankish</surname><given-names>A</given-names></name><name><surname>Diekhans</surname><given-names>M</given-names></name><name><surname>Ferreira</surname><given-names>A-M</given-names></name><name><surname>Johnson</surname><given-names>R</given-names></name><name><surname>Jungreis</surname><given-names>I</given-names></name><name><surname>Loveland</surname><given-names>J</given-names></name><name><surname>Mudge</surname><given-names>JM</given-names></name><name><surname>Sisu</surname><given-names>C</given-names></name><name><surname>Wright</surname><given-names>J</given-names></name><name><surname>Armstrong</surname><given-names>J</given-names></name><name><surname>Barnes</surname><given-names>I</given-names></name><name><surname>Berry</surname><given-names>A</given-names></name><name><surname>Bignell</surname><given-names>A</given-names></name><name><surname>Carbonell Sala</surname><given-names>S</given-names></name><name><surname>Chrast</surname><given-names>J</given-names></name><name><surname>Cunningham</surname><given-names>F</given-names></name><name><surname>Di Domenico</surname><given-names>T</given-names></name><name><surname>Donaldson</surname><given-names>S</given-names></name><name><surname>Fiddes</surname><given-names>IT</given-names></name><name><surname>García Girón</surname><given-names>C</given-names></name><name><surname>Gonzalez</surname><given-names>JM</given-names></name><name><surname>Grego</surname><given-names>T</given-names></name><name><surname>Hardy</surname><given-names>M</given-names></name><name><surname>Hourlier</surname><given-names>T</given-names></name><name><surname>Hunt</surname><given-names>T</given-names></name><name><surname>Izuogu</surname><given-names>OG</given-names></name><name><surname>Lagarde</surname><given-names>J</given-names></name><name><surname>Martin</surname><given-names>FJ</given-names></name><name><surname>Martínez</surname><given-names>L</given-names></name><name><surname>Mohanan</surname><given-names>S</given-names></name><name><surname>Muir</surname><given-names>P</given-names></name><name><surname>Navarro</surname><given-names>FCP</given-names></name><name><surname>Parker</surname><given-names>A</given-names></name><name><surname>Pei</surname><given-names>B</given-names></name><name><surname>Pozo</surname><given-names>F</given-names></name><name><surname>Ruffier</surname><given-names>M</given-names></name><name><surname>Schmitt</surname><given-names>BM</given-names></name><name><surname>Stapleton</surname><given-names>E</given-names></name><name><surname>Suner</surname><given-names>M-M</given-names></name><name><surname>Sycheva</surname><given-names>I</given-names></name><name><surname>Uszczynska-Ratajczak</surname><given-names>B</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Yates</surname><given-names>A</given-names></name><name><surname>Zerbino</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Aken</surname><given-names>B</given-names></name><name><surname>Choudhary</surname><given-names>JS</given-names></name><name><surname>Gerstein</surname><given-names>M</given-names></name><name><surname>Guigó</surname><given-names>R</given-names></name><name><surname>Hubbard</surname><given-names>TJP</given-names></name><name><surname>Kellis</surname><given-names>M</given-names></name><name><surname>Paten</surname><given-names>B</given-names></name><name><surname>Reymond</surname><given-names>A</given-names></name><name><surname>Tress</surname><given-names>ML</given-names></name><name><surname>Flicek</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>GENCODE reference annotation for the human and mouse genomes</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>D766</fpage><lpage>D773</lpage><pub-id pub-id-type="doi">10.1093/nar/gky955</pub-id><pub-id pub-id-type="pmid">30357393</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garber</surname><given-names>M</given-names></name><name><surname>Yosef</surname><given-names>N</given-names></name><name><surname>Goren</surname><given-names>A</given-names></name><name><surname>Raychowdhury</surname><given-names>R</given-names></name><name><surname>Thielke</surname><given-names>A</given-names></name><name><surname>Guttman</surname><given-names>M</given-names></name><name><surname>Robinson</surname><given-names>J</given-names></name><name><surname>Minie</surname><given-names>B</given-names></name><name><surname>Chevrier</surname><given-names>N</given-names></name><name><surname>Itzhaki</surname><given-names>Z</given-names></name><name><surname>Blecher-Gonen</surname><given-names>R</given-names></name><name><surname>Bornstein</surname><given-names>C</given-names></name><name><surname>Amann-Zalcenstein</surname><given-names>D</given-names></name><name><surname>Weiner</surname><given-names>A</given-names></name><name><surname>Friedrich</surname><given-names>D</given-names></name><name><surname>Meldrim</surname><given-names>J</given-names></name><name><surname>Ram</surname><given-names>O</given-names></name><name><surname>Cheng</surname><given-names>C</given-names></name><name><surname>Gnirke</surname><given-names>A</given-names></name><name><surname>Fisher</surname><given-names>S</given-names></name><name><surname>Friedman</surname><given-names>N</given-names></name><name><surname>Wong</surname><given-names>B</given-names></name><name><surname>Bernstein</surname><given-names>BE</given-names></name><name><surname>Nusbaum</surname><given-names>C</given-names></name><name><surname>Hacohen</surname><given-names>N</given-names></name><name><surname>Regev</surname><given-names>A</given-names></name><name><surname>Amit</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A high-throughput chromatin immunoprecipitation approach reveals principles of dynamic gene regulation in mammals</article-title><source>Molecular Cell</source><volume>47</volume><fpage>810</fpage><lpage>822</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2012.07.030</pub-id><pub-id pub-id-type="pmid">22940246</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibson</surname><given-names>DG</given-names></name><name><surname>Young</surname><given-names>L</given-names></name><name><surname>Chuang</surname><given-names>RY</given-names></name><name><surname>Venter</surname><given-names>JC</given-names></name><name><surname>Hutchison</surname><given-names>CA</given-names></name><name><surname>Smith</surname><given-names>HO</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Enzymatic assembly of DNA molecules up to several hundred kilobases</article-title><source>Nature Methods</source><volume>6</volume><fpage>343</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1318</pub-id><pub-id pub-id-type="pmid">19363495</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ginhoux</surname><given-names>F</given-names></name><name><surname>Guilliams</surname><given-names>M</given-names></name><name><surname>Merad</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Expanding dendritic cell nomenclature in the single-cell era</article-title><source>Nature Reviews. Immunology</source><volume>22</volume><fpage>67</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1038/s41577-022-00675-7</pub-id><pub-id pub-id-type="pmid">35027741</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graf</surname><given-names>T</given-names></name><name><surname>Enver</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Forcing cells to change lineages</article-title><source>Nature</source><volume>462</volume><fpage>587</fpage><lpage>594</lpage><pub-id pub-id-type="doi">10.1038/nature08533</pub-id><pub-id pub-id-type="pmid">19956253</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>FL</given-names></name><name><surname>van der Eb</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="1973">1973</year><article-title>A new technique for the assay of infectivity of human adenovirus 5 DNA</article-title><source>Virology</source><volume>52</volume><fpage>456</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1016/0042-6822(73)90341-3</pub-id><pub-id pub-id-type="pmid">4705382</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grajales-Reyes</surname><given-names>GE</given-names></name><name><surname>Iwata</surname><given-names>A</given-names></name><name><surname>Albring</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Tussiwand</surname><given-names>R</given-names></name><name><surname>Kc</surname><given-names>W</given-names></name><name><surname>Kretzer</surname><given-names>NM</given-names></name><name><surname>Briseño</surname><given-names>CG</given-names></name><name><surname>Durai</surname><given-names>V</given-names></name><name><surname>Bagadia</surname><given-names>P</given-names></name><name><surname>Haldar</surname><given-names>M</given-names></name><name><surname>Schönheit</surname><given-names>J</given-names></name><name><surname>Rosenbauer</surname><given-names>F</given-names></name><name><surname>Murphy</surname><given-names>TL</given-names></name><name><surname>Murphy</surname><given-names>KM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Batf3 maintains autoactivation of Irf8 for commitment of a CD8α<sup>+</sup> conventional DC clonogenic progenitor</article-title><source>Nature Immunology</source><volume>16</volume><fpage>708</fpage><lpage>717</lpage><pub-id pub-id-type="doi">10.1038/ni.3197</pub-id><pub-id pub-id-type="pmid">26054719</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heckl</surname><given-names>D</given-names></name><name><surname>Kowalczyk</surname><given-names>MS</given-names></name><name><surname>Yudovich</surname><given-names>D</given-names></name><name><surname>Belizaire</surname><given-names>R</given-names></name><name><surname>Puram</surname><given-names>RV</given-names></name><name><surname>McConkey</surname><given-names>ME</given-names></name><name><surname>Thielke</surname><given-names>A</given-names></name><name><surname>Aster</surname><given-names>JC</given-names></name><name><surname>Regev</surname><given-names>A</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing</article-title><source>Nature Biotechnology</source><volume>32</volume><fpage>941</fpage><lpage>946</lpage><pub-id pub-id-type="doi">10.1038/nbt.2951</pub-id><pub-id pub-id-type="pmid">24952903</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honda</surname><given-names>K</given-names></name><name><surname>Taniguchi</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors</article-title><source>Nature Reviews. Immunology</source><volume>6</volume><fpage>644</fpage><lpage>658</lpage><pub-id pub-id-type="doi">10.1038/nri1900</pub-id><pub-id pub-id-type="pmid">16932750</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>XF</given-names></name><name><surname>Nandakumar</surname><given-names>V</given-names></name><name><surname>Tumurkhuu</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Hong</surname><given-names>B</given-names></name><name><surname>Jones</surname><given-names>L</given-names></name><name><surname>Won</surname><given-names>H</given-names></name><name><surname>Yoshii</surname><given-names>H</given-names></name><name><surname>Ozato</surname><given-names>K</given-names></name><name><surname>Masumi</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>S-Y</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Mysm1 is required for interferon regulatory factor expression in maintaining HSC quiescence and thymocyte development</article-title><source>Cell Death &amp; Disease</source><volume>7</volume><elocation-id>e2260</elocation-id><pub-id pub-id-type="doi">10.1038/cddis.2016.162</pub-id><pub-id pub-id-type="pmid">27277682</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Humblin</surname><given-names>E</given-names></name><name><surname>Thibaudin</surname><given-names>M</given-names></name><name><surname>Chalmin</surname><given-names>F</given-names></name><name><surname>Derangère</surname><given-names>V</given-names></name><name><surname>Limagne</surname><given-names>E</given-names></name><name><surname>Richard</surname><given-names>C</given-names></name><name><surname>Flavell</surname><given-names>RA</given-names></name><name><surname>Chevrier</surname><given-names>S</given-names></name><name><surname>Ladoire</surname><given-names>S</given-names></name><name><surname>Berger</surname><given-names>H</given-names></name><name><surname>Boidot</surname><given-names>R</given-names></name><name><surname>Apetoh</surname><given-names>L</given-names></name><name><surname>Végran</surname><given-names>F</given-names></name><name><surname>Ghiringhelli</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>IRF8-dependent molecular complexes control the Th9 transcriptional program</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>2085</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-017-01070-w</pub-id><pub-id pub-id-type="pmid">29233972</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Bagadia</surname><given-names>P</given-names></name><name><surname>Anderson</surname><given-names>DA</given-names></name><name><surname>Liu</surname><given-names>TT</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Theisen</surname><given-names>DJ</given-names></name><name><surname>O’Connor</surname><given-names>KW</given-names></name><name><surname>Ohara</surname><given-names>RA</given-names></name><name><surname>Iwata</surname><given-names>A</given-names></name><name><surname>Murphy</surname><given-names>TL</given-names></name><name><surname>Murphy</surname><given-names>KM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>High amount of transcription factor IRF8 engages AP1-IRF composite elements in enhancers to direct type 1 conventional dendritic cell identity</article-title><source>Immunity</source><volume>53</volume><fpage>759</fpage><lpage>774</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2020.07.018</pub-id><pub-id pub-id-type="pmid">32795402</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Konermann</surname><given-names>S</given-names></name><name><surname>Brigham</surname><given-names>MD</given-names></name><name><surname>Trevino</surname><given-names>AE</given-names></name><name><surname>Joung</surname><given-names>J</given-names></name><name><surname>Abudayyeh</surname><given-names>OO</given-names></name><name><surname>Barcena</surname><given-names>C</given-names></name><name><surname>Hsu</surname><given-names>PD</given-names></name><name><surname>Habib</surname><given-names>N</given-names></name><name><surname>Gootenberg</surname><given-names>JS</given-names></name><name><surname>Nishimasu</surname><given-names>H</given-names></name><name><surname>Nureki</surname><given-names>O</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Genome-Scale transcriptional activation by an engineered CRISPR-Cas9 complex</article-title><source>Nature</source><volume>517</volume><fpage>583</fpage><lpage>588</lpage><pub-id pub-id-type="doi">10.1038/nature14136</pub-id><pub-id pub-id-type="pmid">25494202</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Konieczna</surname><given-names>I</given-names></name><name><surname>Horvath</surname><given-names>E</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Lindsey</surname><given-names>S</given-names></name><name><surname>Saberwal</surname><given-names>G</given-names></name><name><surname>Bei</surname><given-names>L</given-names></name><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Platanias</surname><given-names>L</given-names></name><name><surname>Eklund</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Constitutive activation of SHP2 in mice cooperates with ICSBP deficiency to accelerate progression to acute myeloid leukemia</article-title><source>The Journal of Clinical Investigation</source><volume>118</volume><fpage>853</fpage><lpage>867</lpage><pub-id pub-id-type="doi">10.1172/JCI33742</pub-id><pub-id pub-id-type="pmid">18246201</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korhonen</surname><given-names>J</given-names></name><name><surname>Martinmäki</surname><given-names>P</given-names></name><name><surname>Pizzi</surname><given-names>C</given-names></name><name><surname>Rastas</surname><given-names>P</given-names></name><name><surname>Ukkonen</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>MOODS: fast search for position weight matrix matches in DNA sequences</article-title><source>Bioinformatics</source><volume>25</volume><fpage>3181</fpage><lpage>3182</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp554</pub-id><pub-id pub-id-type="pmid">19773334</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kühn</surname><given-names>R</given-names></name><name><surname>Schwenk</surname><given-names>F</given-names></name><name><surname>Aguet</surname><given-names>M</given-names></name><name><surname>Rajewsky</surname><given-names>K</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Inducible gene targeting in mice</article-title><source>Science</source><volume>269</volume><fpage>1427</fpage><lpage>1429</lpage><pub-id pub-id-type="doi">10.1126/science.7660125</pub-id><pub-id pub-id-type="pmid">7660125</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurotaki</surname><given-names>D</given-names></name><name><surname>Yamamoto</surname><given-names>M</given-names></name><name><surname>Nishiyama</surname><given-names>A</given-names></name><name><surname>Uno</surname><given-names>K</given-names></name><name><surname>Ban</surname><given-names>T</given-names></name><name><surname>Ichino</surname><given-names>M</given-names></name><name><surname>Sasaki</surname><given-names>H</given-names></name><name><surname>Matsunaga</surname><given-names>S</given-names></name><name><surname>Yoshinari</surname><given-names>M</given-names></name><name><surname>Ryo</surname><given-names>A</given-names></name><name><surname>Nakazawa</surname><given-names>M</given-names></name><name><surname>Ozato</surname><given-names>K</given-names></name><name><surname>Tamura</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>IRF8 inhibits C/EBPα activity to restrain mononuclear phagocyte progenitors from differentiating into neutrophils</article-title><source>Nature Communications</source><volume>5</volume><elocation-id>4978</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms5978</pub-id><pub-id pub-id-type="pmid">25236377</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurotaki</surname><given-names>D</given-names></name><name><surname>Kawase</surname><given-names>W</given-names></name><name><surname>Sasaki</surname><given-names>H</given-names></name><name><surname>Nakabayashi</surname><given-names>J</given-names></name><name><surname>Nishiyama</surname><given-names>A</given-names></name><name><surname>Morse</surname><given-names>HC</given-names></name><name><surname>Ozato</surname><given-names>K</given-names></name><name><surname>Suzuki</surname><given-names>Y</given-names></name><name><surname>Tamura</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Epigenetic control of early dendritic cell lineage specification by the transcription factor IRF8 in mice</article-title><source>Blood</source><volume>133</volume><fpage>1803</fpage><lpage>1813</lpage><pub-id pub-id-type="doi">10.1182/blood-2018-06-857789</pub-id><pub-id pub-id-type="pmid">30796024</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurotaki</surname><given-names>D</given-names></name><name><surname>Kikuchi</surname><given-names>K</given-names></name><name><surname>Cui</surname><given-names>K</given-names></name><name><surname>Kawase</surname><given-names>W</given-names></name><name><surname>Saeki</surname><given-names>K</given-names></name><name><surname>Fukumoto</surname><given-names>J</given-names></name><name><surname>Nishiyama</surname><given-names>A</given-names></name><name><surname>Nagamune</surname><given-names>K</given-names></name><name><surname>Zhao</surname><given-names>K</given-names></name><name><surname>Ozato</surname><given-names>K</given-names></name><name><surname>Rocha</surname><given-names>PP</given-names></name><name><surname>Tamura</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Chromatin structure undergoes global and local reorganization during murine dendritic cell development and activation</article-title><source>PNAS</source><volume>119</volume><elocation-id>e2207009119</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2207009119</pub-id><pub-id pub-id-type="pmid">35969760</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landazuri</surname><given-names>N</given-names></name><name><surname>Krishna</surname><given-names>D</given-names></name><name><surname>Gupta</surname><given-names>M</given-names></name><name><surname>Le Doux</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Retrovirus-polymer complexes: study of the factors affecting the dose response of transduction</article-title><source>Biotechnology Progress</source><volume>23</volume><fpage>480</fpage><lpage>487</lpage><pub-id pub-id-type="doi">10.1021/bp060336y</pub-id><pub-id pub-id-type="pmid">17373825</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langmead</surname><given-names>B</given-names></name><name><surname>Salzberg</surname><given-names>SL</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fast gapped-read alignment with bowtie 2</article-title><source>Nature Methods</source><volume>9</volume><fpage>357</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1923</pub-id><pub-id pub-id-type="pmid">22388286</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname><given-names>CM</given-names></name><name><surname>Tiniakou</surname><given-names>I</given-names></name><name><surname>Perez</surname><given-names>OA</given-names></name><name><surname>Kirkling</surname><given-names>ME</given-names></name><name><surname>Yap</surname><given-names>GS</given-names></name><name><surname>Hock</surname><given-names>H</given-names></name><name><surname>Reizis</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Transcription factor ETV6 regulates functional differentiation of cross-presenting classical dendritic cells</article-title><source>The Journal of Experimental Medicine</source><volume>215</volume><fpage>2265</fpage><lpage>2278</lpage><pub-id pub-id-type="doi">10.1084/jem.20172323</pub-id><pub-id pub-id-type="pmid">30087163</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laurenti</surname><given-names>E</given-names></name><name><surname>Göttgens</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>From haematopoietic stem cells to complex differentiation landscapes</article-title><source>Nature</source><volume>553</volume><fpage>418</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1038/nature25022</pub-id><pub-id pub-id-type="pmid">29364285</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Schulz</surname><given-names>MH</given-names></name><name><surname>Look</surname><given-names>T</given-names></name><name><surname>Begemann</surname><given-names>M</given-names></name><name><surname>Zenke</surname><given-names>M</given-names></name><name><surname>Costa</surname><given-names>IG</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Identification of transcription factor binding sites using ATAC-seq</article-title><source>Genome Biology</source><volume>20</volume><elocation-id>45</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-019-1642-2</pub-id><pub-id pub-id-type="pmid">30808370</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>MF</given-names></name><name><surname>Jungreis</surname><given-names>I</given-names></name><name><surname>Kellis</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>PhyloCSF: a comparative genomics method to distinguish protein coding and non-coding regions</article-title><source>Bioinformatics</source><volume>27</volume><fpage>i275</fpage><lpage>i282</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btr209</pub-id><pub-id pub-id-type="pmid">21685081</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>Q</given-names></name><name><surname>Chauvistré</surname><given-names>H</given-names></name><name><surname>Costa</surname><given-names>IG</given-names></name><name><surname>Gusmao</surname><given-names>EG</given-names></name><name><surname>Mitzka</surname><given-names>S</given-names></name><name><surname>Hänzelmann</surname><given-names>S</given-names></name><name><surname>Baying</surname><given-names>B</given-names></name><name><surname>Klisch</surname><given-names>T</given-names></name><name><surname>Moriggl</surname><given-names>R</given-names></name><name><surname>Hennuy</surname><given-names>B</given-names></name><name><surname>Smeets</surname><given-names>H</given-names></name><name><surname>Hoffmann</surname><given-names>K</given-names></name><name><surname>Benes</surname><given-names>V</given-names></name><name><surname>Seré</surname><given-names>K</given-names></name><name><surname>Zenke</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Epigenetic program and transcription factor circuitry of dendritic cell development</article-title><source>Nucleic Acids Research</source><volume>43</volume><fpage>9680</fpage><lpage>9693</lpage><pub-id pub-id-type="doi">10.1093/nar/gkv1056</pub-id><pub-id pub-id-type="pmid">26476451</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>HK</given-names></name><name><surname>Prescott</surname><given-names>SL</given-names></name><name><surname>Wysocka</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Ever-changing landscapes: transcriptional enhancers in development and evolution</article-title><source>Cell</source><volume>167</volume><fpage>1170</fpage><lpage>1187</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.09.018</pub-id><pub-id pub-id-type="pmid">27863239</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loughran</surname><given-names>SJ</given-names></name><name><surname>Haas</surname><given-names>S</given-names></name><name><surname>Wilkinson</surname><given-names>AC</given-names></name><name><surname>Klein</surname><given-names>AM</given-names></name><name><surname>Brand</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Lineage commitment of hematopoietic stem cells and progenitors: insights from recent single cell and lineage tracing technologies</article-title><source>Experimental Hematology</source><volume>88</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.exphem.2020.07.002</pub-id><pub-id pub-id-type="pmid">32653531</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lutz</surname><given-names>MB</given-names></name><name><surname>Ali</surname><given-names>S</given-names></name><name><surname>Audiger</surname><given-names>C</given-names></name><name><surname>Autenrieth</surname><given-names>SE</given-names></name><name><surname>Berod</surname><given-names>L</given-names></name><name><surname>Bigley</surname><given-names>V</given-names></name><name><surname>Cyran</surname><given-names>L</given-names></name><name><surname>Dalod</surname><given-names>M</given-names></name><name><surname>Dörrie</surname><given-names>J</given-names></name><name><surname>Dudziak</surname><given-names>D</given-names></name><name><surname>Flórez-Grau</surname><given-names>G</given-names></name><name><surname>Giusiano</surname><given-names>L</given-names></name><name><surname>Godoy</surname><given-names>GJ</given-names></name><name><surname>Heuer</surname><given-names>M</given-names></name><name><surname>Krug</surname><given-names>AB</given-names></name><name><surname>Lehmann</surname><given-names>CHK</given-names></name><name><surname>Mayer</surname><given-names>CT</given-names></name><name><surname>Naik</surname><given-names>SH</given-names></name><name><surname>Scheu</surname><given-names>S</given-names></name><name><surname>Schreibelt</surname><given-names>G</given-names></name><name><surname>Segura</surname><given-names>E</given-names></name><name><surname>Seré</surname><given-names>K</given-names></name><name><surname>Sparwasser</surname><given-names>T</given-names></name><name><surname>Tel</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Zenke</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Guidelines for mouse and human DC generation</article-title><source>European Journal of Immunology</source><pub-id pub-id-type="doi">10.1002/eji.202249816</pub-id><pub-id pub-id-type="pmid">36303448</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manguso</surname><given-names>RT</given-names></name><name><surname>Pope</surname><given-names>HW</given-names></name><name><surname>Zimmer</surname><given-names>MD</given-names></name><name><surname>Brown</surname><given-names>FD</given-names></name><name><surname>Yates</surname><given-names>KB</given-names></name><name><surname>Miller</surname><given-names>BC</given-names></name><name><surname>Collins</surname><given-names>NB</given-names></name><name><surname>Bi</surname><given-names>K</given-names></name><name><surname>LaFleur</surname><given-names>MW</given-names></name><name><surname>Juneja</surname><given-names>VR</given-names></name><name><surname>Weiss</surname><given-names>SA</given-names></name><name><surname>Lo</surname><given-names>J</given-names></name><name><surname>Fisher</surname><given-names>DE</given-names></name><name><surname>Miao</surname><given-names>D</given-names></name><name><surname>Van Allen</surname><given-names>E</given-names></name><name><surname>Root</surname><given-names>DE</given-names></name><name><surname>Sharpe</surname><given-names>AH</given-names></name><name><surname>Doench</surname><given-names>JG</given-names></name><name><surname>Haining</surname><given-names>WN</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target</article-title><source>Nature</source><volume>547</volume><fpage>413</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1038/nature23270</pub-id><pub-id pub-id-type="pmid">28723893</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Misteli</surname><given-names>T</given-names></name><name><surname>Finn</surname><given-names>EH</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Chromatin architecture is a flexible foundation for gene expression</article-title><source>Nature Genetics</source><volume>53</volume><fpage>426</fpage><lpage>427</lpage><pub-id pub-id-type="doi">10.1038/s41588-021-00813-2</pub-id><pub-id pub-id-type="pmid">33795865</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murakami</surname><given-names>K</given-names></name><name><surname>Sasaki</surname><given-names>H</given-names></name><name><surname>Nishiyama</surname><given-names>A</given-names></name><name><surname>Kurotaki</surname><given-names>D</given-names></name><name><surname>Kawase</surname><given-names>W</given-names></name><name><surname>Ban</surname><given-names>T</given-names></name><name><surname>Nakabayashi</surname><given-names>J</given-names></name><name><surname>Kanzaki</surname><given-names>S</given-names></name><name><surname>Sekita</surname><given-names>Y</given-names></name><name><surname>Nakajima</surname><given-names>H</given-names></name><name><surname>Ozato</surname><given-names>K</given-names></name><name><surname>Kimura</surname><given-names>T</given-names></name><name><surname>Tamura</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A RUNX-CBFβ-driven enhancer directs the Irf8 dose-dependent lineage choice between DCs and monocytes</article-title><source>Nature Immunology</source><volume>22</volume><fpage>301</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1038/s41590-021-00871-y</pub-id><pub-id pub-id-type="pmid">33603226</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishimura</surname><given-names>S</given-names></name><name><surname>Takahashi</surname><given-names>S</given-names></name><name><surname>Kuroha</surname><given-names>T</given-names></name><name><surname>Suwabe</surname><given-names>N</given-names></name><name><surname>Nagasawa</surname><given-names>T</given-names></name><name><surname>Trainor</surname><given-names>C</given-names></name><name><surname>Yamamoto</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>A GATA box in the GATA-1 gene hematopoietic enhancer is a critical element in the network of GATA factors and sites that regulate this gene</article-title><source>Molecular and Cellular Biology</source><volume>20</volume><fpage>713</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.1128/MCB.20.2.713-723.2000</pub-id><pub-id pub-id-type="pmid">10611250</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nutt</surname><given-names>SL</given-names></name><name><surname>Chopin</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Transcriptional networks driving dendritic cell differentiation and function</article-title><source>Immunity</source><volume>52</volume><fpage>942</fpage><lpage>956</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2020.05.005</pub-id><pub-id pub-id-type="pmid">32553180</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okuno</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>G</given-names></name><name><surname>Rosenbauer</surname><given-names>F</given-names></name><name><surname>Evans</surname><given-names>EK</given-names></name><name><surname>Radomska</surname><given-names>HS</given-names></name><name><surname>Iwasaki</surname><given-names>H</given-names></name><name><surname>Akashi</surname><given-names>K</given-names></name><name><surname>Moreau-Gachelin</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Göttgens</surname><given-names>B</given-names></name><name><surname>Tenen</surname><given-names>DG</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Potential autoregulation of transcription factor PU.1 by an upstream regulatory element</article-title><source>Molecular and Cellular Biology</source><volume>25</volume><fpage>2832</fpage><lpage>2845</lpage><pub-id pub-id-type="doi">10.1128/MCB.25.7.2832-2845.2005</pub-id><pub-id pub-id-type="pmid">15767686</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oudelaar</surname><given-names>AM</given-names></name><name><surname>Beagrie</surname><given-names>RA</given-names></name><name><surname>Gosden</surname><given-names>M</given-names></name><name><surname>de Ornellas</surname><given-names>S</given-names></name><name><surname>Georgiades</surname><given-names>E</given-names></name><name><surname>Kerry</surname><given-names>J</given-names></name><name><surname>Hidalgo</surname><given-names>D</given-names></name><name><surname>Carrelha</surname><given-names>J</given-names></name><name><surname>Shivalingam</surname><given-names>A</given-names></name><name><surname>El-Sagheer</surname><given-names>AH</given-names></name><name><surname>Telenius</surname><given-names>JM</given-names></name><name><surname>Brown</surname><given-names>T</given-names></name><name><surname>Buckle</surname><given-names>VJ</given-names></name><name><surname>Socolovsky</surname><given-names>M</given-names></name><name><surname>Higgs</surname><given-names>DR</given-names></name><name><surname>Hughes</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Dynamics of the 4D genome during in vivo lineage specification and differentiation</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>2722</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-16598-7</pub-id><pub-id pub-id-type="pmid">32483172</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oudelaar</surname><given-names>A.M</given-names></name><name><surname>Higgs</surname><given-names>DR</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The relationship between genome structure and function</article-title><source>Nature Reviews. Genetics</source><volume>22</volume><fpage>154</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1038/s41576-020-00303-x</pub-id><pub-id pub-id-type="pmid">33235358</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Owens</surname><given-names>DDG</given-names></name><name><surname>Anselmi</surname><given-names>G</given-names></name><name><surname>Oudelaar</surname><given-names>AM</given-names></name><name><surname>Downes</surname><given-names>DJ</given-names></name><name><surname>Cavallo</surname><given-names>A</given-names></name><name><surname>Harman</surname><given-names>JR</given-names></name><name><surname>Schwessinger</surname><given-names>R</given-names></name><name><surname>Bucakci</surname><given-names>A</given-names></name><name><surname>Greder</surname><given-names>L</given-names></name><name><surname>de Ornellas</surname><given-names>S</given-names></name><name><surname>Jeziorska</surname><given-names>D</given-names></name><name><surname>Telenius</surname><given-names>J</given-names></name><name><surname>Hughes</surname><given-names>JR</given-names></name><name><surname>de Bruijn</surname><given-names>MFTR</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Dynamic Runx1 chromatin boundaries affect gene expression in hematopoietic development</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>773</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-28376-8</pub-id><pub-id pub-id-type="pmid">35140205</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pang</surname><given-names>ES</given-names></name><name><surname>Daraj</surname><given-names>G</given-names></name><name><surname>Balka</surname><given-names>KR</given-names></name><name><surname>De Nardo</surname><given-names>D</given-names></name><name><surname>Macri</surname><given-names>C</given-names></name><name><surname>Hochrein</surname><given-names>H</given-names></name><name><surname>Masterman</surname><given-names>K-A</given-names></name><name><surname>Tan</surname><given-names>PS</given-names></name><name><surname>Shoppee</surname><given-names>A</given-names></name><name><surname>Magill</surname><given-names>Z</given-names></name><name><surname>Jahan</surname><given-names>N</given-names></name><name><surname>Bafit</surname><given-names>M</given-names></name><name><surname>Zhan</surname><given-names>Y</given-names></name><name><surname>Kile</surname><given-names>BT</given-names></name><name><surname>Lawlor</surname><given-names>KE</given-names></name><name><surname>Radford</surname><given-names>KJ</given-names></name><name><surname>Wright</surname><given-names>MD</given-names></name><name><surname>O’Keeffe</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Discordance in STING-induced activation and cell death between mouse and human dendritic cell populations</article-title><source>Frontiers in Immunology</source><volume>13</volume><elocation-id>794776</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.794776</pub-id><pub-id pub-id-type="pmid">35281062</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Platt</surname><given-names>RJ</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Yim</surname><given-names>MJ</given-names></name><name><surname>Swiech</surname><given-names>L</given-names></name><name><surname>Kempton</surname><given-names>HR</given-names></name><name><surname>Dahlman</surname><given-names>JE</given-names></name><name><surname>Parnas</surname><given-names>O</given-names></name><name><surname>Eisenhaure</surname><given-names>TM</given-names></name><name><surname>Jovanovic</surname><given-names>M</given-names></name><name><surname>Graham</surname><given-names>DB</given-names></name><name><surname>Jhunjhunwala</surname><given-names>S</given-names></name><name><surname>Heidenreich</surname><given-names>M</given-names></name><name><surname>Xavier</surname><given-names>RJ</given-names></name><name><surname>Langer</surname><given-names>R</given-names></name><name><surname>Anderson</surname><given-names>DG</given-names></name><name><surname>Hacohen</surname><given-names>N</given-names></name><name><surname>Regev</surname><given-names>A</given-names></name><name><surname>Feng</surname><given-names>G</given-names></name><name><surname>Sharp</surname><given-names>PA</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>CRISPR-Cas9 knockin mice for genome editing and cancer modeling</article-title><source>Cell</source><volume>159</volume><fpage>440</fpage><lpage>455</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2014.09.014</pub-id><pub-id pub-id-type="pmid">25263330</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Redecke</surname><given-names>V</given-names></name><name><surname>Wu</surname><given-names>R</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Finkelstein</surname><given-names>D</given-names></name><name><surname>Chaturvedi</surname><given-names>V</given-names></name><name><surname>High</surname><given-names>AA</given-names></name><name><surname>Häcker</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Hematopoietic progenitor cell lines with myeloid and lymphoid potential</article-title><source>Nature Methods</source><volume>10</volume><fpage>795</fpage><lpage>803</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2510</pub-id><pub-id pub-id-type="pmid">23749299</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodrigues</surname><given-names>PF</given-names></name><name><surname>Alberti-Servera</surname><given-names>L</given-names></name><name><surname>Eremin</surname><given-names>A</given-names></name><name><surname>Grajales-Reyes</surname><given-names>GE</given-names></name><name><surname>Ivanek</surname><given-names>R</given-names></name><name><surname>Tussiwand</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Distinct progenitor lineages contribute to the heterogeneity of plasmacytoid dendritic cells</article-title><source>Nature Immunology</source><volume>19</volume><fpage>711</fpage><lpage>722</lpage><pub-id pub-id-type="doi">10.1038/s41590-018-0136-9</pub-id><pub-id pub-id-type="pmid">29925996</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodrigues</surname><given-names>PF</given-names></name><name><surname>Tussiwand</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Novel concepts in plasmacytoid dendritic cell (pDC) development and differentiation</article-title><source>Molecular Immunology</source><volume>126</volume><fpage>25</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2020.07.006</pub-id><pub-id pub-id-type="pmid">32739721</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanborn</surname><given-names>AL</given-names></name><name><surname>Rao</surname><given-names>SSP</given-names></name><name><surname>Huang</surname><given-names>SC</given-names></name><name><surname>Durand</surname><given-names>NC</given-names></name><name><surname>Huntley</surname><given-names>MH</given-names></name><name><surname>Jewett</surname><given-names>AI</given-names></name><name><surname>Bochkov</surname><given-names>ID</given-names></name><name><surname>Chinnappan</surname><given-names>D</given-names></name><name><surname>Cutkosky</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Geeting</surname><given-names>KP</given-names></name><name><surname>Gnirke</surname><given-names>A</given-names></name><name><surname>Melnikov</surname><given-names>A</given-names></name><name><surname>McKenna</surname><given-names>D</given-names></name><name><surname>Stamenova</surname><given-names>EK</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Aiden</surname><given-names>EL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Chromatin extrusion explains key features of loop and domain formation in wild-type and engineered genomes</article-title><source>PNAS</source><volume>112</volume><fpage>E6456</fpage><lpage>E6465</lpage><pub-id pub-id-type="doi">10.1073/pnas.1518552112</pub-id><pub-id pub-id-type="pmid">26499245</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sartorelli</surname><given-names>V</given-names></name><name><surname>Lauberth</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Enhancer RNAs are an important regulatory layer of the epigenome</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>27</volume><fpage>521</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1038/s41594-020-0446-0</pub-id><pub-id pub-id-type="pmid">32514177</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schiavoni</surname><given-names>G</given-names></name><name><surname>Mattei</surname><given-names>F</given-names></name><name><surname>Sestili</surname><given-names>P</given-names></name><name><surname>Borghi</surname><given-names>P</given-names></name><name><surname>Venditti</surname><given-names>M</given-names></name><name><surname>Morse</surname><given-names>HC</given-names></name><name><surname>Belardelli</surname><given-names>F</given-names></name><name><surname>Gabriele</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>ICSBP is essential for the development of mouse type I interferon-producing cells and for the generation and activation of CD8α<sup>+</sup> dendritic cells</article-title><source>The Journal of Experimental Medicine</source><volume>196</volume><fpage>1415</fpage><lpage>1425</lpage><pub-id pub-id-type="doi">10.1084/jem.20021263</pub-id><pub-id pub-id-type="pmid">12461077</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schönheit</surname><given-names>J</given-names></name><name><surname>Kuhl</surname><given-names>C</given-names></name><name><surname>Gebhardt</surname><given-names>ML</given-names></name><name><surname>Klett</surname><given-names>FF</given-names></name><name><surname>Riemke</surname><given-names>P</given-names></name><name><surname>Scheller</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>G</given-names></name><name><surname>Naumann</surname><given-names>R</given-names></name><name><surname>Leutz</surname><given-names>A</given-names></name><name><surname>Stocking</surname><given-names>C</given-names></name><name><surname>Priller</surname><given-names>J</given-names></name><name><surname>Andrade-Navarro</surname><given-names>MA</given-names></name><name><surname>Rosenbauer</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>PU.1 level-directed chromatin structure remodeling at the Irf8 gene drives dendritic cell commitment</article-title><source>Cell Reports</source><volume>3</volume><fpage>1617</fpage><lpage>1628</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2013.04.007</pub-id><pub-id pub-id-type="pmid">23623495</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scotto-Lavino</surname><given-names>E</given-names></name><name><surname>Du</surname><given-names>G</given-names></name><name><surname>Frohman</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>3’ end cDNA amplification using classic race</article-title><source>Nature Protocols</source><volume>1</volume><fpage>2742</fpage><lpage>2745</lpage><pub-id pub-id-type="doi">10.1038/nprot.2006.481</pub-id><pub-id pub-id-type="pmid">17406530</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sichien</surname><given-names>D</given-names></name><name><surname>Scott</surname><given-names>CL</given-names></name><name><surname>Martens</surname><given-names>L</given-names></name><name><surname>Vanderkerken</surname><given-names>M</given-names></name><name><surname>Van Gassen</surname><given-names>S</given-names></name><name><surname>Plantinga</surname><given-names>M</given-names></name><name><surname>Joeris</surname><given-names>T</given-names></name><name><surname>De Prijck</surname><given-names>S</given-names></name><name><surname>Vanhoutte</surname><given-names>L</given-names></name><name><surname>Vanheerswynghels</surname><given-names>M</given-names></name><name><surname>Van Isterdael</surname><given-names>G</given-names></name><name><surname>Toussaint</surname><given-names>W</given-names></name><name><surname>Madeira</surname><given-names>FB</given-names></name><name><surname>Vergote</surname><given-names>K</given-names></name><name><surname>Agace</surname><given-names>WW</given-names></name><name><surname>Clausen</surname><given-names>BE</given-names></name><name><surname>Hammad</surname><given-names>H</given-names></name><name><surname>Dalod</surname><given-names>M</given-names></name><name><surname>Saeys</surname><given-names>Y</given-names></name><name><surname>Lambrecht</surname><given-names>BN</given-names></name><name><surname>Guilliams</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>IRF8 transcription factor controls survival and function of terminally differentiated conventional and plasmacytoid dendritic cells, respectively</article-title><source>Immunity</source><volume>45</volume><fpage>626</fpage><lpage>640</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2016.08.013</pub-id><pub-id pub-id-type="pmid">27637148</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="software"><person-group person-group-type="author"><collab>sims-lab</collab></person-group><year iso-8601-date="2022">2022</year><data-title>CapCruncher</data-title><version designator="81786d0">81786d0</version><source>GitHub</source><ext-link ext-link-type="uri" xlink:href="https://github.com/sims-lab/CapCruncher">https://github.com/sims-lab/CapCruncher</ext-link></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stadhouders</surname><given-names>R</given-names></name><name><surname>Filion</surname><given-names>GJ</given-names></name><name><surname>Graf</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Transcription factors and 3D genome conformation in cell-fate decisions</article-title><source>Nature</source><volume>569</volume><fpage>345</fpage><lpage>354</lpage><pub-id pub-id-type="doi">10.1038/s41586-019-1182-7</pub-id><pub-id pub-id-type="pmid">31092938</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Statello</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>CJ</given-names></name><name><surname>Chen</surname><given-names>LL</given-names></name><name><surname>Huarte</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Gene regulation by long non-coding RNAs and its biological functions</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>22</volume><fpage>96</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1038/s41580-020-00315-9</pub-id><pub-id pub-id-type="pmid">33353982</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamura</surname><given-names>T</given-names></name><name><surname>Yanai</surname><given-names>H</given-names></name><name><surname>Savitsky</surname><given-names>D</given-names></name><name><surname>Taniguchi</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The IRF family transcription factors in immunity and oncogenesis</article-title><source>Annual Review of Immunology</source><volume>26</volume><fpage>535</fpage><lpage>584</lpage><pub-id pub-id-type="doi">10.1146/annurev.immunol.26.021607.090400</pub-id><pub-id pub-id-type="pmid">18303999</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamura</surname><given-names>T</given-names></name><name><surname>Kurotaki</surname><given-names>D</given-names></name><name><surname>Koizumi</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Regulation of myelopoiesis by the transcription factor IRF8</article-title><source>International Journal of Hematology</source><volume>101</volume><fpage>342</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1007/s12185-015-1761-9</pub-id><pub-id pub-id-type="pmid">25749660</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theilgaard-Mönch</surname><given-names>K</given-names></name><name><surname>Pundhir</surname><given-names>S</given-names></name><name><surname>Reckzeh</surname><given-names>K</given-names></name><name><surname>Su</surname><given-names>J</given-names></name><name><surname>Tapia</surname><given-names>M</given-names></name><name><surname>Furtwängler</surname><given-names>B</given-names></name><name><surname>Jendholm</surname><given-names>J</given-names></name><name><surname>Jakobsen</surname><given-names>JS</given-names></name><name><surname>Hasemann</surname><given-names>MS</given-names></name><name><surname>Knudsen</surname><given-names>KJ</given-names></name><name><surname>Cowland</surname><given-names>JB</given-names></name><name><surname>Fossum</surname><given-names>A</given-names></name><name><surname>Schoof</surname><given-names>E</given-names></name><name><surname>Schuster</surname><given-names>MB</given-names></name><name><surname>Porse</surname><given-names>BT</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Transcription factor-driven coordination of cell cycle exit and lineage-specification in vivo during granulocytic differentiation: in memoriam Professor Niels borregaard</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>3595</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-31332-1</pub-id><pub-id pub-id-type="pmid">35739121</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trapnell</surname><given-names>C</given-names></name><name><surname>Roberts</surname><given-names>A</given-names></name><name><surname>Goff</surname><given-names>L</given-names></name><name><surname>Pertea</surname><given-names>G</given-names></name><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Kelley</surname><given-names>DR</given-names></name><name><surname>Pimentel</surname><given-names>H</given-names></name><name><surname>Salzberg</surname><given-names>SL</given-names></name><name><surname>Rinn</surname><given-names>JL</given-names></name><name><surname>Pachter</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Differential gene and transcript expression analysis of RNA-Seq experiments with tophat and cufflinks</article-title><source>Nature Protocols</source><volume>7</volume><fpage>562</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1038/nprot.2012.016</pub-id><pub-id pub-id-type="pmid">22383036</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsujimura</surname><given-names>H</given-names></name><name><surname>Tamura</surname><given-names>T</given-names></name><name><surname>Ozato</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Cutting edge: IFN consensus sequence binding protein/IFN regulatory factor 8 drives the development of type I IFN-producing plasmacytoid dendritic cells</article-title><source>Journal of Immunology</source><volume>170</volume><fpage>1131</fpage><lpage>1135</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.170.3.1131</pub-id><pub-id pub-id-type="pmid">12538667</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verlander</surname><given-names>Z</given-names></name><name><surname>Cummings</surname><given-names>A</given-names></name><name><surname>Brown</surname><given-names>HM</given-names></name><name><surname>Sen</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Advances in understanding epigenetic impacts on dendritic cell regulation and function</article-title><source>Clinical and Translational Discovery</source><volume>2</volume><elocation-id>e53</elocation-id><pub-id pub-id-type="doi">10.1002/ctd2.53</pub-id><pub-id pub-id-type="pmid">35844518</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Park</surname><given-names>HJ</given-names></name><name><surname>Dasari</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Kocher</surname><given-names>JP</given-names></name><name><surname>Li</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>CPAT: coding-potential assessment tool using an alignment-free logistic regression model</article-title><source>Nucleic Acids Research</source><volume>41</volume><elocation-id>e74</elocation-id><pub-id pub-id-type="doi">10.1093/nar/gkt006</pub-id><pub-id pub-id-type="pmid">23335781</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilczynski</surname><given-names>B</given-names></name><name><surname>Dojer</surname><given-names>N</given-names></name><name><surname>Patelak</surname><given-names>M</given-names></name><name><surname>Tiuryn</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Finding evolutionarily conserved cis-regulatory modules with a universal set of motifs</article-title><source>BMC Bioinformatics</source><volume>10</volume><elocation-id>82</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2105-10-82</pub-id><pub-id pub-id-type="pmid">19284541</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wildeman</surname><given-names>AG</given-names></name><name><surname>Zenke</surname><given-names>M</given-names></name><name><surname>Schatz</surname><given-names>C</given-names></name><name><surname>Wintzerith</surname><given-names>M</given-names></name><name><surname>Grundström</surname><given-names>T</given-names></name><name><surname>Matthes</surname><given-names>H</given-names></name><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Chambon</surname><given-names>P</given-names></name></person-group><year iso-8601-date="1986">1986</year><article-title>Specific protein binding to the simian virus 40 enhancer in vitro</article-title><source>Molecular and Cellular Biology</source><volume>6</volume><fpage>2098</fpage><lpage>2105</lpage><pub-id pub-id-type="doi">10.1128/mcb.6.6.2098-2105.1986</pub-id><pub-id pub-id-type="pmid">3023918</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>FA</given-names></name><name><surname>Angerer</surname><given-names>P</given-names></name><name><surname>Theis</surname><given-names>FJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>SCANPY: large-scale single-cell gene expression data analysis</article-title><source>Genome Biology</source><volume>19</volume><elocation-id>15</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-017-1382-0</pub-id><pub-id pub-id-type="pmid">29409532</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Look</surname><given-names>T</given-names></name><name><surname>Prithiviraj</surname><given-names>S</given-names></name><name><surname>Lennartz</surname><given-names>D</given-names></name><name><surname>Cáceres</surname><given-names>MD</given-names></name><name><surname>Götz</surname><given-names>K</given-names></name><name><surname>Wanek</surname><given-names>P</given-names></name><name><surname>Häcker</surname><given-names>H</given-names></name><name><surname>Kramann</surname><given-names>R</given-names></name><name><surname>Seré</surname><given-names>K</given-names></name><name><surname>Zenke</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>CRISPR/Cas9 editing in conditionally immortalized HoxB8 cells for studying gene regulation in mouse dendritic cells</article-title><source>European Journal of Immunology</source><volume>52</volume><fpage>1859</fpage><lpage>1862</lpage><pub-id pub-id-type="doi">10.1002/eji.202149482</pub-id><pub-id pub-id-type="pmid">34826338</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoon</surname><given-names>J</given-names></name><name><surname>Feng</surname><given-names>X</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name><name><surname>Shin</surname><given-names>DM</given-names></name><name><surname>Hatzi</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Morse</surname><given-names>HC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Interferon regulatory factor 8 (IRF8) interacts with the B cell lymphoma 6 (BCL6) corepressor BCOR</article-title><source>The Journal of Biological Chemistry</source><volume>289</volume><fpage>34250</fpage><lpage>34257</lpage><pub-id pub-id-type="doi">10.1074/jbc.M114.571182</pub-id><pub-id pub-id-type="pmid">25331958</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zenke</surname><given-names>M</given-names></name><name><surname>Grundström</surname><given-names>T</given-names></name><name><surname>Matthes</surname><given-names>H</given-names></name><name><surname>Wintzerith</surname><given-names>M</given-names></name><name><surname>Schatz</surname><given-names>C</given-names></name><name><surname>Wildeman</surname><given-names>A</given-names></name><name><surname>Chambon</surname><given-names>P</given-names></name></person-group><year iso-8601-date="1986">1986</year><article-title>Multiple sequence motifs are involved in SV40 enhancer function</article-title><source>The EMBO Journal</source><volume>5</volume><fpage>387</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1002/j.1460-2075.1986.tb04224.x</pub-id><pub-id pub-id-type="pmid">3011406</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><table-wrap id="app1keyresource" position="anchor"><label>Appendix 1—key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">C57BL/6 mice (CD45.1 and CD45.2)</td><td align="left" valign="bottom">Jackson Laboratory</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">Mx-Cas9-GFP mice</td><td align="left" valign="bottom">Medical Faculty, RWTH Aachen University <xref ref-type="bibr" rid="bib88">Xu et al., 2022</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>H. sapiens</italic>)</td><td align="left" valign="bottom">HEK293T</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.atcc.org">https://www.atcc.org</ext-link></td><td align="left" valign="bottom">Lentivirus and retrovirus production</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>M. musculus</italic>)</td><td align="left" valign="bottom"><italic>lncIrf8</italic> promoter <break/>KO HoxB8 MPP; Control HoxB8 MPP</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><italic>lncIrf8</italic> promoter KO</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">p<italic>lncIrf8</italic>-pA HoxB8 MPP; pGFP-pA HoxB8 MPP</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><italic>lncIrf8</italic> overexpression and rescue</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>M. musculus</italic>)</td><td align="left" valign="bottom"><italic>Irf8</italic>-VP64 HoxB8 MPP; <italic>lncIrf8</italic>-VP64 HoxB8 MPP; <break/>Non-targeting-VP64-1 HoxB8 MPP; Non-targeting-VP64-2 HoxB8 MPP</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><italic>Irf8</italic> and <italic>lncIrf8</italic> promoters activation</td></tr><tr><td align="left" valign="bottom">Cell line (<italic>M. musculus</italic>)</td><td align="left" valign="bottom"><italic>Irf8</italic>-KRAB HoxB8 MPP; <italic>lncIrf8</italic>-KRAB HoxB8 MPP; <break/>Non-targeting-KRAB-1 HoxB8 MPP; Non-targeting-KRAB-2 HoxB8 MPP</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><italic>Irf8</italic> and <italic>lncIrf8</italic> promoters repression</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">APC/Cyanine 7 <break/>anti-mouse/human B220 (rat monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 103223;<break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_313006">AB_313006</ext-link></td><td align="left" valign="bottom">FACS (1:400)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Brilliant Violet 510 anti-mouse/human CD11b (rat monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 101245;<break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2561390">AB_2561390</ext-link></td><td align="left" valign="bottom">FACS (1:400)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE/Cyanine 7 <break/>anti-mouse CD11c (Armenian hamster monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 117317;<break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_493569">AB_493569</ext-link></td><td align="left" valign="bottom">FACS (1:400)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">APC anti-mouse CD115 (rat monoclonal)</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">Cat# 17-1152-80;<break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1210789">AB_1210789</ext-link></td><td align="left" valign="bottom">FACS (1:400)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE/Cyanine 7 <break/>anti-mouse CD117 (rat monoclonal)</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">Cat# 25-1172-82;<break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_469646">AB_469646</ext-link></td><td align="left" valign="bottom">FACS (1:400)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE anti-mouse CD135 (rat monoclonal)</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">Cat# 12-1351-82;<break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_465859">AB_465859</ext-link></td><td align="left" valign="bottom">FACS (1:400)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Biotin anti-mouse CD19 (rat monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 115503;<break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_313638">AB_313638</ext-link></td><td align="left" valign="bottom">FACS (1:800)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Biotin anti-mouse CD3e (Armenian hamster monoclonal)</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">Cat# 13-0031-82;<break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_466319">AB_466319</ext-link></td><td align="left" valign="bottom">FACS (1:800)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">APC/Cyanine 7 <break/>anti-mouse CD45.2 (mouse monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 109823;<break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_830788">AB_830788</ext-link></td><td align="left" valign="bottom">FACS (1:400)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Biotin anti-mouse F4/80 (rat monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 123105;<break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_893499">AB_893499</ext-link></td><td align="left" valign="bottom">FACS (1:800)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Alexa Fluor 700 <break/>anti-mouse Gr1 <break/>(rat monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 108421;<break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_493728">AB_493728</ext-link></td><td align="left" valign="bottom">FACS (1:400)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PerCP/Cyanine 5.5 anti-mouse Gr1 <break/>(rat monoclonal)</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">Cat# 45-5931-80;<break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_906247">AB_906247</ext-link></td><td align="left" valign="bottom">FACS (1:400)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Alexa Fluor 700 <break/>anti-mouse Ly6C <break/>(rat monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 128023;<break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10640119">AB_10640119</ext-link></td><td align="left" valign="bottom">FACS (1:400)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Biotin anti-mouse Ly6G <break/>(rat monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 127603;<break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1186105">AB_1186105</ext-link></td><td align="left" valign="bottom">FACS (1:800)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Brilliant Violet 785 anti-mouse MHCII <break/>(rat monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 107645;<break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2565977">AB_2565977</ext-link></td><td align="left" valign="bottom">FACS (1:2000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Biotin anti-mouse NK1.1 (mouse monoclonal)</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">Cat# 14-5941-82;<break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_467736">AB_467736</ext-link></td><td align="left" valign="bottom">FACS (1:800)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Super Bright anti-mouse Siglec-H <break/>(rat monoclonal)</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# 63-0333-82<break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2784853">AB_2784853</ext-link></td><td align="left" valign="bottom">FACS (1:400)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">PE/Dazzle 594 Streptavidin</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 405247</td><td align="left" valign="bottom">FACS (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Biotin anti-mouse Ter119 (rat monoclonal)</td><td align="left" valign="bottom">eBioscience</td><td align="left" valign="bottom">Cat# 14-5921-82;<break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_467727">AB_467727</ext-link></td><td align="left" valign="bottom">FACS (1:800)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Brilliant Violet 421 anti-mouse/rat XCR1 (mouse monoclonal)</td><td align="left" valign="bottom">Biolegend</td><td align="left" valign="bottom">Cat# 148216;<break/>RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2565230">AB_2565230</ext-link></td><td align="left" valign="bottom">FACS (1:400)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">7-Aminoactinomycin D (7-AAD)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# A1310</td><td align="left" valign="bottom">FACS (3 μl per test)</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">β-estradiol (E2)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# E2758</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">β-mercaptoethanol <break/>(β-ME)</td><td align="left" valign="bottom">Gibco</td><td align="left" valign="bottom">Cat# 31350010</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">BsmBI-v2</td><td align="left" valign="bottom">New England Biolabs</td><td align="left" valign="bottom">Cat# R0739S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Chondroitin sulfate sodium salt from shark cartilage (CSS)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# C4384</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">cOmplete Mini</td><td align="left" valign="bottom">Roche</td><td align="left" valign="bottom">Cat# 11836153001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">dATP</td><td align="left" valign="bottom">New England Biolabs</td><td align="left" valign="bottom">Cat# N0440S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Dimethysulfoxide (DMSO)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# D8418</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Doxycycline hyclate</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# D9891</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">DpnII</td><td align="left" valign="bottom">A kind gift from A. Marieke Oudelaar, Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany. DpnII enzyme with a similar activity is also available from New England Biolabs.</td><td align="left" valign="bottom">Cat# R0543M</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">DMEM</td><td align="left" valign="bottom">Gibco</td><td align="left" valign="bottom">Cat# 41965039</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">DTT</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# 20290</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">EDTA</td><td align="left" valign="bottom">Gibco</td><td align="left" valign="bottom">Cat# 15575–038</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Fetal calf serum (FCS)</td><td align="left" valign="bottom">PAA</td><td align="left" valign="bottom">Cat# A01125-499</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Fetal calf serum (FCS)</td><td align="left" valign="bottom">Gibco</td><td align="left" valign="bottom">Cat# 10270106</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Formaldehyde <break/>(37%)</td><td align="left" valign="bottom">AppliChem</td><td align="left" valign="bottom">Cat# A0877</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Recombinant human Flt3-Ligand (Flt3L)</td><td align="left" valign="bottom">Peprotech</td><td align="left" valign="bottom">Cat# 300–19</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Recombinant <break/>murine stem cell factor (SCF)</td><td align="left" valign="bottom">Peprotech</td><td align="left" valign="bottom">Cat# 250–03</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Human IGF-1 long range</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# 85,580 C</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Recombinant IL-6/soluble IL-6 receptor fusion protein</td><td align="left" valign="bottom">A kind gift from S. Rose-John, Kiel, Germany <xref ref-type="bibr" rid="bib24">Fischer et al., 1997</xref>. R&amp;D Systems provides a similar product with the same activity.</td><td align="left" valign="bottom">Cat# 9038 SR</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">HEPES</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# H4034</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">L-glutamine</td><td align="left" valign="bottom">Gibco</td><td align="left" valign="bottom">Cat# 25030081</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">M-270 Streptavidin Dynabeads</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat# 65305</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Mouse interferon α (mIFNα)</td><td align="left" valign="bottom">Miltenyi Biotec</td><td align="left" valign="bottom">Cat# 130-093-131</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Murine RNase Inhibitor</td><td align="left" valign="bottom">New England Biolabs</td><td align="left" valign="bottom">Cat# M0314S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Pancoll human, density 1.077 g/ml (Ficoll)</td><td align="left" valign="bottom">PAN-Biotech</td><td align="left" valign="bottom">Cat# P04-601000</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Penicillin/streptomycin</td><td align="left" valign="bottom">Gibco</td><td align="left" valign="bottom">Cat# 15140122</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Phenol-Chloroform-Isoamyl alcohol (PCI)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# 77617</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Phosphate buffered saline (PBS)</td><td align="left" valign="bottom">Gibco</td><td align="left" valign="bottom">Cat# 10010023</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Polybrene (PB, Hexadimethrine bromide)</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# H9268</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Q5 high fidelity <break/>DNA polymerase</td><td align="left" valign="bottom">New England Biolabs</td><td align="left" valign="bottom">Cat# M0491L</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">RPMI 1640</td><td align="left" valign="bottom">Gibco</td><td align="left" valign="bottom">Cat# 31870025</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">SalI</td><td align="left" valign="bottom">New England Biolabs</td><td align="left" valign="bottom">Cat# R0138S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Supernatant from Flt3L-producing B16F1 cells (1%)</td><td align="left" valign="bottom">Homemade. Flt3L from Peprotech has the same activity (1:1000)</td><td align="left" valign="bottom">Cat# 300–19</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Supernatant from CHO KLS C6 cells expressing soluble murine SCF (1%)</td><td align="left" valign="bottom">Homemade. Peprotech provides a similar product with the same activity (1:1000).</td><td align="left" valign="bottom">Cat# 250–03</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">SYBR-green fluorescence</td><td align="left" valign="bottom">Applied Biosystems</td><td align="left" valign="bottom">Cat# 4385610</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">T4 DNA HC ligase</td><td align="left" valign="bottom">Life Tech</td><td align="left" valign="bottom">Cat# EL0013</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Taq DNA polymerase</td><td align="left" valign="bottom">Homemade</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Taq buffer (10 x)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# B33</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Template-switching RT enzyme mix</td><td align="left" valign="bottom">New England Biolabs</td><td align="left" valign="bottom">Cat# M0466</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">XhoI</td><td align="left" valign="bottom">New England Biolabs</td><td align="left" valign="bottom">Cat# R0146S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Gibson Assembly kit</td><td align="left" valign="bottom">New England Biolabs</td><td align="left" valign="bottom">Cat# E5510S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">High-Capacity cDNA Reverse Transcription Kit</td><td align="left" valign="bottom">Applied Biosystems</td><td align="left" valign="bottom">Cat# 4368814</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">KAPA Hyper <break/>Capture Reagent <break/>Kit</td><td align="left" valign="bottom">Roche</td><td align="left" valign="bottom">Cat# 9075828001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">NEBNext Ultra II <break/>DNA Library Prep <break/>Kit for Illumina</td><td align="left" valign="bottom">New England Biolabs</td><td align="left" valign="bottom">Cat# E7645S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">NEBNext Multiplex Oligos for Illumina (Index Primers Set 1)</td><td align="left" valign="bottom">New England Biolabs</td><td align="left" valign="bottom">Cat# E7335S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">NEBNext Multiplex Oligos for Illumina (Index Primers Set 2)</td><td align="left" valign="bottom">New England Biolabs</td><td align="left" valign="bottom">Cat# E7500S</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">NucleoSpin RNA kit</td><td align="left" valign="bottom">Macherey-Nagel</td><td align="left" valign="bottom">Cat# 740955.250</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">PCR clean-up kit</td><td align="left" valign="bottom">Macherey-Nagel</td><td align="left" valign="bottom">Cat# 740609.50</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">TA cloning kit</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# K202020</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">5'RACE-TSO</td><td align="left" valign="bottom">New England Biolabs</td><td align="left" valign="bottom">5’ RACE PCR primers</td><td align="left" valign="bottom">GCTAATCATTGCAAGCAGTGGTATC<break/>AACGCAGAGTACATrGrGrG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">5'RACE-TSO-Specific</td><td align="left" valign="bottom">New England Biolabs</td><td align="left" valign="bottom">5’ RACE PCR primers</td><td align="left" valign="bottom">CATTGCAAGCAGTGGTATCAAC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">5'RACE-GSP-<italic>lncIrf8</italic>-R1</td><td align="left" valign="bottom">New England Biolabs</td><td align="left" valign="bottom">5’ RACE PCR primers</td><td align="left" valign="bottom">TGTCAGTGATGGGGGCTGGAGAAAT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">5'RACE-GSP-<italic>lncIrf8</italic>-R2</td><td align="left" valign="bottom">New England Biolabs</td><td align="left" valign="bottom">5’ RACE PCR primers</td><td align="left" valign="bottom">GCTCAGGATGCCAGGTCCCTTCTT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">3'RACE-QT</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib73">Scotto-Lavino et al., 2006</xref></td><td align="left" valign="bottom">3’ RACE PCR primers</td><td align="left" valign="bottom">CCAGTGAGCAGAGTGACGAGGACTC<break/>GAGCTCAAGCTTTTTTTTTTTTTTTTT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">3'RACE-Q0</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib73">Scotto-Lavino et al., 2006</xref></td><td align="left" valign="bottom">3’ RACE PCR primers</td><td align="left" valign="bottom">CCAGTGAGCAGAGTGACG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">3'RACE-QI</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib73">Scotto-Lavino et al., 2006</xref></td><td align="left" valign="bottom">3’ RACE PCR primers</td><td align="left" valign="bottom">GAGGACTCGAGCTCAAGC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">3'RACE-GSP-<italic>lncIrf8</italic>-F1</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">3’ RACE PCR primers</td><td align="left" valign="bottom">ATTTCTCCAGCCCCCATCACTGACA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">3'RACE-GSP-<italic>lncIrf8</italic>-F2</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">3’ RACE PCR primers</td><td align="left" valign="bottom">AAGAAGGGACCTGGCATCCTGAGC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>lncIrf8</italic>-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Genotyping primers</td><td align="left" valign="bottom">TCCTGAAGGGACAGGCAAG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>lncIrf8</italic>-R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Genotyping primers</td><td align="left" valign="bottom">CTTGGACATTGAGGACGCC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">cDC1 +32 kb-F1</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Genotyping primers</td><td align="left" valign="bottom">GTGACTGCAAGTAAGTTCTTCGG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">cDC1 +32 kb-F2</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Genotyping primers</td><td align="left" valign="bottom">AAGTAGAGATTCCCTTTCTAAGCC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">cDC1 +32 kb-R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Genotyping primers</td><td align="left" valign="bottom">ATCAGGCTGGGTGGTGGTT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Sc-<italic>lncIrf8</italic>-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Cloning primers</td><td align="left" valign="bottom"><underline>ACACTCGAG</underline>ACTGTCAGATGCAGGGG; <break/>the underline sequences represent cloning sites</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">Sc-<italic>lncIrf8</italic>-R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Cloning primers</td><td align="left" valign="bottom"><underline>AAAAAAGTCGA</underline>CGCATCAGATTTAATATA<break/>GAACTAGGACA; the underline sequences represent cloning sites</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">CMV-<italic>lncIrf8</italic>-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Genotyping primers</td><td align="left" valign="bottom">TGGGCGTGGATAGCGGTTT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">CMV-<italic>lncIrf8</italic>-R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Genotyping primers</td><td align="left" valign="bottom">CACTGAGACTTAGCAAGGGGGA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">CMV-GFP-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Genotyping primers</td><td align="left" valign="bottom">TGGGCGTGGATAGCGGTTT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">CMV-GFP-R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Genotyping primers</td><td align="left" valign="bottom">TGGGGGTGTTCTGCTGGTAG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">m<italic>lncIrf8</italic>-tQ-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">RT-qPCR primers</td><td align="left" valign="bottom">ACTGTCAGATGCAGGGG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">m<italic>lncIrf8</italic>-tQ-R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">RT-qPCR primers</td><td align="left" valign="bottom">TCACAATCGTCTGTAACTCCG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">m<italic>Irf8</italic>-tQ-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">RT-qPCR primers</td><td align="left" valign="bottom">GAGCGAAGTTCCTGAGATGG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">m<italic>Irf8</italic>-tQ-R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">RT-qPCR primers</td><td align="left" valign="bottom">TGGGCTCCTCTTGGTCATAC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">m<italic>GAPDH</italic>-tQ-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">RT-qPCR primers</td><td align="left" valign="bottom">ACCTGCCAAGTATGATGACATCA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">m<italic>GAPDH</italic>-tQ-R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">RT-qPCR primers</td><td align="left" valign="bottom">GGTCCTCAGTGTAGCCCAAGAT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">m3C-F</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib19">Downes et al., 2021</xref>; <xref ref-type="bibr" rid="bib20">Downes et al., 2022</xref></td><td align="left" valign="bottom">Capture-C qPCR primers</td><td align="left" valign="bottom">GGAGAAAGAAGGCTGGTGTTAT</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">m3C-R</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib19">Downes et al., 2021</xref>; <xref ref-type="bibr" rid="bib20">Downes et al., 2022</xref></td><td align="left" valign="bottom">Capture-C qPCR primers</td><td align="left" valign="bottom">TATCTGAGTTGGACAGCATTGG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">m3C-control-F</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib19">Downes et al., 2021</xref>; <xref ref-type="bibr" rid="bib20">Downes et al., 2022</xref></td><td align="left" valign="bottom">Capture-C qPCR primers</td><td align="left" valign="bottom">TTATCTTGCATTTGCCAACTCG</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">m3C-control-R</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib19">Downes et al., 2021</xref>; <xref ref-type="bibr" rid="bib20">Downes et al., 2022</xref></td><td align="left" valign="bottom">Capture-C qPCR primers</td><td align="left" valign="bottom">TGGGTTTCCCTGATTCTGAAA</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Irf8</italic>_P_L</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Capture probes</td><td align="left" valign="bottom">GATCCGTGCATCACCAGCCTCC<break/>TTGACCTTAGGCAGACGCCCCA<break/>GCCCCCCGGCCATTTTTGGGGCAGCC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom"><italic>Irf8</italic>_P_R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">Capture probes</td><td align="left" valign="bottom">CCAAATGAACAAACACCTCTCCC<break/>TTTAAAATCTGCCTGATGGCCAA<break/>CTTCATAATGAAGAGAAATAGATC</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">gRNA-1-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">gRNAs</td><td align="left" valign="bottom"><underline>CACCG</underline>TCCATTATACTAAGATACCC; <break/>the underline sequences represent cloning sites</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">gRNA-1-R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">gRNAs</td><td align="left" valign="bottom"><underline>AAAC</underline>GGGTATCTTAGTATAATGGA<underline>C;</underline> <break/>the underline sequences represent cloning sites</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">gRNA-2-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">gRNAs</td><td align="left" valign="bottom"><underline>CACC</underline>GGTGCCGAGAAAGGACACGT; <break/>the underline sequences represent cloning sites</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">gRNA-2-R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">gRNAs</td><td align="left" valign="bottom"><underline>AAAC</underline>ACGTGTCCTTTCTCGGCACC; <break/>the underline sequences represent cloning sites</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">gRNA-KO1-5‘F</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib22">Durai et al., 2019</xref></td><td align="left" valign="bottom">gRNAs</td><td align="left" valign="bottom"><underline>CACC</underline>GTTGTGATCTTTGAGGTAGA; <break/>the underline sequences represent cloning sites</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">gRNA-KO1-5’R</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib22">Durai et al., 2019</xref></td><td align="left" valign="bottom">gRNAs</td><td align="left" valign="bottom"><underline>AAAC</underline>TCTACCTCAAAGATCACAAC; <break/>the underline sequences represent cloning sites</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">gRNA-KO1-3‘F</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib22">Durai et al., 2019</xref></td><td align="left" valign="bottom">gRNAs</td><td align="left" valign="bottom"><underline>CACC</underline>GAACTGGCCTGGGGCAGGTC; <break/>the underline sequences represent cloning sites</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">gRNA-KO1-3’R</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib22">Durai et al., 2019</xref></td><td align="left" valign="bottom">gRNAs</td><td align="left" valign="bottom"><underline>AAAC</underline>GACCTGCCCCAGGCCAGTTC; <break/>the underline sequences represent cloning sites</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">gRNA-KO2-5’F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">gRNAs</td><td align="left" valign="bottom"><underline>CACC</underline>GACATTCTGCACCCCAGTCA; <break/>the underline sequences represent cloning sites</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">gRNA-KO2-5’R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">gRNAs</td><td align="left" valign="bottom"><underline>AAAC</underline>TGACTGGGGTGCAGAATGTC; <break/>the underline sequences represent cloning sites</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">gRNA-KO2-3’F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">gRNAs</td><td align="left" valign="bottom"><underline>CACCG</underline>AGGATCGCACCTCACCTACT; <break/>the underline sequences represent cloning sites</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">gRNA-KO2-3’R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">gRNAs</td><td align="left" valign="bottom"><underline>AAAC</underline>AGTAGGTGAGGTGCGATCCT<underline>C;</underline> <break/>the underline sequences represent cloning sites</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">gRNA-<italic>Irf8</italic>-VP64-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">gRNAs</td><td align="left" valign="bottom"><underline>CACCG</underline>ACGGTCGCGCGAGCTAATTG; <break/>the underline sequences represent cloning sites</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">gRNA-<italic>Irf8</italic>-VP64-R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">gRNAs</td><td align="left" valign="bottom"><underline>AAAC</underline>CAATTAGCTCGCGCGACCGT<underline>C;</underline> <break/>the underline sequences represent cloning sites</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">gRNA-<italic>Irf8</italic>-KRAB-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">gRNAs</td><td align="left" valign="bottom"><underline>CACC</underline>GCGGCAGGTAGGACGCGATG; <break/>the underline sequences represent cloning sites</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">gRNA-<italic>Irf8</italic>-KRAB-R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">gRNAs</td><td align="left" valign="bottom"><underline>AAAC</underline>CATCGCGTCCTACCTGCCGC; <break/>the underline sequences represent cloning sites</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">gRNA-<italic>lncIrf8</italic>-VP64-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">gRNAs</td><td align="left" valign="bottom"><underline>CACC</underline>GGTGCCGAGAAAGGACACGT; <break/>the underline sequences represent cloning sites</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">gRNA-<italic>lncIrf8</italic>-VP64-R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">gRNAs</td><td align="left" valign="bottom"><underline>AAAC</underline>ACGTGTCCTTTCTCGGCACC; <break/>the underline sequences represent cloning sites</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">gRNA-<italic>lncIrf8</italic>-KRAB-F</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">gRNAs</td><td align="left" valign="bottom"><underline>CACC</underline>GAGTCACTCGTCCTTTGGGG; <break/>the underline sequences represent cloning sites</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">gRNA-<italic>lncIrf8</italic>-KRAB-R</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">gRNAs</td><td align="left" valign="bottom"><underline>AAAC</underline>CCCCAAAGGACGAGTGACTC; <break/>the underline sequences represent cloning sites</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">gRNA-non-targeting-1-F</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib55">Manguso et al., 2017</xref></td><td align="left" valign="bottom">gRNAs</td><td align="left" valign="bottom"><underline>CACCG</underline>CGAGGTATTCGGCTCCGCG; <break/>the underline sequences represent cloning sites</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">gRNA-non-targeting-1-R</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib55">Manguso et al., 2017</xref></td><td align="left" valign="bottom">gRNAs</td><td align="left" valign="bottom"><underline>AAAC</underline>CGCGGAGCCGAATACCTCG<underline>C</underline>; <break/>the underline sequences represent cloning sites</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">gRNA-non-targeting-2-F</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib55">Manguso et al., 2017</xref></td><td align="left" valign="bottom">gRNAs</td><td align="left" valign="bottom"><underline>CACCG</underline>ATGTTGCAGTTCGGCTCGAT; <break/>the underline sequences represent cloning sites</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">gRNA-non-targeting-2-R</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib55">Manguso et al., 2017</xref></td><td align="left" valign="bottom">gRNAs</td><td align="left" valign="bottom"><underline>AAAC</underline>ATCGAGCCGAACTGCAACAT<underline>C;</underline> <break/>the underline sequences represent cloning sites</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Bamtofastq</td><td align="char" char="." valign="bottom">10 x Genomics</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://support.10xgenomics.com/docs/bamtofastq">https://support.10xgenomics.com/docs/bamtofastq</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Bowtie2</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib46">Langmead and Salzberg, 2012</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://bowtie-bio.sourceforge.net">http://bowtie-bio.sourceforge.net</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">CapCruncher (v0.1.1a1)</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib20">Downes et al., 2022</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://github.com/sims-lab/CapCruncher">https://github.com/sims-lab/CapCruncher</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">CPAT</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib84">Wang et al., 2013</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://code.google.com/p/cpat/">http://code.google.com/p/cpat/</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Cufflinks <break/>(version 2.0)</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib81">Trapnell et al., 2012</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://cufflinks.cbcb.umd.edu/">http://cufflinks.cbcb.umd.edu/</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">FlowJo V10</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">IGV browser</td><td align="left" valign="bottom">Broad Institute</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">MOODS</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib40">Korhonen et al., 2009</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.cs.helsinki.fi/group/pssmfind/">https://www.cs.helsinki.fi/group/pssmfind/</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Oligo</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib61">Oudelaar et al., 2020</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://oligo.readthedocs.io/en/latest/index.html">https://oligo.readthedocs.io/en/latest/index.html</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">PhyloCSF</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib50">Lin et al., 2011</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://compbio.mit.edu/PhyloCSF">http://compbio.mit.edu/PhyloCSF</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Prism</td><td align="left" valign="bottom">GraphPad</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Scanpy</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib87">Wolf et al., 2018</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Star aligner (version 2.4)</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib18">Dobin et al., 2013</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://code.google.com/p/rna-star/">http://code.google.com/p/rna-star/</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Snapgene</td><td align="left" valign="bottom">GSL Biotech</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">UMAP</td><td align="char" char="." valign="bottom"><xref ref-type="bibr" rid="bib7">Becht et al., 2019</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr></tbody></table></table-wrap></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83342.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ginhoux</surname><given-names>Florent</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/036wvzt09</institution-id><institution>Agency for Science Technology and Research</institution></institution-wrap><country>Singapore</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.08.11.503623" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.08.11.503623"/></front-stub><body><p>Authors provide valuable evidence identifying a lncRNA transcribed specifically in the pDC subtype from the +32Kb promoter region which is also the region for the enhancer for Irf8 specifically in the cDC1 subtype. With convincing methodology, they provide in-depth analysis about the possible role of lncIrf8, and its promoter region and cross-talk with Irf8 promoter to identify that it is not the lncIRF8 itself but its promoter region that is crucial for pDC and cDC1 differentiation conferring feedback inhibition of Irf8 transcription. The work will be of interest to immunologists working on immune cell development.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83342.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Ginhoux</surname><given-names>Florent</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/036wvzt09</institution-id><institution>Agency for Science Technology and Research</institution></institution-wrap><country>Singapore</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Nutt</surname><given-names>Stephen L</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01b6kha49</institution-id><institution>Walter and Eliza Hall Institute of Medical Research</institution></institution-wrap><country>Australia</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.08.11.503623">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.08.11.503623v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;A lncRNA identifies <italic>IRF8</italic> enhancer element in negative feedback control of dendritic cell differentiation&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Satyajit Rath as the Senior Editor. The following individual involved in the review of your submission has agreed to reveal their identity: Stephen L Nutt (Reviewer #2).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) Demonstrate the presence of lncRNA selectively in ex-vivo splenic pDC sub-type and confirm its expression in human pDCs.</p><p>2) To clarify the role of irf8 in pdc development in regards to published data comparing the lncIrf8 and +32kb activity in their system: The authors conclude that lncIRF8 promoter KO hematopoietic progenitors are not capable of differentiating to pDCs (Figure 2C, Figure 2 Suppl 3D). However, it is now understood that Irf8 is not essential for pDC development (see Sichien Immunity 2016 where they study WT:IRF8-/- BM chimeras) and that Irf8 deregulates some key markers, including CD11b. The authors need to account for this discrepancy. Are pDCs with aberrant marker expression produced in the lncIRF8 promoter KO, and if not, why does this phenotype differ from the Irf8 KO? In addition, it is essential that authors delete the +32 Kb enhancer region (as defined in Durai 2019) in their culture system and analyze the same with respect to +32Kb lncIRF8 promoter deletion in terms of expression of IRF8, lncIRF8 and its effect on the development of pDC vs cDC1.</p><p>3)( Provide evidence that IRF8 binds in the lncIRF8 promoter. Authors showed show DNA binding motifs for Irf8 in the lncIrf8, but no evidence of actual binding. Perhaps the +32kb enhancer is also physically involved, but either way more evidence is needed to fully support the authors' models. Instead, IRF8 binds in the more 5' part of the +32kb enhancer identified by Durai 2019. How then is a putative IRF8 repressor complex linked to the lncIRF8 promoter as the authors propose? Moreover, the model does not appear to address why the IRF8 repressor complex binding to the lncIRF8 would be active in cDC1 and not pDC.</p><p>4) Authors should acknowledge/discuss clearly that one limitation of their study is that lncIRF8 might have other roles in DC/pDC biology which is yet unidentified in the current study.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>1. While refining the cross-talk between promoter and enhancers authors have completely overlooked the functional significance of lncIRF8 in pDCs. Authors have demonstrated the expression of lncIRF8 is specific to pDCs, it is not evident whether all pDCs express it or a fraction of the same.</p><p>a. Further authors should confirm the expression of lncRNA in ex vivo pDCs from various murine tissues. Is the expression of lncRNA also conserved in human pDCs?</p><p>b. How is the expression of lncIRF8 modulated upon CpG stimulation/viral infection of pDCs?</p><p>c. Is there any significance of lncIRF8 in pDC functions (TLR stimulations, cytokine production, etc.) these aspects could be studied without much effort as authors already have systems that can knockout lncIRF8 promoter or overexpress lncIRF8.</p><p>2. Though authors have identified that lncIRF8 is specifically expressed in pDC subtype but while understanding its significance and regulation, it was preferred to study bulk DC cultures overlooking the finding regarding specificity. Experiments performed by employing dCas9 VP64/KRAB-GFP constructs, do provide some direction in terms of mechanistic understanding of the cross-talk between the promoter of IRF8 and lncIRF8. This data needs to be further strengthened by sorting pDC, cDC1 and cDC2 populations and studying the effect of the genetic manipulations on IRF8 and lncRNA expression in each cell type.</p><p>3. One of the most important findings of the submitted study is to demonstrate that knocking out the lncIRF8 promoter also diminishes the expression of IRF8, pDC as well as cDC1 development (Figure 2). Once the IRF8 expression is suppressed the analysis of pDC and cDC1 differentiation is redundant. It is previously reported that the deletion of +32 Kb enhancer (Durai et al. 2019) in a mouse model did not affect pDC but specifically depleted cDC1 development. Authors should examine the deletion of only the +32 kb enhancer region in their culture system to sort out the hierarchy between the +32 Kb enhancer and +32 Kb lncRNA promoter in terms of DC subtype development (cDC1 Vs pDC). Does the deletion of the lncIRF8 promoter lead to epigenetic changes at the overall +32 region? It is expected that due to interactions and chromatin loop formation between IRF8 promoter with various enhancers elements; deletion of lncIRF8 promoter might play an important role in defining these interactions in a cell type-specific manner. These interactions become more valuable by the fact that activation of the lncIRF8 promoter leads to enhanced cDC1 differentiation. Does this simply mean more open chromatin conformation around the cDC1-specific +32 Kb region rather than correlating with the lncIRF8?</p><p>Can authors analyze the epigenetic changes by performing similar experiments in some of the available pDC and cDC1 cell lines? As these cell lines are likely to have active IRF8 transcription and it would help to measure the effect of lncIRF8 promoter deletion/mutation/activation/repression on IRF8 expression and specific DC subtype maintenance.</p><p>4. Based on the various earlier published reports and results from the current study authors have shown a schematic representation of the pDC and cDC1-specific interactions. Can these interactions be validated in primary/ex-vivo DCs and be correlated with lncIRF8 as well as IRF8 expression? Will it be possible for authors to validate these interactions in light of the lncIRF8 promoter deletion/mutation/activation/repression? Authors may be careful to perform these experiments in purified pDC and cDC1 fractions to get meaningful data.</p><p>In case it is not possible to perform experiments with primary DCs/genetically modified HOXB8 cultures; if required, some of these experiments may be performed in the cell lines wherein overall interaction between various enhancer elements and promoters can be validated.</p><p>5. Authors have also identified a TCONS_00190258 which is specifically expressed in the cDC1 subtype. Why not look at the expression levels of this transcript in the various experiments in the current study as enhancer element crosstalk will help in cell type-specific transcription of IRF8, lncIRF8, and TCONS_00190258?</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>I find the quality and interpretation of the genomics data to be excellent and I have no major concerns with that data. I do have some specific comments around the interpretation of the cellular data and the model presented.</p><p>Specific comments</p><p>1. The authors conclude that lncIRF8 promoter KO hematopoietic progenitors are not capable of differentiating to pDCs (Figure 2C, Figure 2 Suppl 3D). However, it is now understood that Irf8 is not essential for pDC development (see Sichien Immunity 2016 where they study WT:IRF8-/- BM chimeras) and that Irf8 deregulates some key markers, including CD11b. The authors need to account for this discrepancy. Are pDCs with aberrant marker expression produced in the lncIRF8 promoter KO, and if not, why does this phenotype differ from the Irf8 KO?</p><p>2. There does not appear to be compelling evidence that IRF8 binds in the lncIRF8 promoter in cDC1. Instead, IRF8 binds in the more 5' part of the +32kb enhancer identified by Durai 2019. How then is a putative IRF8 repressor complex linked to the lncIRF8 promoter as the authors propose? Moreover, the model does not appear to address why the IRF8 repressor complex binding to the IRF8 repressor complex would be active in cDC1 and not pDC.</p><p>3. The authors use 2 versions of the HoxB8 MPP differentiation system (lines 207-234). Firstly, it is unclear, why two similar approaches are used, but more importantly, the second system outlined in figure 2 Suppl 3 shows that the lncIRF8 promoter is also required for cDC2 differentiation. This is a concern, as IRF8 is not expressed in cDC2, and Irf8-/- mice produce cDC2.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.83342.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) Demonstrate the presence of lncRNA selectively in ex-vivo splenic pDC sub-type and confirm its expression in human pDCs.</p></disp-quote><p>Point 1: Presence of lncRNA selectively in ex-vivo splenic pDC sub-type.</p><p>This is interesting and we addressed this point by re-analyzing public scRNA-seq and bulk RNA-seq datasets for spleen. We also included the analysis of lncRNA expression in bone marrow. The scRNA-seq data of murine <italic>ex-vivo</italic> spleen pDC and bone marrow pDC were obtained from GSE114313 (Rodrigues et al., <italic>Nat. Immunol.,</italic> 2018). The bulk RNA-seq dataset of splenic DC subsets pDC, cDC1 and cDC2 are from GSE188992 (Pang et al., <italic>Front. Immunol.</italic>, 2022).</p><p>These new results are now shown in new Figure 1—figure supplement 3 (page 32) and described in the Results section, page 6, lines 151-154 as follows:</p><p><italic>“lncIrf8</italic> and <italic>TCONS_00190258</italic> show the same expression pattern in pDC and cDC1, respectively, in BM and spleen (Figure 1—figure supplement 3), as revealed by reanalyzing scRNA-seq and bulk RNA-seq data (<italic>Rodrigues et al., 2018; Pang et al., 2022</italic>).”</p><p>The Materials and methods section was updated accordingly (page 17, lines 536-548).</p><p>More specifically, the scRNA-seq data from GSE114313 (Rodrigues et al., <italic>Nat. Immunol.,</italic> 2018) were downloaded, BAM files were converted back into FASTQ files and a custom reference genome of mm9 was created now including the novel <italic>lncIrf8</italic> (GenBank: ON134061) and <italic>Tcons_00190258</italic> lncRNA (GenBank: ON134062). Data were subjected to bioinformatic processing as described in the Materials and methods section on page 17, lines 536-548 and visualized in UMAPs.</p><p>In Dress et al., <italic>Nat. Immunol</italic>., 2019 authors are critical on the pDC-like cells in GSE114313. Therefore to better define the pDC population in GSE114313, we included the pDC marker genes <italic>Tcf4</italic>, <italic>Bst2</italic> and <italic>Siglec-H</italic> in our analysis and used the cDC marker genes <italic>Zbtb46</italic>, <italic>Cx3cr1</italic> and <italic>Xcr1</italic> as negative controls. We observed that <italic>lncIrf8</italic> is expressed in bone marrow (BM) and spleen pDC (new Figure 1—figure supplement 3, page 32)<italic>.</italic> Expression of the cDC1 specific <italic>Tcons_00190258</italic> lncRNA in BM and spleen pDC is very low to absent.</p><p>To further extend this analysis, we analyzed the bulk RNA-seq dataset of splenic DC subsets pDC, cDC1 and cDC2 from GSE188992 (Pang et al., <italic>Front. Immunol.</italic>, 2022). <italic>lncIrf8</italic> and <italic>Tcons_00190258</italic> lncRNA were visualized by IGV browser. As expected, <italic>lncIrf8</italic> and <italic>Tcons_00190258</italic> lncRNA were expressed in pDC and cDC1 of spleen, respectively, and the expression pattern was the same as in our in vitro bone marrow DC (new Figure 1—figure supplement 3).</p><p>Point 2: Confirm its expression in human pDCs.</p><p>To address this point, we checked the transcripts around the <italic>Irf8</italic> gene in different species using data from NCBI, including mouse, human and zebrafish. We found a lncRNA downstream of human <italic>Irf8</italic> gene, referred to as <italic>LINC02132</italic>, but no lncRNA was observed downstream of zebrafish <italic>Irf8</italic> gene (see <xref ref-type="fig" rid="sa2fig1">Author response image 1A</xref>).</p><fig id="sa2fig1" position="float"><label>Author response image 1.</label><caption><title>Mouse <italic>lncIrf8</italic> is not conserved across species.</title><p>(A) Visualization of lncRNA downstream of <italic>Irf8</italic> gene in mouse, human and zebrafish using data from NCBI. Red box indicates lncRNA. (B) Sequence alignment of mouse <italic>lncIrf8</italic> and human <italic>LINC02132</italic> using MEGA 6.0. (C) Visualization of human <italic>LINC02132</italic> by UCSC browser. Data of gene transcription, H3K27ac signal and DNase signal are from ENCODE. (D) Gene expression of human <italic>LINC02132</italic> in different tissues. Data are from GTEx RNA-seq in 54 tissues of 17382 samples, 948 donors.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83342-sa2-fig1-v2.tif"/></fig><p>We found that the sequences of mouse <italic>lncIrf8</italic> and human <italic>LINC02132</italic> are not conserved (<xref ref-type="fig" rid="sa2fig1">Author response image 1B</xref>). The human <italic>LINC02132</italic> locus also shows potential enhancer activities, as revealed by H3K27ac and open chromatin (DNase) signals (<xref ref-type="fig" rid="sa2fig1">Author response image 1C</xref>). The human <italic>LINC02132</italic> is mainly expressed in lymphocytes, spleen and whole blood (<xref ref-type="fig" rid="sa2fig1">Author response image 1D</xref>). Data of H3K27ac (7 cell lines) and DNase signal are from ENCODE; gene expression of human <italic>LINC02132</italic> are from GTEx RNA-seq (54 tissues, 17382 samples, 948 donors).</p><p>Taken together, the pDC specific <italic>lncIrf8</italic> is not conserved across species, which is in line with the general characteristics of lncRNA. We have now included this information in the Results section, page 7, lines 200-202.</p><disp-quote content-type="editor-comment"><p>2) To clarify the role of irf8 in pdc development in regards to published data comparing the lncIrf8 and +32kb activity in their system: The authors conclude that lncIRF8 promoter KO hematopoietic progenitors are not capable of differentiating to pDCs (Figure 2C, Figure 2 Suppl 3D). However, it is now understood that Irf8 is not essential for pDC development (see Sichien Immunity 2016 where they study WT:IRF8-/- BM chimeras) and that Irf8 deregulates some key markers, including CD11b. The authors need to account for this discrepancy. Are pDCs with aberrant marker expression produced in the lncIRF8 promoter KO, and if not, why does this phenotype differ from the Irf8 KO? In addition, it is essential that authors delete the +32 Kb enhancer region (as defined in Durai 2019) in their culture system and analyze the same with respect to +32Kb lncIRF8 promoter deletion in terms of expression of IRF8, lncIRF8 and its effect on the development of pDC vs cDC1.</p></disp-quote><p>Point 1: Are pDCs with aberrant marker expression produced in the lncIRF8 promoter KO?</p><p>We appreciate the point raised and know the work by Sichien et al., 2016 on WT:<italic>Irf8-/-</italic> BM chimeras and the conclusions reached from their work that IRF8 is dispensable for pDC development. Previous studies, including the study of Sichien et al., 2016, showed that pDC are reduced in <italic>Irf8</italic> knockout mice (Murakami et al., <italic>Nat. Immunol.,</italic> 2021; Schiavoni et al., <italic>J. Exp. Med.,</italic> 2002; Tsujimura et al., <italic>J. Immunol.,</italic> 2003). Thus, there is the possibility that the conclusions reached by Sichien et al., 2016 on the impact of IRF8 on pDC function, is on the pDC population, which is left in the <italic>Irf8-/-</italic> mice. In addition the results in Sichien et al., 2016 are based on WT:<italic>Irf8-/-</italic> BM chimeras upon transplantation in lethally irradiated mice and thus the divergent results might be due to the experimental set-up WT:<italic>Irf8-/-</italic> BM chimeras versus <italic>Irf8</italic> knockout mice.</p><p>Sichien et al., 2016, report on altered marker expression (CD11b, CD11c and MHC II), which for CD11b and CD11c was not very prominent. In our study on the <italic>lncIrf8</italic> promoter KO we used immunophenotyping of CD11c+ CD11b- B220+ cells for in vitro pDC (Figure 2C and Figure 2—figure supplement 3) and CD45.2+ Gr1- Siglec H<sup>+</sup> cells for pDC following transplantation (Figure 3A and D, G and J; Figure 3—figure supplement 1B). Thus, we are confident to correctly detect pDC.</p><p>A potentially altered DC marker expression on <italic>lncIrf8</italic> promoter KO pDC cannot be measured because cells are absent in <italic>lncIrf8</italic> promoter KO. Nevertheless, we visualized CD11c and CD11b expression on cells which are present by gating on single cells on day 7 and 9 of Flt3L directed DC differentiation in <italic>lncIrf8</italic> promoter KO and control cultures. In <italic>lncIrf8</italic> promoter KO cells CD11c expression was slightly reduced and CD11b expression was slightly increased (see <xref ref-type="fig" rid="sa2fig2">Author response image 2</xref>). This indicates that <italic>lncIrf8</italic> promoter KO does not have a major effect on the expression of CD11c and CD11b. Given this negative result we prefer not to include these data in the manuscript.</p><fig id="sa2fig2" position="float"><label>Author response image 2.</label><caption><title>CD11c and CD11b median fluorescence intensity (MFI) of single cells in <italic>lncIrf8</italic> promoter KO and Control cells.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83342-sa2-fig2-v2.tif"/></fig><p>Point 2: Deletion of the +32 kb enhancer region as defined in Durai et al. 2019.</p><p>We followed the request of the reviewers and deleted the +32 kb enhancer region by using the same gRNAs as described in Durai et al., <italic>Nat. Immunol</italic>., 2019, referred to as cDC1 specific +32 kb enhancer KO (see new Figure 2—figure supplement 4C, page 35). In parallel, we also designed a new pair of gRNAs to delete this +32 kb enhancer region. We followed the same procedure as in the <italic>lncIrf8</italic> promoter KO experiments (Figure 2—figure supplement 1A) for both the Durai et al. gRNAs and our new self-designed gRNAs to obtain homozygous clones of cDC1 specific +32 kb enhancer KO. Five out of 165 single-cell clones were subjected to DC differentiation and further analyzed at day 7 and 9. Frequencies of pDC were unaffected by +32 kb enhancer KO at the end of culture (day 9). There was some effect at day 7, however this was not statistically significant. The cDC1 specific +32 kb enhancer KO compromised cDC1 development at day 7 and day 9, which is in line with the phenotypes described by Durai et al., <italic>Nat. Immunol</italic>., 2019 and Murakami et al., <italic>Nat. Immunol</italic>., 2021 in mice.</p><p>These new results are now shown in new Figure 2—figure supplement 4 in the revised manuscript (Results section, page 8, lines 235-249 and page 35). The Materials and methods section was also updated accordingly (page 18, lines 576-605). Source data of new Figure 2—figure supplement 4B are also provided and described on page 36 (Figure 2—figure supplement 4-source data 1 and source data 2)</p><p>In summary, our data show that deletion of cDC1 specific +32 kb enhancer affects cDC1 development while the <italic>lncIrf8</italic> promoter KO affects both pDC and cDC1 development (Figure 2). This indicates that the <italic>lncIrf8</italic> promoter element has further functions compared to the cDC1 specific +32 kb enhancer, e.g. to control pDC development. We have now indicated this point in the Discussion (Discussion section, page 13, lines 422-427).</p><disp-quote content-type="editor-comment"><p>3) Provide evidence that IRF8 binds in the lncIRF8 promoter. Authors showed show DNA binding motifs for Irf8 in the lncIrf8, but no evidence of actual binding. Perhaps the +32kb enhancer is also physically involved, but either way more evidence is needed to fully support the authors' models. Instead, IRF8 binds in the more 5' part of the +32kb enhancer identified by Durai 2019. How then is a putative IRF8 repressor complex linked to the lncIRF8 promoter as the authors propose? Moreover, the model does not appear to address why the IRF8 repressor complex binding to the lncIRF8 would be active in cDC1 and not pDC.</p></disp-quote><p>We appreciate the reviewers’ point and can very well agree with the reviewers that the cDC1 specific +32 kb enhancer element by Durai et al. 2019 might also be involved in the negative feedback regulation of <italic>Irf8</italic> during DC differentiation. The full +32 kb enhancer is delineated by the H3K27ac and H3K4me3 marks (Figure 2A and new Figure 2—figure supplement 4A) and comprises both the +32 kb enhancer element by Durai et al. 2019 and the <italic>lncIrf8</italic> promoter described here. Both elements appear to be important for full <italic>Irf8</italic> +32 kb enhancer function in DC differentiation: (i) Deletion of the <italic>lncIrf8</italic> promoter compromised both pDC and cDC1 differentiation (Figure 2); (ii) Deletion of the +32 kb enhancer element by Durai et al. 2019 compromised cDC1 and to some extent also pDC differentiation (new Figure 2—figure supplement 4; although not statistical significant); (iii) positioning the dCas9-VP64 at the <italic>lncIrf8</italic> promoter for CRISPR activation prominently enhanced cDC1 differentiation (Figure 5A, B and E) and (iv) positioning the dCas9-KRAB at the <italic>lncIrf8</italic> promoter for CRISPR interference compromised both pDC and cDC1 differentiation (Figure 6A-E).</p><p>In our model we proposed that binding of the putative IRF8 repressor to the +32 kb enhancer is mainly in the 5’ part of the +32 kb enhancer, as demonstrated by the ChIP-seq of IRF8. There is a strong IRF8 binding signal detected in cDC and weak to no IRF8 binding signal in pDC (Figure 1A, Figure 1—figure supplement 1, Figure 2—figure supplement 2 and Figure 7B, ChIP-seq IRF8 signal).</p><p>Thus, we propose the putative IRF8 repressor complex is only active in cDC and not pDC (Figure 7B). We agree with the reviewers that at this stage of analysis we do not know why IRF8 binds to the 5’ part of the +32 kb enhancer in cDC but not in pDC. Addressing this point should be subject for further studies.</p><disp-quote content-type="editor-comment"><p>4) Authors should acknowledge/discuss clearly that one limitation of their study is that lncIRF8 might have other roles in DC/pDC biology which is yet unidentified in the current study.</p></disp-quote><p>We appreciate the suggestion made by the reviewer. We have now indicated that <italic>lncIrf8</italic> might have other roles in DC biology which is yet unidentified in the current study (Discussion section, page 13, lines 435 and 436).</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>1. While refining the cross-talk between promoter and enhancers authors have completely overlooked the functional significance of lncIRF8 in pDCs. Authors have demonstrated the expression of lncIRF8 is specific to pDCs, it is not evident whether all pDCs express it or a fraction of the same.</p><p>a. Further authors should confirm the expression of lncRNA in ex vivo pDCs from various murine tissues. Is the expression of lncRNA also conserved in human pDCs?</p></disp-quote><p>The question by the reviewer on the expression of the novel <italic>lncIrf8</italic> and <italic>Tcons_00190258 lncRNA</italic> in ex vivo pDC is well taken. We addressed this point be re-analyzing scRNA-seq data of BM and spleen pDC of GSE114313 (Rodrigues et al., <italic>Nat. Immunol.,</italic> 2018) and bulk RNA-seq data of the splenic DC subsets pDC, cDC1 and cDC2 of GSE188992 (Pang et al., <italic>Front. Immunol.</italic>, 2022).</p><p>The scRNA-seq data showed that <italic>lncIrf8</italic> is expressed in BM and spleen pDC. Expression of the cDC1 specific <italic>Tcons_00190258</italic> lncRNA in BM and spleen pDC is very low to absent. The bulk RNA-seq data fully support these results: <italic>lncIrf8</italic> and <italic>Tcons_00190258</italic> lncRNA are expressed in pDC and cDC1 of spleen, respectively, and the expression pattern is the same as in in vitro bone marrow DC.</p><p>These new data are in new Figure 1—figure supplement 3 <italic>(</italic>please see above our response to Essential Revision 1).</p><p>We also addressed the question on the conservation of the novel <italic>lncIrf8</italic> across species. A lncRNA downstream of the human <italic>Irf8</italic> gene was identified, referred to as <italic>LINC02132</italic>, but no lncRNA was observed downstream of zebrafish <italic>Irf8</italic> gene (see <xref ref-type="fig" rid="sa2fig1">Author response image 1A</xref>). By sequence alignment we demonstrate that the sequences of mouse <italic>lncIrf8</italic> and human <italic>LINC02132</italic> are not conserved (<xref ref-type="fig" rid="sa2fig1">Author response image 1B</xref>; see also above our response above to Essential Revision 1 for further details).</p><p>We conclude that the pDC specific <italic>lncIrf8</italic> is not conserved across species. This is a common characteristic, which is very frequently found for lncRNA. We now include this information in the Results section, page 7, lines 200-202.</p><disp-quote content-type="editor-comment"><p>b. How is the expression of lncIRF8 modulated upon CpG stimulation/viral infection of pDCs?</p></disp-quote><p>This is an interesting question and we addressed this point by re-analyzing public RNA-seq data of FACS sorted pDC (CD3- CD19- CD11c+ CD11blow B220+ Siglec-H<sup>+</sup> CD317+) from BM cells of in vitro Flt3L cultures (GSE170750, Mann-Nuettel et al., <italic>BMC Genom. Data</italic>, 2021). In this study pDC were stimulated by CpG 2216 for 0, 2, 6 and 12 hours and subjected to RNA-seq analysis. Our analysis showed that <italic>Irf8</italic> expression was upregulated with time upon CpG stimulation, while <italic>lncIrf8</italic> expression was downregulated (<xref ref-type="fig" rid="sa2fig3">Author response image 3A</xref>). Obviously, pDC activation by CpG stimulation affects the expression of hundreds of transcription factors within a few hours (<xref ref-type="fig" rid="sa2fig3">Author response image 3B, C</xref> taken from Mann-Nuettel et al., <italic>BMC Genom. Data</italic>, 2021), including IRF8. CpG stimulation of pDC occurs within hours and is different from pDC differentiation, which takes a few days.</p><fig id="sa2fig3" position="float"><label>Author response image 3.</label><caption><title>Gene expression after pDC activation by CpG 2216 stimulation.</title><p>(A) Visualization of <italic>lncIrf8</italic> and <italic>Irf8</italic> expression in BM cell-derived pDC upon CpG 2216 stimulation after 0, 2, 6 and 12 hours recalculated from RNA-seq data of FACS sorted pDC (CD3- CD19- CD11c+ CD11blow B220+ Siglec-H<sup>+</sup> CD317+; GSE170750 from Mann-Nuettel et al., <italic>BMC Genom. Data</italic>, 2021). (B and C) Differentially expressed transcription factors in CpG 2216 stimulated pDC. Panel (A) is our calculation, panels (B) and (C) are from Mann-Nüttel et al., <italic>BMC Genom. Data</italic>, 2021 Figure 2B and Figure 2F.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-83342-sa2-fig3-v2.tif"/></fig><p>Therefore, it is not easy to explain the gene expression patterns of <italic>lncIrf8</italic> and <italic>Irf8</italic> in pDC upon CpG stimulation and a potential cross talk between <italic>lncIrf8</italic> and <italic>Irf8</italic> using our model that builds on DC differentiation. Given these rather different scenarios and the complexity of both systems, we prefer to not include these data in the paper.</p><disp-quote content-type="editor-comment"><p>c. Is there any significance of lncIRF8 in pDC functions (TLR stimulations, cytokine production, etc.) these aspects could be studied without much effort as authors already have systems that can knockout lncIRF8 promoter or overexpress lncIRF8.</p></disp-quote><p>We understand the reviewer’s point on the interest in a potential significance of lncIRF8 on pDC functions using knockout or overexpression studies. However this point is difficult to address: (i) The <italic>lncIrf8</italic> promoter KO severely compromises pDC development and pDC are essentially absent in <italic>lncIrf8</italic> promoter KO cultures. (ii) lncIRF8 overexpression is difficult, as overexpression of lncRNA in general, which is challenging. This is because lncRNA overexpression in lentivirus vectors is very different from protein overexpression. To limit <italic>lncIrf8</italic> overexpression to the <italic>lncIrf8</italic> sequence a polyA signal for transcription termination has to be inserted at the 3 ’end of <italic>lncIrf8</italic> (Figure 4B). This polyA signal decrease the titer of lentivirus, which limits the overexpression capacity. We would expect to need a much higher <italic>lncIrf8</italic> overexpression than the one achieved here (Figure 4 and Figure 4—figure supplement 1) to reveal a potential significance of <italic>lncIrf8</italic> in pDC functions, such as TLR stimulations and/or cytokine production.</p><p>We are in accord with the reviewer that <italic>lncIrf8</italic> might have other roles in DC biology than the one identified in our study. We now included a sentence on the potential other roles of <italic>lncIrf8</italic> in DC biology, which are not yet identified in the current study (Discussion section, page 13, lines 435 and 436).</p><disp-quote content-type="editor-comment"><p>2. Though authors have identified that lncIRF8 is specifically expressed in pDC subtype but while understanding its significance and regulation, it was preferred to study bulk DC cultures overlooking the finding regarding specificity. Experiments performed by employing dCas9 VP64/KRAB-GFP constructs, do provide some direction in terms of mechanistic understanding of the cross-talk between the promoter of IRF8 and lncIRF8. This data needs to be further strengthened by sorting pDC, cDC1 and cDC2 populations and studying the effect of the genetic manipulations on IRF8 and lncRNA expression in each cell type.</p></disp-quote><p>We appreciate the reviewer’s suggestion on studying the effects of dCas9-VP64/KRAB-GFP constructs targeting the <italic>lncIrf8</italic> and <italic>Irf8</italic> promoters in sorted pDC, cDC1 and cDC2 populations. However, this is difficult and in some cases not possible, since the dCas9-VP64/KRAB-GFP constructs are introduced in HoxB8 multipotent progenitors (HoxB8 MPP) (Figure 5—figure supplement 1A) and following Flt3L directed DC differentiation some DC subsets are very low in abundance to even absent (Figures 5 and 6). For example, in the dCas9-KRAB experiment in Figure 6A-E, frequencies of cDC1 and pDC are very low to absent. In the dCas9-VP64 experiment in Figure 5 cDC1 and pDC are there, but the impact of targeted CRISPR activation on the <italic>lncIrf8</italic> promoter is mainly seen in HoxB8 MPP at day 0 of DC differentiation (Figure 5C) and the activation effect is largely lost in the differentiated cells at later time points. Thus, studying the impact of targeted CRISPR activation and interference on IRF8 and lncRNA expression in DC subsets should include also MPP/CDP and pre-DC, and should be ideally performed by scRNA-seq and scATAC-seq. This analysis is beyond the scope of the present study and will be subject of our future work.</p><disp-quote content-type="editor-comment"><p>3. One of the most important findings of the submitted study is to demonstrate that knocking out the lncIRF8 promoter also diminishes the expression of IRF8, pDC as well as cDC1 development (Figure 2). Once the IRF8 expression is suppressed the analysis of pDC and cDC1 differentiation is redundant. It is previously reported that the deletion of +32 Kb enhancer (Durai et al. 2019) in a mouse model did not affect pDC but specifically depleted cDC1 development. Authors should examine the deletion of only the +32 kb enhancer region in their culture system to sort out the hierarchy between the +32 Kb enhancer and +32 Kb lncRNA promoter in terms of DC subtype development (cDC1 Vs pDC). Does the deletion of the lncIRF8 promoter lead to epigenetic changes at the overall +32 region? It is expected that due to interactions and chromatin loop formation between IRF8 promoter with various enhancers elements; deletion of lncIRF8 promoter might play an important role in defining these interactions in a cell type-specific manner. These interactions become more valuable by the fact that activation of the lncIRF8 promoter leads to enhanced cDC1 differentiation. Does this simply mean more open chromatin conformation around the cDC1-specific +32 Kb region rather than correlating with the lncIRF8?</p></disp-quote><p>We agree with the reviewer that deletion of the <italic>lncIrf8</italic> promoter might lead to epigenetic changes in the entire +32 region and might have multiple effects, such as affecting transcription factor binding, histone modifications, open chromatin regions and chromatin interactions. Similarly, targeting dCas9-VP64 to the <italic>lncIrf8</italic> promoter for CRISPR activation caused more cDC1 differentiation, which might be also due to multiple effects, such as changes in transcription factor binding, chromatin interactions and/or chromatin conformation. Here CRISPR activation of the <italic>lncIrf8</italic> promoter might cause +32 kb enhancer activation and as a consequence IRF8 activation and more cDC1 (Figure 5A-E).</p><p>We now followed the request of the reviewer and deleted the +32 kb enhancer region with the four 4 AICE elements as described by Durai et al., <italic>Nat. Immunol</italic>., 2019 by using the same gRNAs as described in Durai et al., in the following referred to as cDC1 specific +32 kb enhancer KO. In parallel, we also designed a novel pair of gRNAs to delete this +32 kb enhancer region. We followed the same procedure as the <italic>lncIrf8</italic> promoter KO experiments (Figure 2—figure supplement 1A) to obtain homozygous clones of cDC1 specific +32 kb enhancer KO. Five out of 165 single-cell clones were subjected to DC differentiation and further analyzed. cDC1 specific +32 kb enhancer KO did not affect pDC differentiation but compromised cDC1 development, which is in line with the phenotypes described by Durai et al., <italic>Nat. Immunol</italic>., 2019 and Murakami et al., <italic>Nat. Immunol</italic>., 2021 in mice.</p><p>These new results are now shown in new Figure 2—figure supplement 4 in the revised manuscript (Results section, page 8, lines 235-249 and page 35). The Materials and methods section was also updated accordingly (page 18, lines 576-605). Please see above our response to Essential Revision 2.</p><disp-quote content-type="editor-comment"><p>Can authors analyze the epigenetic changes by performing similar experiments in some of the available pDC and cDC1 cell lines? As these cell lines are likely to have active IRF8 transcription and it would help to measure the effect of lncIRF8 promoter deletion/mutation/activation/repression on IRF8 expression and specific DC subtype maintenance.</p></disp-quote><p>We thank the reviewer for the suggestion to study the epigenetic changes reported here in some of the available pDC and cDC1 cell lines. However, we hesitate to do so, since established cell lines have inevitably suffered from mutation and multiple alterations, which are often unknown and/or hard to control. We rather have built our study on conditional immortalization of mouse bone marrow cells by HoxB8 (referred to as HoxB8 MPP; Figure 1—figure supplement 2A).</p><p>These conditionally immortalized HoxB8 MPP exhibit an essentially unlimited lifespan when grown with estrogen (E2), when HoxB8 is active (Xu et al., <italic>Eur. J. Immunol.</italic>, 2022). Additionally, they stop proliferating when E2 is removed and faithfully recapitulate hematopoietic stem cell commitment, DC differentiation and allow genetic manipulations by CRISPR/Cas tools. Thus, we consider HoxB8 MPP a particularly versatile and useful model to study gene regulations during DC differentiation. Repeating the study in pDC and cDC1 cell lines will, in our opinion, only provide limited new information but entails the risk of picking up aberrant phenomena, which are inherent to studies in cell lines.</p><disp-quote content-type="editor-comment"><p>4. Based on the various earlier published reports and results from the current study authors have shown a schematic representation of the pDC and cDC1-specific interactions. Can these interactions be validated in primary/ex-vivo DCs and be correlated with lncIRF8 as well as IRF8 expression? Will it be possible for authors to validate these interactions in light of the lncIRF8 promoter deletion/mutation/activation/repression? Authors may be careful to perform these experiments in purified pDC and cDC1 fractions to get meaningful data.</p><p>In case it is not possible to perform experiments with primary DCs/genetically modified HOXB8 cultures; if required, some of these experiments may be performed in the cell lines wherein overall interaction between various enhancer elements and promoters can be validated.</p></disp-quote><p>We agree with the reviewer that validating the pDC and cDC1-specific interactions mediated by <italic>lncIrf8</italic> and <italic>Irf8</italic> in primary/ex-vivo DC should be interesting. In this context we now provide data that <italic>ex-vivo</italic> pDC express <italic>lncIrf8</italic> similar to in vitro BM pDC (new Figure 1—figure supplement 3), which indicates that the gene regulation patterns we found in our in vitro systems also exist in vivo.</p><p>Primary/<italic>ex-vivo</italic> DC have a limited lifespan in vitro, thus it will be challenging to impossible to generate genetically modified cells for studying gene regulations in primary cells. In particular, deletions of cis-regulatory elements (such as enhancer or promoter sequences) that require single-cell clones, are not possible with primary mouse cells due to lifespan restrictions. These limitations made us to develop the conditional immortalized mouse bone marrow HoxB8 MPP system (Figure 1—figure supplement 2A; Xu et al., <italic>Eur. J. Immunol.</italic>, 2022). Experimental details of the HoxB8 MPP-DC differentiation system are now included in a Guideline paper by Lutz et al., <italic>Eur. J. Immunol.</italic>, 2022. We added this reference to the reference list and cite this paper along with the Xu et al., 2022 paper as indicated.</p><disp-quote content-type="editor-comment"><p>5. Authors have also identified a TCONS_00190258 which is specifically expressed in the cDC1 subtype. Why not look at the expression levels of this transcript in the various experiments in the current study as enhancer element crosstalk will help in cell type-specific transcription of IRF8, lncIRF8, and TCONS_00190258?</p></disp-quote><p>We really appreciate the suggestion made by the reviewer. We have now provided evidence that <italic>Tcons_00190258</italic> is also express in <italic>ex-vivo</italic> tissue (new Figure 1—figure supplement 3C). Studying the impact of <italic>Tcons_00190258</italic> on DC differentiation and its potential crosstalk with <italic>lncIrf8/Irf8</italic> both in vitro and in vivo will be subject of our future work and described elsewhere.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>I find the quality and interpretation of the genomics data to be excellent and I have no major concerns with that data. I do have some specific comments around the interpretation of the cellular data and the model presented.</p><p>Specific comments</p><p>1. The authors conclude that lncIRF8 promoter KO hematopoietic progenitors are not capable of differentiating to pDCs (Figure 2C, Figure 2 Suppl 3D). However, it is now understood that Irf8 is not essential for pDC development (see Sichien Immunity 2016 where they study WT:IRF8-/- BM chimeras) and that Irf8 deregulates some key markers, including CD11b. The authors need to account for this discrepancy. Are pDCs with aberrant marker expression produced in the lncIRF8 promoter KO, and if not, why does this phenotype differ from the Irf8 KO?</p></disp-quote><p>We appreciate the point made by the reviewer. In our study on DC differentiation of <italic>lncIrf8</italic> promoter KO in vitro and following transplantation into sublethally irradiated mice in vivo<italic>,</italic> we observed low to absent CD11c+ CD11b- B220+ pDC (Figure 2C, Figure 2—figure supplement 3) or Gr1- Siglec H<sup>+</sup> pDC (Figure 3A and D, G and J), respectively.</p><p>We know the work by Sichien et al., 2016 on WT:<italic>Irf8-/-</italic> BM chimeras and the conclusions reached from their work that IRF8 is dispensable for pDC development. The results in Sichien et al., 2016 are based on WT:<italic>Irf8-/-</italic> BM chimeras upon transplantation in lethally irradiated mice and thus the divergent results compared to the classical <italic>Irf8-/-</italic> mice might be due to the experimental set-up WT:<italic>Irf8-/-</italic> BM chimeras versus <italic>Irf8</italic> knockout mice (see also our response above to Essential revisions 2).</p><p>We now followed the advice of the reviewer and checked whether the <italic>lncIrf8</italic> promoter KO had an impact on DC marker genes, such as CD11c and CD11b. We visualized CD11c and CD11b expression (gating on single cells) on day 7 and 9 of Flt3L directed DC differentiation in <italic>lncIrf8</italic> promoter KO and control cells. In <italic>lncIrf8</italic> promoter KO cells CD11c expression was slightly reduced and CD11b expression was slightly increased (see above <xref ref-type="fig" rid="sa2fig2">Author response image 2</xref> and our response to Essential revisions 2).</p><p>This indicates that <italic>lncIrf8</italic> promoter KO does not have a major effect on CD11c and CD11b expression. Given this negative result we prefer not to include these data in the manuscript.</p><disp-quote content-type="editor-comment"><p>2. There does not appear to be compelling evidence that IRF8 binds in the lncIRF8 promoter in cDC1. Instead, IRF8 binds in the more 5' part of the +32kb enhancer identified by Durai 2019. How then is a putative IRF8 repressor complex linked to the lncIRF8 promoter as the authors propose? Moreover, the model does not appear to address why the IRF8 repressor complex binding to the IRF8 repressor complex would be active in cDC1 and not pDC.</p></disp-quote><p>The point made by the reviewer is well taken. In our model we proposed that binding of the putative IRF8 repressor to the +32 kb enhancer is mainly in the 5’ part of the +32 kb enhancer, as demonstrated by the ChIP-seq of IRF8. There is a strong IRF8 binding signal detected in cDC and weak to no IRF8 binding signal in pDC (Figure 1A, Figure 1—figure supplement 1, Figure 2—figure supplement 2 and Figure 7B, ChIP-seq IRF8 signal).</p><p>Thus, we propose the putative IRF8 repressor complex is only active in cDC and not pDC (Figure 7B). We agree with the reviewer that at this stage of analysis we do not know why IRF8 binds to the 5’ part of the +32 kb enhancer in cDC but not in pDC. Addressing this point should be subject for further studies. See also our response above to Essential revisions 3.</p><disp-quote content-type="editor-comment"><p>3. The authors use 2 versions of the HoxB8 MPP differentiation system (lines 207-234). Firstly, it is unclear, why two similar approaches are used, but more importantly, the second system outlined in figure 2 Suppl 3 shows that the lncIRF8 promoter is also required for cDC2 differentiation. This is a concern, as IRF8 is not expressed in cDC2, and Irf8-/- mice produce cDC2.</p></disp-quote><p>In the present study we used two approaches to differentiate the <italic>lncIrf8</italic> promoter KO cells, thereby following the DC differentiation systems described in Xu et al., <italic>Eur. J. Immunol.</italic>, 2022:</p><p>The first system is spontaneous DC differentiation, where we just remove estrogen (E2) and keep SCF, Flt3L (low concentration), hyper-IL6 and IGF1 in culture. Under these conditions most of the <italic>lncIrf8</italic> promoter KO cells moved to Gr1+ monocytes (Figure 2E). This spontaneous DC differentiation mimics in vitro the differentiation potential of these cells in vivo upon cell transplantation, where most of the <italic>lncIrf8</italic> promoter KO cells also differentiated into Gr1+ monocytes (Figure 3B and H).</p><p>The second system is Flt3L directed DC differentiation, where estrogen (E2) and the growth promoting cytokines SCF, Flt3L (low concentration), hyper-IL6 and IGF1 are removed and high Flt3L concentration is applied to direct HoxB8 MPP differentiation towards DC, and all DC subsets (cDC1, cDC2 and pDC) are obtained. In the manuscript we used both approaches, spontaneous DC differentiation (-E2) and Flt3L directed DC differentiation, to support the conclusions reached.</p><p>Concerning the reduced cDC2 population in Figure 2—figure supplement 3G, this is because the cDC2 population was gated from CD11c+ cells and calculated based on living single cells. In the <italic>lncIrf8</italic> promoter KO most cells differentiated into Gr1+ monocytes (Figure 2E) and thus CD11c+ cDC2 were much lower in the <italic>lncIrf8</italic> promoter KO compared to control.</p><p>We now also calculated cDC2 based on CD11c+ cells and show these data as new Figure 2—figure supplement 3H. We did not observe significant differences between <italic>lncIrf8</italic> promoter KO and control cells on day 8 and 10. On day 6 the spontaneous DC differentiation of control cells progressed slower than the <italic>lncIrf8</italic> promoter KO cells, thus lower frequency of cDC2 was observed. We added this information to the legend for Figure 2—figure supplement 3 (page 34, lines 1214-1217).</p></body></sub-article></article>